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Abstract
Multiple sclerosis is the most common demyelinating disease oCme central
nervous system. It typically affects young adults. and as ",ith many autoimmune
diseases, MS affects more women than men.
A large number of studies have concentrated on the identification ofthe antigen(s)
responsible for inciting MS, but the "causative agent(s)" has yet to be found. Some of
these studies demonstrated that T and B lymphocytes isolated from MS patients are
reactive with autoantigens, sucb as myelin basic protein, myelin oligodendrocyte protein,
proteolipid protein, and myelin assoc:iated protein, and with viruses, such as Epstein-Barr
virus. measles, and varicella·zoster. However, a role for anyoftbese antigens in the
initiatioo ofmultiple sclerosis bas not yet been established.
This study was undertaken as an attempt to identify potential autOllDugens in
multiple sclerosis by using a modification of the SEREX (1erological identification of
antigens by recombinant ~xpressioncloning) technique developed. by Sahin et aI. (1995).
This techniq~, unlike many ofthe techniques previously used by investigators to
identify autoaotigens in MS, makes DO apriori assumptions as to the identity oCthe
autoantigen.. Messenger RNA was isoI.a.ted from multiple sclerosis brain tissues and used
to COl'lSttUCt a eDNA Library in a lambda phage vector. This vector was tIanSfected into
&cJrerichia coli, protein expression was induced with isopropyll!-D-
thiogalactopynmoside, and the proteins were transferred to nitrocellulose membranes.
The membranes were screened with patients' sera and positive clones were detected with
a color reaction which recognizes IgG in patients' sera bound to the recombinant protein
Positive clones were subcloned to clonality and sequenced,. and the sequences compared
with DNA and RNA sequences in various databases. Three positive clones W'CI"C used as
probes in Nortbcm blotting experiments to determine their relative expression levels in
various tissues. One of these clones was identified as testican,. the otbertwo appear to be
relaled gene products of the c100e F4 transmembrane protein and KlAAOS30.
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1.0 Multiple Sclerosis
Multiple sclerosis (MS) is the most common demyelinating disease ofme central
nervous system (CNS) (Antel and Amason, 1991). Some authors estimate the risk of
developing this disease as lin 800 for individuals ofNotthem Ew-opean descent (BeU and
Lathrop, I9%). MS typically occurs in young adults with the mean age ofonsct about 30
years ofage(Coyle, 1996) and affects twice the number of women as men (Steinman,
1996). Multiple sclerosis is generally believed to be an autoimmune disease with genetic
and environmental components.
Although experimenters have yet to identify a ususceptibility gene(s)" for this
disease. there are a Dumber ofpieces of evidence which do indicate a genetic
ptedisposition for MS. Flrst, the incidence ofMS among immediate relatives ofMS
patients is 15 to 20 times higher than expected in the absence of a genetic compooent
(Compston, 1991a). Second, the coocordanoe rate of multiple sclerosis in mooozygotic
twins is 25 to 30 percent (Oksenberg and Hauser, 1997), whereas the concordance is only
about 4 percent for dizygotic twins (Ebers et al., 1986). Third,. there is an association of
the FD..A-DRB1'1501.DQAI·0102-DQB1·0602 haplotype, also known as the DRl
haplotype, in caucasian MS patients who are ofNonhem European descent (Ok:senberg
and Hauser, 1997). Wucherpfcnnig etal. (1991) estimated that between 50 and 70
percent ofpaticots with multiple sclerosis cany this DR2 haplotype which is found in
only 20 to 30 percent ofthe normal population in North America. Fourth,. multiple
genetic regions have been linked. to multiple sclerosis in gene mapping studies (Ebers et
aL. 1996; Kuold:anen et al., 1996; 1be Multiple Sclerosis Genetics Group, 1996; Sawa:r
etal,I996).
From the genetic work completed to date, it appealS that multiple sclerosis is not
simply a genetic disease. Instead multiple sclerosis seems to be due to multiple genes
which confer Suscepllbility in combination with environmeDtal factors (Wucherpfennig et
al., 1991; Compston et aL, 1994; The Multiple Sclerosis Genetics Group, 1996; Sawcer et
al.• 1997). The importance of environmental factors can be deduced from the fact that
there is an incomplete penetranee of multiple sclerosis in monozygotic twins (Stinissen et
at.. 1997). Compston et al. (1994), suggested that genetic factors are neitbecneoessary
nor sufficeDt for the development ofMS. It is poss1Dle that the HLA associations
observed in MS patients do not ~Oect a genetic predisposition to MS, but rather that
these loci are linked markers to ODe or more oftbe other 200 genes known to map to this
region (Oksenberg and Hauser, 1997). Perhaps the best summary ofthe genetics of
multiple sclerosis is as follows: "Autoimmune diseases result from the action of
environmental factors on a predisposed genotype. AutOlmmUDe diseases are not inherited
as entities but as constitutions which confer an increased probability ofdeveloping
disease." (Baxter, 1997).
1.1 Cliak:al Feanues and Diaposis of MaltipIe Sclerosis
Multiple sclerosis may include any ofa large number ofclinical features. Some
ofthe most commonly occWTing symptoms and clinical features include: optic neuritis,
vertigo, vomiting, scanning speech, weakness. spasticity, bladder and bowel dysfunction.
electric shock-like seusationon flexion ofthe DelCk. tingling 01" tigbJ.ness of the
~es, band-like sensations about the trunk. depression. weight loss. fatigue. and
intention tremor (founelloue et al, 1983; Antel and Amason, 1991; Raine, 1997a). 'The
manifestation ofthese symptoms is extremdy variable, with the number of symptoms
experienced by each patient and the order in which they oecur varying from patient to
patient. The fact that there is no "pattern" ofsymptoms can be explained by the
observation that myelinated axOt'lS anywhere in the central nervous system can be
involved (Mcfarland and McFarlin, 1995).
Since a laboratory test specific for multiple sclerosis has yet to be elucidated, the
diagnosis ofthe disease relies mainly on clinical history and oeurologic examination.
Perhaps the most widely used set ofcriteria for the clinical diagnosis ofMS are those
proJXlSed by Poser et al. in 1983. These authors divided multiple sclerosis diagnosis into
clinically definite, laboratory-supported definite, clinically probable, and labonilory-
supported probable multiple sclerosis. In general, the age ofonset must be between 10 to
59 years inclusive, and no other coodition(s) must be able to aceoWlt for the symptoms.
A.. Clinically Defiaite Multiple Sclerosis
I. Two attacks and clinical evidence of two separate lesions
2. Two attacks; clinical evidence ofone lesion and paraclinical evideoce of
another separate lesion.
B. Labon.tory-supported Defi.aite Multiple Sclerosis
l. Two attacks; either clinical orparaclinical evidence ofone lesion; and
cerebrosplnal fluid (CSF) oligoclonal bands or increased intrathecal synthesis
of immunoglobulin G (180).
2. One anac.k; clinical evidence oftwo separate lesions; llDdCSF oligoclonal
bands or increased intrathecal synthesis ofIgG.
3. One attack; clinical evidence ofone lesion and paraclinica1 evidence of
another, SCpaIate lesion; and CSF oligoclonal bands or increased intrathcca1
synthesis of 19O.
C Cldically Probable Multiple Sclerosis
I. Two anac.k:s and clinical eviden¢c ofone lesion.
2. One attack and clinical evidence oftwo separate lesions.
3. One anac.k; clinical evidence ofone lesion and pataclinical evidence of
another separate lesion.
D. Labonatory-sapported Probable MaJtipie Sclerosis
1. Two attacks and CSF oligoclonaI bands or increased intrathecal synthesis of
IgG.
III each ofthcsc categories the attacks must involve different partS of the CNS,
must occur at least ooc month apart. and must eacb last at least 24 hours. In the
laboratory-supportcdcriteria oligoclonal bands must DOt be present in patient's serum and
the level ofigO in the serum must be normal.
From reading this list ofcriteria it is easy to see how tbe development ofa
specific laboratory test for MS would be useful. There are a number oflaboratory
findings, which can be used as sopponing iofonnation when a diagnosis of multiple
sclerosis is 5lJ5pected based on clinical and neurological observations (including
oligoclooal bands and iDcreascd synthesis ofIgG as mentioned above):
I. An increased synthesis rate ofCSF IgO, observed in 80 to 90 percent ofMS
patients (Link and Tibbling, 1977; Towtellotte, 1985).
2. The presence ofoligoclonal bands ofIgG in the CSF ofmore than 90 percent
of patients with multiple sclerosis (Mehta et aI., 1982; Gonsette et al.., 1984;
Towtellottc.1985). These bands. are believed to be syntbesizcd within the
CNSbya limited numberofB lympbocytes(Compstonetal., 1994; Garrenet
aI., 1998). It is important to note that the detection of such bands is not
exclusive to MS. as oligoclonal hands are also found in diseases such as
syphilis. herpes simplex encepbalitis, aod subacute sclerosing paocncepbalitis
(Chuetal... 1983; Antel andAma.son, 1991; McFarland and McFarlin, 1995).
Nevertheless the detection oftbesc: bands is helpful in the diagnosis of
multiple sclerosis.
3. Evoked potentials response tests sbow slowing ofconduction indicative of
loss ofmyelin from axons in approximately 80 pcn::ent ofMS patients (Antel
andAmasoo, 1991; Waxman, 1998).
4. "'Multifocal CCf"ebral white matter lesions" are detected with magnetic
resonance imaging (MRl) in more than 90 percent ofpatients with MS (Ante1
and Amason, 1991; McFarland and McFarlin., 1995; Miller, 1996).
1.2 CliDal Counc ofMaltipk: Sclerosis
Like the symptoms ofmultiple sclerosis. the course aod severity of this disease
are variable and unpredictable. The majority of patients, approximately 85 percent,
endure a relapsingfremitting type ofdisease (Coyle, 1996) which can continue for more
than 30 years. Relapses may present with DeW symptoms, the worsening ofold
symptoms, or both (Ra.ioe, 1997a). Forbc:tween 40 aod65 pen:ent of patients who
present with a relapsiDgfremitting disease. a secondary progressive disease develops
(Coyle, 1996). lbat is to say that aJthough the patient experiences relapses followed by
remissions. the extent of recovery from each relapse is not complete and so with time a
gradual worsening of the patient is observed.
In contrast to this relative majority ofmultiple sclerosis patients, there is a
minority ofpatients for whom the disease is primary progressive. These patients do not
undergo the relapsing/remitting form ofdisease., but rather become progressively worse
from the onset ofdisease without any remissions (McDonald, 1994).
There is also a very small group ofmultiple sclerosis patients for whom the
disease bas a progressive-relapsing course (lublin aDd Reingold, 1996). Similar to the
primary progressive patients. the progressive-relapsing patients experience a progressive
disease from onset. However, in contrast to the primaty progressive patients, they also
experience clear acute relapses.. Recovery from these relapses mayor may oot be
complete. As well, then: is continuing progression of the disease between these relapses.
1.3 Tbe ImmuDopatbology of Ibe Multiple Sclerosis Lesion
The cbaracteristic pathology of multiple sclerosis includes inflammation of the
CNS, demyelination with relative sparingofaxons., and astroglial scarring (Sobel. 1995;
Lassmann et aI., 1998). Although this is the characteristic pathoIogyofMS, the
iocidence of lnflammatiOD, demyelination, and remyelination differs not only with the
form and stages of the disease, but also from patient to patient (Bruck et aI., 1994; Ozawa
et aI., 1994). Based on their observations ofthe variability ofMS pathology, Lucchinetti
et aL (1996) suggested the following classifications: (1) demyelination with relative
preservation ofoLigodendrocytes. (2) myelin destruction with coocomitant and complete
destruction ofoligodendrocytes. (3) primary destruction oc distwbance ofmyelinating
cells with secondary demyelination. This Lack ofa cbaracteristic pathology may reflect
the actions ofdifferent immune responses.
Demyelination (eads to the formation of multifocallesions known as plaques,
whicb are typical of MS. These plaques are weU demarcated from the surrounding tissue,
can be of various sizes, and can be formed in almost any region oCthe CNS (Antel and
Amason, 1991; Richardson, 1994;Ma.rtin, 1997). As previously mentiooed, this
variable distribution pattern is thought to be partly responsible foc the fact that there is DO
cornmon course of symptoms between patients. However, there are a few areas where
plaques are know to predominate; the cerebeUum, the optic nerves and tract, the brain
stem. the spinal cord,. and the perive:ntricular white matter (Luccbinetti and Rodriguez,
1997; Martin, 1997; Stinissen et aI.. 1997). Plaques are genCIa1J.y limited to white matter
(Boccaccio and Steinman, 1996) and to the CNS (Antd and Amason, 1991).
Typically the acute MS lesion is inflammatory and contains cytokinc secreting T
lymphocytes (mostly CD4+ T lymphocytes). activated macropbages and microglia, and a
few B lymphocytes and plasma cells (Prineas, 1985; Hauser et aI., 1986; Raine
1991a,1994; Lassmann et aI., 1995). The chronic MS lesion diffe~ from the acute lesion
in several ways: it contains more CDS'" T lymphocytes than CD4+ T lymphocytes (Raine.
1994). the number ofB Iympbocytes and plasma cells is greater(Princas and Wrigl1t,
1978; 02awa et al.. 1994; Bruck ct.al., 1995). there is less inflammation, and glial scar
formation occurs due to incomplete remyelination (Martin, 1997). The topic of
rcmyelination is discussed later.
In general, the inflammation and demyelination observed. in multiple sclerosis are
believed to occur with "relative sparing ofaxons". However. this does not mean that
axons arc entirely protected. Some invcstigato~suggest that axooalloss occun in all
MS plaques to some degree (Rodriguez and Scbcitbauer. 1994; Storch and Lassmann.
1997). Evidence ofaxonal injury has been demonstrated in the brains ofpatienu with
multiple sclerosis. and is believed to be mediated by inflammation (Ferguson et al.. 1997;
Trapp et al.. 1995). McDonald (1994) even cited inflammation as the "earliest detectable
event in the development ofa new lesion". Perhaps the demyelination of the axons
makes them susceptible to damage by macrophages, lymphocytes. or antibodies
(Rodriguez and Schcithaucr, 1994).
Whatever the mechanism of injury to the axoos., it seems that axooalloss may be
directly related to clinica.I deficits (McDooald, 1994; Ferguson etai-, 1997; Trapp et al.,
1998). Losseffet al. (1996) bad already proposed that axonal loss was a more reliable
correlate of permanent neurological deficit than the total extent of demyelination.
1.4 The Target of Delllyeliutioe ID Multiple Sclernsis
Befon: addressing the specifics oftbe immunology of multiple sclerosis it is
important to consider the posstole targets of this immune response.. The most likely
candidates are the myelin sheath, or compollCDtS ofthe myelin sheath, and the
oligodendrocyte. To date there is 00 verdict as to which of these. ifeither, is actually the
target in MS.
1.4.1 Myeli1l Compositioe add F.eclio.
In the centralllClVOUS system, myelin sheaths are actually multiply WIapped
oligodendrocyte cell membranes (Rjchardsoo, 1994). In the peripbetal DCTVOUS system
(PNS), myelin is produced by $chwann cells. Myelin is composed mostly of lipids,
particularly cholesterol and cerebrosides (Williams and Deber, 1993). The protein
content ofmyelin is low. Proteolipid protein (PLP), the most abundant myelin protein,
accounts for approximately 50 percent of tile total myelin (Williams and Deber, 1993}.
Myelin basic protein (MBP) accounts for 25 to 30 percent of myelin (Stinissen et aI.,
1997). Myelin-associated glycoprotein (MAG), myelin oligodendrocyte glyaJprotein
(MOO), and i, 3'<yclic nucleotide 3'-pbosphodiesterase (CNP) are minor constituents
(Stinissen et al.., 1997). MOO and PLP are found only in CNS myelin (McFarland and
McFarlin, 1995;Bematdetal,l997;Stinissenetal.,I997). SinceMSisknownto
prefereotially affect the CNS. this makes MOO and PLP good potential targets. In
addition to this, MOO is located on the extracellular surface of oligodeodrocytes and the
myelin sheath. making it easily accesSIble for an immune attaek(Bemard et al., 1997;
Stinissen et al., 1997). PLP is an integral hydropb.obic membrane protein that may also
be accessible to the immune system through its extramembranous domains (Sobel et al.•
1994).
Myelin acts as an insulator for axons and as such increases the speed of
conduction ofan impulse along the axon from the nerve cell body to the synaptic junction
(Deber aDd Reynolds. 1991; Lemke, 1996; Waxman. 1998).
lbe majority ofevidence pointing to myelin or myelin components as possible
targets in multiple sclerosis consists oftbe isolation ofT lymphocytes, plasma cells. and
antibodies specific for CNP. MOO, MBP, PLP. or MAG. lbese observations are fully
discussed in the section" The Roles Played by Specific Immune Cells in Multiple
Sclerosis",
1.4.2 OligodeDdrocytes
The preservation of oIigodendrocytes not only varies with the type of plaque
observed, but also with the individual MS patient investigated (Bruck et a!., 1994;
Lucchinetti eta!., 1996). Typically chronic inactive lesions show a loss of
oligodendrocytes when compared with the normal surrounding tissue (perier and
Gregoire,I96S;Ozawaetal,I994;Ricbardson. 1994; Rodriguez and Miller, 1994). The
state of oligodendrocytes in early. active lesions is more complex.. Oligodendrocytes
have been reported to be J){CSent in such lesions, sometimes even in "high density"
(Raine et al, 1981; PriDeas, 1985; Raine, 1997b; Raine and Wu. 1993; Brucket al, 1994;
Ozawa et aI., 1994). It bas also been reported that theR: is a ..striking loss" of
oligodendrocytes in the early stages of demyelination followed by proliferation ofthese
cells al the edges ofpLaqoes (Prineas et al, 1989,1993a). The best summary oftbese
observations was given by Bruck et aI. (1994) who stated tbaJ: in activelydemyelioating
plaques oligodendrocytes are intact, but that the Dumber of oligodendrocytes present
ranges from Dormal to absent. The presence of oligodendrocytes in these early plaques is
considered by many to be prooftbat this cell is oot a primary wget in multiple sclerosis
(Raine et al., 1981; Ozawaet ai, 1994).
Rodriguez et aI. (1993) and Rodriguez and Scbeithauer (1994) proposed that
demyelination is the result of "dying-back oligodendrogJiopathy"'. That is, it is oot the
oligodendrocyte itself which is damaged in MS, but ratber its "luxury- function, namely
myelination. Such damage would result in the production ofabnormal myelin. which
may elicit an immune response. Support for this theory comes from the observation of
degeneration in the inner myelin sheaths and in the inner glial loops of oligodendrocytes
and the accumulation oforganelles within the inner glial loops oCthe myelin sheaths
(Kirk. 1979; Ludwin and Johnson, 1981; Rodriguez, 1985; Rodriguez et aI., 1993).
Rodriguez et al (1993) argue that ifdemyelination is solely the result of a lymphocytic
reaction in the CNS, then the outer myelin sheath should be destroyed first as this is the
structure to which the lymphocytes have access. They therefore suggest that the
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oligodendrocyte or some other cell(s) oecc:ssary for the production and maintenance of
myelin is the target in multiple sclerosis.
Lending support to this hypothesis, is a study by Ban.Ici et al (1994). They found
annbodies to a recombinant hlJllllm transaldolase in the serum and CSF ofa subset ofMS
patients, but not in normal individuals or patients with other neurological disorders. They
also dcmonstratcd that this transaldolase was able to induce prolifcm.tion ofperipbcraJ
blood lymphocytes from patients with multiple sclerosis. The human transaldolase gene
(TAL.H) is expressed selectively in oligode:ndrocytes at high levels and may have a role
in the initiation of multiple sclerosis.
In direct contrast, Poser (1993) argues against the oligodendrocyte as a multiple
sclerosis target based on the following observations:
1. The areas of demyelination in MS are sharply demarcated A single
oligodendrocyte typically myelinates severaJ axODS, it is unlikely that the area
over which a particular oligodendrocyte extends would have sharply defined
~
2. The lesions in MS are scattered throughout the white matter, while diseases in
which the oligodendrocyte is known to be the primary target show large confluent
areas ofdemyelination.
1.5 The ImIDUDoiogy of Multipie Sclef"OSis
The immune system is thought to be responsible for the damage lncurred. in
multiple sclerosis.. At the present time. it is DOt !mown iftbe destructive immUDC
response l:;; primanly directed against the CNS or if the damage seen in MS is the result
ofan immune response to some other antigen or infectious agent.
In a normal individual the central nervous system is a sequestered site. due to the
presence ofan intact blood brain barrier (BBS). The BBB is composed mostly of IlOn-
fenestrated endothelial cells connected via tigbtjunctions (Steinman, 1996). As its name
implies. the blood btain barrier fuDctioQS to separate the brain from blood, blood derived
leukocytes. aDd serum proteins (Williams et aL. 1994a). Tbercfore, in order for T and B
Iympbocytes and blood mooocytes to enter the CNS and for inflammation and
demyelination to occur. the BBB must somehow be breached Blood brain banier
breakdown has been observed in MS patients by using MRl and is considered to be an
early feature in lesion formation (Kermode et al.• 1990; McDonald et al .• 1992;
McDonald. 1994). In faet Compston (l99lb) referred to penetration of the BBB as the
~ disease process without which none ofthe events direc::tly responsible for
myelin injwy would occur".
Activated T lymphocytes are able to penetrate the BBB in an antigen oon-spccific
manner. that is the antigen for which a T lymphocyte is specific need not be pesetlt in the
CNS(WekerleelaL.1986;Hickeyelal.I991; Williams et al.. 1994a;McFarland,
1995). This movement across the BBB is dependent upon the expression of eenain
adhesion molecules. In the nonna! CNS. adhesion molecule expression on endothelial
ceUs is low or absent (Wong and Korovini-Zis, 1992; WashingtOn et d. 1994; Cannella
and Raine, 1995; Brosnan and Raine. 1996). As a result, tbcendothclial cell layer is
relatively resistant to leukocyte adhesion and allows only a few cells, such as activated
lymphocytes, to enter the CNS (Hatler and Weiner, 1987).
Endothelial ceUs in MS lesions are activated (Sobel.., 1995) and have increased
expression of vascular cell adhesion molecules (VCAMs) and intercellular adhesion
molecules (lCAMs) particularly VCAM-I and ICAM-I (Sobel etal.• 1990; BrockeetaI.,
1994; Washington et al., 1994; CanDella and Raine. 1995; Be et d. 1996). The levels of
soluble VCAM-I and tCAM-I are significantIy increased in the CSF of relapsing MS
patients, as compamd with patients with other neurologic diseases (Droogan et aI., 1996)_
The lncreased expression ofadhesion molocules may be due to the action ofcytokines.
such as interleukin-2 (D..-2), interferon-y (IFN-y), and tumor necrosis faetor-a. (TNF-a),
which are secreted by activated T lymphocytes and macrophages (Dustin et al., 1986;
Sharief etal., 1993a; Williams et at, 1994a). In fact, levels offree circulating soluble
reAM-l in serum and CSF of patients with active MS correlate with TNF-a. levels and
BBB disruption (Shariefet al_. 1993b). The levels ofVCAM-l and L-selectin have been
shown to correlate with the CODCCDtratiOD oftbe soluble TNF receptor(Hammget aL,
1995a).
Activated T lymphocytes which express very late antigen4 (VLA4) are able to
cross the BBB by binding to the VCAM-I molecule on endothelial cells (Brocke et aI_,
1994). The binding ofICAM-l with lymphocyte function- associated- antigen-l (LFA-
I), expressed on activated T lymphocytes, may also be involved in T lymphocyte
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penetration oftbc: blood brain barrier (Sobel etal, 1990). T lymphocytes in the CSF and
plaques of multiple sclerosis patients have increased expression ofUA-I and VLA-4
(Svenningsson et al., 1993; CanDella and Raine, 1995). Almost: all invading leukocytes
inMS lesions express LFA-I (Boetal., 1996).
Several studies have shown that increased expressionofadhesion molecules
correlate with disease activity. For example, Dore-Duffy et al. (1995) showed that serum
levels ofICAM-I and eodothc:lialleukocyte adhesion molecule (E-selectin) were
increased in patients with chronic progressive MS as compared with controls. These
same patients also had increased CSF levels ofVCAM-1 and E-selectin when compared
Yom controls. ADother study found VCAM-I and L-selectin to be increased in the serum
ofboth relapsin&,remitting aDd chronic progressive patients when compased with controls
(Hartung et al., 1995a). Increased sennn levels ofICAM-l were also found during
relapses ofMS (Hartung et al, 1993; Sbariefet al, 1993b; Tsukadaetal., 1993).
The activated T lymphocytes that have broken through one "layer" of the blood
brain bamer must cross the extnl.ceUular mattix composed of type IV collagen. In order
to accomplish this task, matrix metalloproteases specific for type IV collagen are
R:quired. These are kno"''U as gclatinase A and B (Steinman, 1996). It is possible that
these proteases are secreted by the T lymphocytes themselves (Coyle, 1996). The
importance ofthese gelatinases is indicated by the detection ofboth gelatina.se A and B in
the tissue surrounding inflamed brain endothelium (Steimnan, 1996), and in the CSF of
MS patients (Gijbels et at.• 1992). Gelatinase B is also present in MS lesions. endothelial
cells, pericytes. macrophages and astroeytes (Steinman., 1996). A study by Rosenberg et
al (1996) fouodgclaDnaseB lobe ~inpat:iemswithMRIevidenceofBBB
_wn.
Once inside the CNS the activated T lymphocytes spc:cific for CNS antigens
remain, T lymphocytes which do DOt find their specific antigens return to the peripbeTal
circulation (Hickey et al, 1991; WI1l.iams et al., 1994a). The remaining T lymphocytes
are able to incite a number of responses through the secretion ofcytokines. These
include the induction of inflammation (Williams et at, 1994a), the activation of
endothelial cells., the recruiunem of lymphocytes and macrophages (Mcfarland, 1995).
and alterations to the permeability ofme BBB thereby allowing the entry ofB
lymphocytes, macrophages, immunoglobulins, and complement (Williams et al, 1994a;
Gay and Esm, 1991). It is also posstDle that the cytOkiDes themselves may directly
damage the tissue oftbe CNS (Wisniewski and Bloom, 1975; Probert et aL, 1995).
An interesting study by Barnes et al. (1991) suggested that the repair of the BBB
may not be complete in multiple sclerosis and that it may take quite some time for the
BBB to be restored. This finding has important implications for the disea.se. In theory,
the opening of the BBB for an extended period oftime would allow exchanges to both
directions between the CNS and the peripheral blood system which could aid in the
pe:rpetuationofMS.
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1.6 The Roles Played by Specific ImJuDc Cells in Mllltiple Sclerosis
Ooce T and B lymphocytes as well as ma.crophages have gained entty into the
CNS it is important to consider the roles played by each type ofcell in the induction and
perpetuation ofmultiple sclerosis.
1.6.1 Thc Rolc of tbe T Lymphocyte
Since the discovery that the animal model ofmultiple sclerosis. experimental
allergic (autoimmune) encepbalomyelitis (EAE). is mediated by CD4" T lymphocytes
(pettinelti and McFarlin., 1981; Swanberg, 1983). many investigatorS have coocluded that
MS must also be a T lymphocyte mediated disease. There are an~ ofobservations
that indicate a role for T Iympbocyte:s in multiple sclerosis. To dale. a decisioo regarding
the exact role of the T Iympbocyte cannot be made. These observations are listed below:
1. T lymphocytes are nearly always found in and around MS lesions (Adams,
1983; Poser. 1993). and have even been identified beyond the plaque/normal
tissue border (Prineas and Connell, 1978). In addition, increased nwnbers of
activated lymphocytes have been demonstrated in the CSF ofMS patients
(Noronhaetal.• 1980; Bellamyetal.• 198S)
2. TIle fact that there is an association between certain patients with multiple
sclerosis and the class II MHC molecule. fll.A-DR2. is evidence ofT
lymphocyte involvement in MS as CD4" T lymphocytes are known to
recognize antigen in the context ofclass II MHC molecules. In addition. the T
lymphocyte response to myelin basic protein has been found to be particularly
restricted by HLA-DR (pene et al.• 1990).
3. T Iympbocytes specific for MBP, PLP, and MOO, or-peptides of these
proteins, have been isolated from the blood and CSF ofmultip!e sclerosis
patients, patients with other neurologic diseases, and healthy individuals.
However, in each ofthese studies the frequency ofMBP-, PLP·, or MOO-
specific T lymphocytes is highest in MS patients (Ota etal., 1990; Olsson et
aI., 1990a,1992; Sun et at., 1991a,b; Cbouet at., 1992). Another study found
T lymphocytes specific for MAG could be isolated from the peripberal blood
ofMS patients., but not from controls (Johnson et al., 1986). Wallstrom cr: al
(1998) recently fOWld that peripheral blood lymphocytes isolated from MS
patients with the m..A haplotype DR2 showed greater numbers of cells
secreting IFN-y in response to several MOO peptides than lymphocytes from
HLA matched normal controls. Studies by Kerlero de Rosbo et aI.
(1993.1997) found T lymphocytes isolated from multiple sclerosls patients
predominantly responded to MOO and MOG peptides over :MBP. PLP. and
MAG.
4. The fact that autoreaetive T lymphocyteS could be isolated from MS patients
and healthy individuals implies that the presence ofthese cells is not enough
to produce multiple sclerosis (Ewing and Bernard, 1998). This led some
investigators to search for differmces between the cells ofthe two groups.
Allegretta etal (1990) found increased rates of somatic mutations in MBp·
specific T lymphocytes isolated from the blood ofpatients with MS. Somatic
mutations are a marker of antigen-driven T lymphocyte proliferation or
activation. As these mutations were not observed in MBP-specific T
lympbocytes ofhea.1thy individuals, it can be concluded that these T
Iympnocytes are oot activated Zhang et aI. (1994) were also able to snow that
MBP-reactive T lymphocytes of MS patients are in a different state of
activation than those ofcontrols. They demonstrated a higher frequency of
MBP- and PLP·specific T lymphocytes from the blood and CSF ofMS
patients over controls after primary stimulation with recombinant ll.·2 (rll.-2).
Bieganowska et aI. (1997) also demonstrated a high frequency ofactivated
autoreaetive T lymphocytes in MS patients. Hermans etaL (1997) found that
a higher percc:nt:age ofprimary T lymphocyte cultures produce IFN-y in
response to MBP in MS patients than in controls. The MBP-specific T
lymphocytes isolated from MS patients also produced higher levels ofTNF·
a than those ofcontrols. These differences in cytokine secretion may be the
result of in vtvo activation ofT lymphocytes specific for MBP io patients with
multiple sclerosis. These findings are extremely important to the
understanding of multiple sclerosis as it is known that only activated T
lymphocytes are able to traverse the blood brain batTier.
The events leading to the activation and proliferation of autoreactive T
lymphocytes in MS are still under investigation. Such cells may be present in MS in
high frequencies as part of the immlme response to the targetantigen(s). In contrast, the
autoreactive T lymphocytes may be a part oftbe normal T cell repertoire and are
activated by the release of myelin breakdown products into the peripheral circulation
(Martin eta1., 19928; Poser, 1993; Hohlfeld etal, 1995). This implies that the myelin
reactive T lymphocytes themselves are oot sufficient to indl.l:e demyelination.
1.6.1.1 T CeU Receptor Usaae ia Multiple Sclerosis
Much work: bas coocc:nttated upon elucidating the specific T ceU receptor (TCR)
genes used by the MBP.specific T Iympbocytes in multiple sclerosis. Unfortunately it
seems that with each study differing results were obtained. For example, Kotzin et aI.
(1991) found vpS.2 and6.1 to be over....epresented, while other studies demoostIa!ed that
the TCR usage was more beterogeneous (Martin et aI. 1992b; Meinl et aI., 1993).
Wucberpfenniget aI. (1990) sbowed that the VI3 chain used by the TCRdepended upon
the epitope recognized by the T lymphocyte line. For example, T lympbocyte lines
specific for MBP84-102 predominantly expressed Vln7 or 12. In COIltrast, V1317 was
rarely detected in T lymphocyte lines specific for MBP143·168. Oksenberg et aI. (1993)
fouod rearranged vpS.2 genes in all MS patients who were HLA.DRBloISOI,
OQAloOl02,DQB1°0602,DPBlo0401. However, these same paticuts frequently had
V136, 7. 8, and 12 as weU. It is nowtbought thattbeTCR-V gene usage bas limited
combinations in any given individual, but that between individuals there is mucb
heterogeneity (Wucberpfennig et at, 1990; Ben-Nun et aI., 1991; Meinl etal., 1993;
Vandevyer et at, 1995; Hafleret al., 1996). There is aIso evidence that TCR gene usage
is oot static during the course of multiple sclerosis. Whereas it bas been reported that the
TO. VI} gene ttanseripts are diverse in acute lesions. but more restricted in chronic
lesions (Wucherpfennig et aI., 1992). and that TCR usage becomes more diverse with the
duration of the disease (Utz et aI., 1994).
1.6-1.2 Row Specif".c is tile T ceO Receptor?
1be T cell receptor was considered for many decades to be extremely antigen
specific., however recent studies question whctbcr the TCR is as stringent as previously
believed. In 1995 Wucherpfcnnig and Sttominger were investigating molecular mimicry
in multiple sclerosis using various viral and bacterial peptides. They were successful in
identifying several pcptidcs capable of stimulating MBP-specific T lymphocytes, but
more imponantly they noticed that only one oftbcsc pcptidcs would have been identified
as a possible mimic by sequence homology with the sequence ofMBP. 1be other
pcptidcs shown to mimic MBP, but baving less scqueocc homology, had amino acid
substitutions which the T cell receptor "'tolcra1od". Thus the TCR was not as restricted as
others believed.
A mort: rccc:nt repon by Hemmer et ai (1998&) pointed out that the majority of
the interaction between a T lymphocyte and an antigen-presenting cell involves contact
between the T cell receptor and the MHC molecule and not with the antigenic peptide.
Garboczi ct al. (1996) found they could change key T cell receptor contaCt positions of
peptidcs without affecting the stability oftbc TCR·M}{C complex.. Experiments using
sets ofpcptides with single or multiple amino acid substitutions have shown that the T
cell receptor is able to recognize a number of modified pcptidcs (Wucherpfennig et ai,
1994; EvavoldetaL, 1995; Cbcnetai.• 1996; Vcrgclli etal., 1997). It was also shown
that T lymphocyte clones could be stimulated with pcptides which were DOt at all
homologous with the antigen used to establish the T lymphocyte clone (Hemmer et al.,
1998b). This led to the conclusion that although some ofthe amino acids in a peptide
sequence are more important than others. none of them is strictly required for T
lymphocyte recognition. Taken together. these observations indicate that the antigen
recognition by T lymphocytes is highly degenerate., that the TCR-MHC interaction
contnbutes more to the stimulation ofa T lymphocyte than the TCR-MHC-peptide
interaction. and 1haJ T cell recognition ofantigenic peptidcs is less restricted than
originallytbougbt.
1.6.1.3 Cytokiae Productioa by T Lymphocytes ia the CNS or Multiple Sclerosis
Patients
It has been suggested that the nwnber ofT lympbocyteS present in the CNS ofMS
patients is not large enough to inflict direct injwy on myelin (Richardson, 1994). Perbaps
the T lymphocytes are able to indirectly injure myelin sbeaths through the release of
various cytokincs. Activated T lymphocytes are capable of releasing numerous cytokines
Icnown to be involved in immune responses and in inflammation and posstbly in
demyelination (Ewing and Bernard, 1998).
The cytokines produced by CD4+ T lymphocytes are typically divided into the
pro-infla.mmatory and anti- inflammatory categories. The ~inflammatorycytokincs
include tumor necrosis factor (TNF). interleukin-l (ll..r 1). interleukin-2, and interferon-To
1besc: cytokines are produced by a subset ofCD4·T lymphocytes known as Tbl
lympbocytes. The anti-inflammatory cytOkines include tIanSforming growth factor-13
(TGF-13)' interferon-a (IFN-a). interferon-13 (IFN-13). interleukin4 (IlA). and
interleukin-lO (IL-IO). These cytolcines are produced by tbe Tt.2 subset ofCD4+ T
lymphocytes. It sbould be noted that the classification ofTbl and T~ derives from
murine models. It bas not been proven that this simplistic sub-typing is applicable to
humans. In fact. Navikas and Link (1996) argue that this system does not reflect the
complexity of the interaction ofcytokines seen in humans and should DOt be used when
discussing human immunology. In the foUowiDg discussion ofcytOlcines in multiple
sclerosis, cytokines will be tefmed to as pro-in£lamm.atory or anti-inflammatory.
It is believed that the pro-inflammatory cytOkiDes promore the immune responses
leading to the damage observed in multiple sclerosis, while the anri·infI.ammatory
cytokines act to down.regulate this effect (Navikas and Link. 1996). These two groups of
cytokines may even act simultaneously. Probably the most important, and certainly the
most studied, cytokines involved in the disease process are lFN-y, TNF-a, TNF-I3, and
TGF-13. The evidence pointing to a role for each oftbese cytokines is discussed below.
Although these cytokines may play important roles in the initiation and
perpetuation of multiple sclerosis, it must be remembered that the cytokine profile
observed in MS patients is DOt exclusive to this disease. Similar cytokine patterns an:
seen in other inflammatory, non-demyelinating, CNS diseases (Brosnan et al., 1995;
Navikas and Link, 1996).
A. ID.terfero T
IFN-y is present in active MS lesions (Traugott and Lebon, 1988a,b) but DOt in the
surrounding normal tissue (Voskuhl etal., 1993; Vartanian et aI., 1995). As weu. the
number of mononuclear ceOs isolated from blood and CSF which secrete IFN-y in
response to in vitro stimulation with myelin proteins or vinJ antigens is greater in MS
patients than in control subjects (Olsson et aL, 1990a; Sunet aI., 199Ia.,b; Link et ai,
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1992). Levels ofmononuelear cells expI"eSSing IFN-y messenger RNA (mRNA) are
increased in the blood aDd CSF ofMS patients. as compared with controls (Link et al.•
1994a,b). Link: et al. (l994a) also found that multiple sclerosis patients with moderate or
severe disability had high levels ofIFN-y c:xpressingcells. The production ofIFN-ybas
been shown to increase before: exacerbations of multiple sclerosis (Beck et al.. 1988).
Perhaps the most convincing piece ofevideoc:e suggesting a role for IFN-y in the
pathogenesis of multiple sclerosis is the demonstration that administration oflFN-y to
MS patients results in exacerbations ofthe disease: (paniteh et al., 1987). 00 the other
hand, administration ofIFN-a. or IFN-j3 reduces the rate and severity ofexacerbations
(The Interferon-j3 Multiple Sclerosis Group. 1993; Durelli et a1 .• 1994). This is an
important finding since IFN-j3 reduces lFN-y production and interferes with the induction
ofMHC class llexpression by IFN-y(Noronhaetal.• 1993; Durellietal., 1994).
The effects ofIFN·y include ~ationorMHCclassn molecules on
microglia., and therefore inctea.sed antigen ~tiOQ (Vass and La.ssmann. 1990;
Ewing and Bernard, 1998). activatioo of macropbages., and up-ceguIation ofadhesion
molecules which promotes T cell homing to the CNS (Dustin et al. 1986; Poberetal.
1986; Wong and Korovini-Zis, 1992; Navikas and Link, 1996). Thiscytolcinebasalso
been shown to induce apoptosis ofoligodendrocytes in \litro(Vananian et aL. 1995).
B. TDmor Necrosis Fador
Tumor necrosis faetor-a. and TNF-13 (lympbolOxin) are present in the plaques and
CSF of multiple sclerosis patients (Hofinan et al.• 1989; Selmaj et al. o 1991a.; Cannella
and Raine, 1995). The level ofTNF-a is typically low in normal CNS tissue, but is
increased in MS lesions (Cannella and Raine, 1995). Patients with multiple sclerosis also
have higher serum TNF-a receptOr levels than controls (Hanung et al., 1995a). As well,
there is an increase in the number ofboth mononuclear cells and MBP specific cells
expressing TNF-a mRNA in the peripheral blood and CSF ofMS patients (Navikas et
al.,1996).
Relationships have been detected between TNF and different stages ofMS. CSF
levels ofTNF-a are elevated in active MS as compared with stable MS or controls
(Sbariefand Hentges, 1991; Trotteretal., 1991; Sbariefaod Thompson, 1992). In the
chronic progressive patients these high levels were found to correlate with the degree of
disability and the rate of neurologic deficit. Increased levels ofTNF-a and TNF-f3
mRNA have been identified prior to clinical relapses (Rieckmann et aI., 1995). In active
multiple sclerosis TNF-cr. levels have been shown to correlate with BBS damage (Sharief
and Thompson, 1992).
The effects ofTNF-a are similar to those ofIFN-y, such as the up-regulation of
the expression ofadhesion molecules (pober et aI., 1986,1987; Wong and Korovini-Zis,
1992; Barten and Ruddle, 1994), and the induction ofMHC class II expression (Cannella
and Raine. 1989). In addition, TNF-a. may induce the production of ather cytokines
(Zoja et aI., 1991) and may act synergistically with lFN-y(Navikas and Link, 1996).
TNF-a. and TNF-f3 have also been shown to damage myelin and oligodendrocytes in vitro
(Brosnan et aI., 1988; Selmaj and Raine, 1988; Selmaj et aI.• 1991b; Zajiceket aI.,
1992a).
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c. Tnlltsfonli.ag Growtll Fador~
lncreased levels ofmooonuclearceUs eJqXeSSlng TGF-jl have beendetectcd in the
CSF and peripheral blood ofpatieDtS with MS (Link et aI., 1994a). Funher studies have
directly and indirectly demonstrated that TGF-jl is associated with remissions (Correale
et aI., 1995a). For example, TGF-jl mRNA levels have been shown to decline prior to
relapse (Rieckmannet al., 1995), while TGF-P like activity is detected more frcqw:mJy in
MS patients recovering from exacc:rbariODS than from stable patients (Beck: et al., 1991).
As weU, MS patients with no or slight disability had high levels ofTGF-~mRNA
expressing ceUs (Link et al., 1994a).
1.6.2 The Role of the B Lymphocyte
There is no doubt that T lymphocytes play an integral role in the development and
progression of multiple sclerosis. However, there DOW seems to be consensus !bat
multiple sclerosis is not solely the result ofthe actions ofautoreactive T lymphocytes. At
a recem com:erence it was staled that, ft ••• the pathogenesis of multiple sclerosis lesions is
more complex. and cannot be explained on the basis of a T lymphocyte mediated
response alone. The mechanisms of demyelination may be diverse in different patients"
(Lassmannetal,I998). Tbereare a number of immune anomalies in multiple sclerosis
patiems which suggest that B lymphocytes and their immunoglobulins are important
mediators in the pathogenesis ofMS. Some oftbese abnormalities have already been
mentioned: the presence ofoligoclocal [gO in CSF (Link and Tibbling, 1977;
Tourtellotte, 1985), the elevated synthesis rate ofIgG in CSF (Mehta et aI., 1982;
Gonsette et aI., 1984; Tourtellotte. 1985), and the presence ofbigb numbers ofB
lymphocytes in chronic MS lesions (Prineas and Wright. 1978; Bnack: et al, 1995).
Others include: high COoce:ntraboos ofoligoclonal IgG in the brain ofMS patients
(Mattson et al. 1980; Owens et al, 1998), oligocloaal bands in the serum ofat least 50
percent ofMS patients (Zeman et al, 1996a), a large increase in the proportion ofIgG
producing cells in the CSF ofMS patients compared with COQtrols (Link: et aI., 1989) and
high levels oflgG heavy chain mRNA in MS plaques as compared with normal white
matter (Owens et al, 1998). The B lymphocyte response in acute multiple sclerosis is
limited and restricted. suggesting a specific local immune response, that is intrathecal
synthesis of immunoglobulins (Owens et al., 1998).
In general, MS patients who are negative for the presence ofoligoclonal bands
tend 10 have less disability than those patients who do possess these bands (Stendahl-
Bodin and Link, 1980; Zeman et a1., 1996b). It was also noted in a small study that
serum anbbodies reactive with brain tissue were not detected in most oftbe patients with
relapsingfremitting multiple sclerosis. Oftbe patients which did test positive for such
antibodies, the majority had a chronic progressive form. ofMS (Henneberg etal, 1991).
1De identification ofautoantigens andfor antigens for which the majority of the
antibodies are specific bas been the topic ofresearch for many yean. To date the
mystery has not been resolved. but a number ofa.otigens have been fOtmd to react with
some of the antibodies.
Several studies have identified antibodies in the CSF ofMS patients which are
shown to react with a variety of viral antigens. These include measles, mumps, rubeUa.,
herpes simplex type I, varicella·zoster, vaccinia., Epstein·Barr virus, cytomegalovirus,
and adenovirus (Adams and Imagawa., 1962; Adams et at, 1970; Vandal et at, 1980;
Brayetal., 1983; Baig etal, 1989; R.ederand Amason, 1985). Tbeseanti-vinJ.
antibodies have IIOt been found to acem.mt for the oligoclooal bands cbaIacteristic of
multiple sclc:ro:sis (Vartdal et d. 1980).
Other SlUdies have discovered antibodies and/or annbody secreting cells specific
for myelin compooems in the CSF ofMS patients. These myelin components include
MBP(Panitchetal..,1980; GomyetaL.1983;WajgtandGomy,1983;Cruzetal., 1987;
Link et aL, 1989,1990; Baigetal., 1991; Gerritse et al., 1994),MAG(Linketal.• 1989;
MoUeretaL. 1989; Wajgtand Gomy, 1983; Baigetal., 1991), PLP (Sunet al., 1991a),
and MOO (Sun et al., 1991b). These antibody responses were nOt found to be specific
for MS as they were also detected in control subjects and patients with other neurologic
diseases. In geo.eral, the number ofantlOody secreting cells was higher in MS patients
than in CODttOls or patients with other neurologic diseases. The annbody producing
responses appeared 10 be sequestered in the CNS (Olsson, 1990b) as cells secreting
antlbodies against MAG and MBP v.tere rarely detected in peripheral blood (Link: et at,
1989; Baig etaL. 1991). A study by Gerritse et at. (1994) fOUDd Bntl"body secreting cells
specific for MBP to be present in both plaques and normal CNS tissue of MS patients,
but absent from the CNS tissues ofpatic:nts with other neurologic diseases. As with the
anti-viIaI antibodies, the myelin reactive annbodies do not represent: a significant amount
ofthe oligoclooal bands in the CSF ofMS patients (Kaiser et al., 1997). This is
reinforced by the finding that the absorptioo. ofCSF from multiple sclerosis patients with
myelin does not remove oligocloDal bands from the CSF samples (Nobile-Orazio et at,
1987}
Similarly, Walsh and Murray(l998) dem.ODStIated the presence ofannbodics to
i, 3'-eyclic nucleotide 3'-pbospbodiesterase in the serum of74 percent ofMS patients
tested. These anobodics were immunoglobulin M (IgM) and were also present in the
CSF of patients. They also found CNP to be a pan of immune complexes in MS brain.
CNP is a membrane associated protein oftbe oligodendrocyte (Sprinkle., 1989), but is
also expressed by lymphocytes (Bemieret at, 1987) and in retina (Giulian and Moore,
1980). The immune response to CNP may elCplain the retinal manifestations that often
are present in patients with multiple sclerosis
Circulating immune complexes in the CSF and serum orMS patients have been
shown to contain MBP (Dasgupta et aI., 1983; Coyle, 1985). Dissociation ofthese
complexes resulted in an increase in anti-MBP specific annbodies (Wanen and Can.,
1987). The level of bound versus free anti-MBP annbodies diffeB depending upon the
phase ofMS investigated. 10 the chronic progressive form the majority ofannbodies
appear to be bound, whereas during and after relapses most ofthe anobodies seem to be
free (Warren and Catz, 1987.1989).
1bere are a number of ways in which the annbody secreting cells or the antlbodies
they produce could contribute to the pathogenesis ofmultiple sclerosis:
1. The annbody-secreting cells express MIle class IT and therefore may act as
antigen-presenting cells to activated T 1)'lDpbocytes (Gerritse et aI., 1994;
Sobel. 1995).
29
2. The antibodies may participate in anD.Ood:y-depeodcnt cell mediated
cytotoxicity (Baig et aI., 1991; Gerritse et al.. 1994). Satohet al.. (1991)
showed that in vitro cytOlysis ofbovine oLigodendrocytes is due to the action
ofhumaD killer cells in the preseoce ofanti-oligodendrocyte antiserum.
3. The antibodies may be important in complemeut.-mediated lysis. IgG and
complement can be observed attached to oLigodeDdrocytcs in thc CNS ofMS
patients (Prineas and Graham., 1981; Yamadaet al., 1990a), and are deposited
in areas ofactive demyelination (Storch et aI., 1998). Activated complemcnt
and terminal complement complexes have been identified in the CNS tissue
and CSF of patients with MS (Lumsden, 1971; .Morgan et al., 1984; Sanders et
al, 1986; Compston et al., 1987,1989). As weU, in vitro studies have shown
that hwnan oligodendrocytes are not susceptible to complement attack in the
absence of antibody (Zajicek: et al.., 1995), and that the degradation ofMBP
and PLP mRNA in cultured oligodendrocytes can be c:nhanoed by the addition
ofactivated complemeot complexes (ShiJUi etal, 1993). C9neo antigen. a
marker of activated lytic complement complexes, is prcscDl only in active
areas ofdemyetination (Storche:t al., 1998) and the cooc:entratioo ofC9 is
decreased in the CSF of multiple sclerosis patients compared with controls
(Morganet aI., 1984). Macrophages and vessel walls in MS plaques
frequently possess particles coated with C3d, C9, JgG and JgM., but these
particles are not observable in normal CNS tissue (Gay and Esiri, 1991). In
addition. macropbages in MS lesions contain degrada..tion products with
myelin antigcos., immuooglobulin, and C9neo antigen (Storch etal. 1998).
Ga.y and Esiri (1991) statetbat,. "When complement and immunoglobulin are
detected at the same location in tissues....tbis provides evidence that antIbody
has reacted with antigen and that complement has been fixed by the classical
pathway....
4. The binding ofantibodies to the myelin membrane may activate myelin
proteases (Kerlero de Rosbo andBemard, 1989). A study by these two
experimenters showed MBP degradation to be greater ifmyelin was incubated
with antibodies from MS patients than ifmyelin was incubated without such
antibodies or with control annbodies. They believed the degradation was due
to the action ofa oeutral protease. It has been shown that MAG and MBP are
susceptl"ble to neutral protease degradation (Sato et at.• 1982). A similar. but
more specific study by Menon et aI. (1997) identified anti-MOO monoclonal
antibodies as the amibodies responsible for MBP degradation. This
degradation was not observed when anti-MAG or anti-MBP antibodies were
odded
5. The production ofTNF-u by B lympboc}'tCS may aid in damaging myelin
andIortbe otigodendroc:ytes (Hartunget al. 1995b).
Regardless of the probable roles for these anu"bodies" it remains a possibility that
the anu"bodies are merely the products ofan immune response elicited by the breakdown
ofmyelin (Baig et aI.• 1991). In which case, the antibodies are not important to the
pathogenesis of multiple sclerosis. It is also poss1ole that the annbodies important in the
pathogenesis ofMS are bound to their antigen(s). lftbis is so, then the targets ofthese
antibodies will not be identified with conventional stn1egies (Cash et al., 1992; Olssoll,
1994). Or perhaps the anbbod1es are specific for an infectious agent orCNS component
which has not yet been identified (Martin c:t al, 1992a).
1.6.3 The Role of Maeropbges
According to Richardson (1994), "Macropbages ace Cae mate likely candidates as
ceUular agents of demyelination (than T lymphocytes)", Although macropbages ace
present in all MS lesions, they an:: most numerous in active lesions where they are
generally found to contain myelin. degradation products giving them a "foamy"
appearance (Adams, 1983; Esiri and Reading, 1987; Esiri and Morris. 1991; Ricbardsoll,
1994; Bruck et aI., 1994,1995,1996). Macrophages have been found to OlIblumbe:r T
lymphocytes several fold in acute and cbronic lesions (Btuek: et al, 1994; Lassm.ann et aL,
1994).
Macropbages may cootnbute to demyelination in a number of ways:
I. Macropbages have been observed actively phagocytosing myelin (Raine et aL,
1981) and, as mentioned above, are frequently found to contain byproducts of
myelin brea.kdo'ND. Wbetherthis phagocytosis ofmyetin is active removal of
myelin or scavenging ofthe debris resulting from myelin degradation is still
under debate (Richardson, 1994). However, PriDeas et al (1984) did report
macrophages in active MS plaques seemingly stripping and phagocytosing
MAG·positive fragments from intact myelin sheaths.
2. Macropbages may release cytokines. such as TNF-a, which are capable of
damaging myelin and oligodendrocytes (Se1maj and IWne., 1 988) and up-
regulate the expression of adhesion molecules (Pober et al.. 1.:.987; Bancn and
Ruddle. 1994).
3. These cells may participate in compIement-medialed lysis. ~vated
macrophages produce complement (Levi-$trauss and Mallat, 1987) and
receptors for components of complement, such as C3b (Gay and Esiri, 1991).
Macrophages in active lesions not only contain myelin degraaiation products.
but also C9neo antigen and immunoglobulin (Storch et aL. 1998), The
addition ofantlbodies against complement receptor type 3 (c:R3) or cobra
venom factor to cultures was shown to inhibit phagocytosis 0:;[ myelin by
macropbages (Bruck and Friede. 1990). An interesting expeniment by De
Jong and Smith (1997) investigated the role ofcomplement io med.iaring
demyelination. 1bey found that complement was required fo:::r maximal
myelin pbagocytosis by cultured macrophages. However. ode myelin was
previously sonicated. complement was DO longer needed. Thiis SlIggests that
complement is oeoessary to fragment myelin, making it easie. for the
macropbages to phagocytose.
4. Macrophages inaetivelydemyelinating lesions express MHC class II
molecules (Esiri and Reading. 1987; 50 et al. o 1994a) which suggests that
these cells may act as antigen-presc:nting cells to CD4+ T lymlPhocytes. In
addition, macrophages in MS lesions have also been shown teD express C().
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stimulatory molecules,. such as B7 (Williams et al. 1994b; De Simooc et at,
1995; Windbagen et aI.• 1995a), also implying an antigeo-presentiDg role for
these cells. It is interesting to note that B7 molecules are not normally
expressed in CNS tissue (Williams et aI.• 1994a).
S. These cells may participate in antibody-dependent cell mediated cytotoxicity.
Scolding and Compston (1991) found that macrophages were able to lyse
oligodendrocytes in vim) in the presence ofanti-myd.in ann"bodies.
6. Macrophages have: been shown to phagocytose myelin via receptor mediated
phagocytosis. Briefly, this refers to the phagocytosis of myelin being
mediated by c1athrin-coated pits present on the surface of "foamy"
macrophages with IgG acting as the ligand between the myelin debris and the
pits (Prineas and Connell. 1978; Prineas., 1985; Raine and Scbeinberg. 1988).
7. Macrophages may damage myclin sheaths through the release of various
mediators, including proteolytic enzymes. nitric oxide. and oxygen radicals
(MacMicking et al. 1992; McrrilI et aL. 1993; Brosoanet aI., 1994; Cross et
aI.• 1994). Oxygen radicals and nitric oxide have: been detected in the center
and edge ofacute MS lesions(Bo et aI., 1994b}.
1.6.4 The Role of Microglia
Although micrnglia are a pan. ofthe central. nervous system. they ace
essc:ntiallytbc indigenous macropbagesofthe CNS. Typically. these cells possess a
dendritic mCKPhology, but upon activation they take on the morphology of a phagocytic
macrophage (Bo et at, 1994a; Ulvestadet al, 1994a). The potential roles for microglia
in demyelination resemble those of macropbages;
1. Microglia may act as antigen-presenting cells for CD4+T lymphocytes. The
low levels ofMHC class 11 molecules constitutively expressed by these: cells
an: up-regulated in active MS lesions due to the release ofIFN-y(Vass and
Lassmann, 1990; Williams et at., J993.1994b; Bo et at., 1994a; Ulvcstad et
at., 1994a). These cells also express B? co-stim.u1atory molecules (Williams
et at.• 1993, 1mb; De Simone et aI., 1995), molecules which are not typical
ofCNS tissue. Expression orB? molecules can be up-regulated by
stimulation with IFN-r (Williams et al.• 1994a,b; De Simone et at. 1995).
This finding is especially important when it is remembered that activated T
lymphocytes produce IFN-r. The administration or monoclonal anubody
specific for this co-stimulatolj' molecule inhibits antigen presentation by
microglia in virro (Williamset at, 1994b).
2. Activated microglia poduce cytokines, such as TNF- a (Hartung et at.
1995b), which are capable ofdamaging myelin and oligodendrocytes.
3. Microglia express receptors for the umlumoglobulin constant region
suggesting a role in anubody-dependent cell mediated cytotoxicity. These
receptors are more frequent in MS plaques than in the surrounding ""nonna.l"
tissue{U1vestadetal.• I994a,b,c).
4. Microglia atso express complement receptOrs and some components of
complement (Levi-Stnluss and Mallat, 1987; mvestad et al., 1994a),
J5
indicative ofa role in complement-mediated lysis. It bas been demonstrated
that activated tal microglia are able to phagocytose MBP in the presence of
complement (Zajicek: et aL, (9913).
S. These cells express the adhesion molecules. ICAM-I, LFA-I. and LFA-3,
(Williams etal. 1993; De Simone et al.• 1995).
6. Microglia also produce nitric oxide and oxygen radicals (Griot et aI.• 1989;
Merrill et al.• 1993; Brosnan et al, 1994).
1.7 Hypotbeses of DemyeliaatioD ia MaJtipie Sclerosis
TIle cause of multiple sclerosis is still unknown. Many investigators believe MS
to be an autoimmune disease, while others point to a viral etiology. Several hypotheses
have been put forward to explain the inability to identify a specific antigen or infectious
agent responsible for the initiation of MS. It is possible that multiple sclerosis is not
actually the result of a single infectious agent or autoantigen, but instead represents a
common immunopathologic path resulting from a multitude ofantigens (Kennedy and
Steiner, 1994; Sobel. 1995). This may explain the heterogeneity with respect to clinical
symptoms, pathology. and response to immunomodulatory treatments observed between
patients with multiple sclerosis (Lassmann and Vass, I99S; Bieganowska et al, 1997;
Lassmann et ai. 1998). In contrast. it could be a common endpoint for a varielyof
immunological mechanisms (Lucchinetti et ai, 1996). It is also possible that the target
antigen(s) in multiple sclerosis is an as yet unknown protein. or infectious agent (Bansil
etal.• I995).
1.7.1 Autoillua.uDe Hypothesis
The majority of investigators believe tba1 multiple sclerosis is an autoimmune
disease. Perhaps the suongest "evidence" supporting such a conclusion is first. that EAE
can be iDduced in suscepa'ble animals through lmmunizatioo with compooents of nervous
tissue or even nervous tissue bomogenateS and second, that MS is associated with over-
representation ofm..A-DRl. Some investigators suggest that the failure to identify an
infectious agent responsible for multiple sclerosis is also evidence ofan autoimmune
pathology.
It has already been established that only activated T lymphocytes are able to gain
access to the CNS. Oftbe activated T lymphocytes which enter the CNS only those
specific for CNS antigens remain. As myelin components are sequestered in the CNS,
these T lymphocyteS must be activated in the periphery. Putting the requirements for
activation and CNS specificity together with the auloimmunity theory leads to a number
of probable mechanisms by which activation ofT lymphocytes can lead to the
inflammation and demyelination cbaracteristic of multiple sclerosis. 1bese include
molecular mimicry, activation by superantigens, and T ceWT cell activation.
1.7.1.1 Molecular Mimicry
Molecular mimicry is best explained as the sharing ofan epitope(s) between a
virus or bacterium which is capeble ofinduciDg an immune response against the host's
seIfproteins (Wucherpfennig et aI., 1991). Therefote. an immune response may
eliminate the immUDOgen which initiated the response but may also lead to cross-reaction
with ODC or more self-antigens which share an epitopc:(s) with the immunogen (von
Herratb. aDd 01dstone, 1996). In this way, an immune response directed at a viral or
bacterial antigen can inadvertently activate autoreactive cells. This may be the case in
MS. Thus, the T lymphocyte specific for a CNS constituent would be "accidentally"
activated by a viral or bacterial antigen with homology for the autoantigen, would cross
the BBB, become reactivated by its autoantigen., and the inflammal:ory process would
There is evidence of molecular mimicry in multiple sclerosis. Wucberpfeonig and
Strominger(I99S) found that MBP-specific T lymphocyte clones isolated. from MS
pabeIllS could also be stimulated with seven viral peptides and a bacterial peptide,
including peptides from Epstein-Barr virus, influenza, adenovirus, and Pseudomonas
aeruginosa. Atkins et al. (1990) found sequence homologies between rubella and
measles and PLP. These results led both groups to conclude that it is unlikely that MS is
the result ofautoimmunity initialed by a single virus. Banki et at (1994) demonstrated
cross-reactive epitopes between recombinant human transaldolase and human T cell
Iympbotropic virus type I (EITLV-I). A1vord(198S) and Jahnke et al (1985) identified
sequence bomologies between a number of viruses, Epstein-Barr virus, influenza.
adenoviIus, and measles, and MBP. Talbot et aL (1996) demonstzatcd that T lymphocyte
lines isolated from MS patients were cross-reactive for MBP and coronavirus..
Lodge et al. (1996) suggested that molecular mim.icry would explain the induction
ofMS ifthe lmmUIle respoose were directed against a viral or bacterial antigen which
mim.ics an epitopc: of myelin whicb is normally hidden, that is a cryptic epitope.
However. with the fiDdiIlg that the T cell receptor is able to recognize peptides
which bave limited ifany sequence homology (Hemmer ct ai. 1998b). the number of
potential molecular mimics increases dramatically.
1.7.1.2 Superaatigcms
It bas also been suggested that autoimmunity may result from the activation of
autoreactive T Iympbocytes by supcrantigens (Brocke ct ai. 1994.1996). Superantigens
are proteins produced by microorganisms which are capable of "linking'" the class 1I
MHC molecule on the antigen presenting cell with the V13 portion ofthc T cell receptor.
This "linkage" is indepcodcntofthe specificity of the T lymphocyte or the MHC class II
molecule as the superantigen does not bind to the pcptide·binding groove of the MHC
molecule (Scherer ct aI.• 1993). The binding ofa supcrantigen is restricted only by the
VJ} expressed by the T cell receptor. For example. staphylococcal enterotoxin A can
activateTlymphocytes bearingTcell receptors with the V133.12, 14. IS. 17. or 20
chains. lfwe assume that an individual cxpres.sc:s V13I-60. and thateacb oftbese V13
gene segments is equally expressed. then 1 out ofcvery 60 T lymphocytes expn::sse:s a
given Vp chain in its T cell receptor. Therefore. supcrantigens are capable ofactivating a
large number ofap T lymphocytes man individual (Schercret al.. 1993). In this
situation, the superantigen--activBted T lymphocyte would cross the BBB. be reactivated
by its corresponding autoantigcn and induce inflammation.
"
Hermans ct aI. (1997) found tbaJ: MBP-specific T Iympbocyte clones isolated
from MS patients produced IFN-y after stimulation with staphylococcal enterotoxin B (a
superantigen) and that the amouDtofIFN-y produced was comparable with the amount
produced after stimulation with MBP. A study by Zhang et aL (1995) found MBP-
reactive T lymphocyte clooes capable offeSlKX,lding to staphylococcal enterotoxins A and
B and toxic shock syndrome toxin-I.
1.7.1.3 Epitope Spreadina:
Epitope spreading is an interesting phenomenon that may explain why MS
patients have T and B lymphocytes specific for so many CNS antigens and why patients
have relapses. Simply defined, epitope spreading is the ..... development of immune
responses to endogenous epitopes secondary to the release of self-antigens during a
chronic autoimmune or inflammatory response" (Vanderlugt and Miller. 1996). Epitope
spreading in MS could be the result ofmyelin degradation. With the subsequent release
of myelin components. cryptic epitopes are "uncovered"'. Therefore. autoreactive T
lympbocytes specific for cryptic myelin epitopes are DOW able to recognize their specific
antigens (Lchmann etal. 1992; VandedugtandMiller, 1996). Epitopespreadingba.s
been dcm.onstIatod in MS by the finding that T lymphocytes isolated from MS patients
are specific for multiple MBP or PLP epitopes (Olsson et al. 1992; Cortea1e et at.
1995b).
It must be DOted that epitope spreading is not cross-reactivity. The autoreactive T
lymphocytes are activated by the self-antigens released during the disease process,
regardless of the antigen which gave rise to the initial immune response.
1.7.1.4 T CelVT CeU Activation
There is some evidence foc T celVT ceU activation. Activated T lymphocytes can
activate nearby, resting T lymphocytes via adhesion molecules (Brod et aI., 1990). In this
case, the aetiva1cd T lymphocyte could activate a resting auroceactive T lymphocyte.
This theory does DOt place any restrictions on the viral or bacterial antigens activating the
first T lymphocyte. There are DO requirements that these antigens share any sequence
homology with the autoantigens for which the autoreactive T lymphocyte is specific
(Wucberpfennigetal,1991)
1.7.2 Viral Hypothesis
There are researcbers who believe that multiple sclerosis is a viral disease and that
the infIam.matory response observed in the disease is pw-ely an anti-viral response
(Wucberpfennig et aI., 1991). To date there is no conclusive evidence whicb links a
specific virus or viruses to multiple sclerosis (Luccbinetti and Rodriguez, 1997). but there
is indirect evidence which implicates environmental factors in the acquisition ofthe
disease (Cook et aI.• 1996).
I. Intrathecal synthesis ofaotibodies against viral antigens is detectable is
approximately 80 percent of patients with multiple sclerosis (SchadJicb et al.,
1990). As ,","CII, a number of studies have shown that titers ofmeasles
annbodies in both the serum and CSF are higher in MS patients than in normal
controls (Adams and Imagawa, 1962; Scbadlich et aI., 1987). However, these
increased annbody titers do not represent the major annbody response in
multiple sclerosis (Owens et at., 1997).
2. The preseocc of otigoclonal bands in CSF is not exclusive to MS patients and
similar bands have been observed in CNS infections. sucb as syphilis and
subacute sclerosing paneocc:pbaliti (Antel and Amason. 1991; McFarland
and McFarlin. 1995). In most of these diseases the oligoclonal bands are
specific for the virus responstble for disease induction (Vandvik ct al.. 1976).
For example. ill subacute sclerosing pane:ocepbalitis the majority of the
oligoclooal bands llIC annbodies agaiost measles virus. Gilden ct at. (1996)
stated that the presence ofoligoclooal bands in CSF is found almost
exclusively in infectious disorders ofthe CNS.
3. The majority ofmultiple sclerosis patients are positive for Epstein-Barr virus
annbodies (Dalgleish, 1991).
4. There are DNA and RNA viruses capable of causing spontaneous
demyelination (Cook et al.. 1996).
5. There appealS to be a world-wide pattern ofMS prevalence, with anortb to
south gradient in North America and Europe. a low pr-eva.Ienoe in Asia,
Africa, and South America, and. a south to nonh gradient in Australia
(Kmttke. 1993).
Many viruses have and are being considered as candidates for multiple sclerosis
induction based on their ability 10 explain the worldwide dismbution ofMS. their ability
to induce demyelination in humans or animals. or the fact that antibodies against. the virus
are elevated in the serum and CSF ofMS patients, their viral genome has been identified
in MS brain, or they have been isolated from MS tissue (Burks et a1.• 1980; Murray et at.•
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1992; Cook et al 1995,1996). These viroses include: measles, b1wnan coronavirus,
Epstein-Barr virus, several retroViruses., aDd human berpe:s vinas type 6. The evidence
implicating these viruses in multiple sclerosis is "sketchy"' to say the least.
There are a variety of ways in which viral infectionsco~ give rise to the damage
to myelin sbea1hs observed in multiple sclerosis.
1. The bystaDdercffcet. The damage incwTed. bytbe CNS may result from an
immune system. attack. against a virus residing in the CNS, such as measles or
rabics(Johnsonetal., 1984; Steinman and ConJon, D997).
2. During an anti-viral response, immune celis may gain access to the CNS, and
encounter CNS antigens. As these antigens arc nomnally sequestered, the
immune cells would recognize them as foreign and attack. them (Steinman and
Conlon, 1997).
3. Viral infections may activate tIanscription in a hypnmll1able area ofthe
genome, such as an Alu repeat.. This may result in tIbe expre:s.sion of
neoantigcns which the immune system would treat a:s foreign and attack
(panning and Smiley, 1995; Arcbclos et aL, 1998).
4. Systemic viral infections often cause cytOkinc reteasoe by immune cells.. These
cytok:ines may induce changes in the endothelial cells oftbe CNS, such as the
~regulationof adhesion molecules, which could lID. tum effect iofl.ammation
and demyelination oftbe CNS (Allen and Brankin, L993; Cristallo etal.,
1997).
5. viruses capable ofcausing latent or persistent infections may lead to chronic
stimulation of autoreactive T Iympbocytcs via epitope spreading (Kennedy
and Steiner, 1994; WucbeJpfennig and Strominger. 1995; Milleret at, 1997).
1.8 h1ayeliaation ofM.ltipie Sclerosis Plaques
For many years myelin repair or remyclination was DOt thought to occur in
multiple sclerosis or was believed to be so negligfble that it was unimportant. This
opinion bas changed Numerous studies have reported the presence of shadow plaques,
thinly myelinated nerve fibers with short internodes at the edge of inactive plaques
(pener and Gregoire, 1965; Suzulci et aI., 1969; Gledhill and McDonald, 1911;
Lassmann, 1983; Prineas et aI., 1993a; Rodriguez et al., 1993; Bruck et aI., 1994;
Rodriguez and Scheithauer. 1994). These observations are DOW known to represent
remyelination.
Remyelination is now believed to be a common occurrence in multiple sclerosis
lesions (Storch and I...assmann. 1991). Evidence ofmyelin repair is found in both chronic
and acute MS lesions (Raine, 1994.1997b), bm. is typically observed at the edge of
chronic (inactive) plaques (Raine 1997b; Lassmann et aI., 1998). Remyelination can
occur simultaneously with demyelination (Lassmann, 1983; Ghatak: etaL. 1989; PriDeas
et al., 1993a; Rodriguez and Scbeithauer, 1994), and in the presence ofinflammation
(Rodriguez and Scheithauer. 1994; Hunter and Rodriguez. 1995). Usually remyelination
repairs only a small area ofa plaque, but areas ofextensive myelin repair have been seen
(La.ssmann. 1983; Princas et al., 1993a; Rodriguez and Scheithauer, 1994; Raine, 1991b).
It bas been suggested that entire plaques may be repaired (Lassmann et aL. 1998). The
myelin sheath produced by remyelination is chemically and st:ruetunl1.ly norma1, but is
always shorter and thinner than that found in nonna! CNS tissue (Ludwin. 1996.1997).
]be extent of remyelination varies between multiple sclerosis patients. In
general, spontaneous rem.yelination occurs in MS plaques which have a high density of
oligodendrocyteS (Bruck et a1. 1994; Ozawa et a1. 1994). and is more effective and
complete in MS lesions in the early stages ofdisease (lassmann. 1983; Prineas. 1985;
Raine and Wu, 1993). Remyelinated plaques are oot protected against further
demyelination (Prineas et aI.• 1993a; Raine 1997b) andarejust as suscepnble to
demyelination as any nonnaI myelinated areas ofthe CNS.
Very little is known about what trigger.; remyelination to begin or to terminate.
why some lesions remyelinale, while others do DOt, or why remyelination in MS lesions
is typically incomplete. It is Icnown that myelin repair requires proliferation ofan
adequate number of oligodendrocytes which have access to the axon(s) (Ludwin,
1996.1997; Raine, 1997b). II bas been suggested. that demyelinated lesions remyelinale
unless they are interrupted by recurrent demyelination (PriDea.s et al, 1993a) OT are
somehow prevented from doing so by the presence ofcertain immune factors in the
demyelinated lesion (Ludwin, 1980; Rodriguez and Lindsley, 1992). Prineas et a1
(l993b) suggested that permanent myelin loss may be partly due to recWTCD.t
demyelination in a previously remyelinated area.. Another possibility is that there are
"remyelination promoting factors" present in some MS lesions. Therefore, lesions
devoid of such factors would not undergo remyelinatioQ (Rodriguez and Lindsley. 1992).
"
For example, insulin·likc growth factor bas been shown to enhance oligodendrocyte
regenen.tion in culture and increase remye1ination in an animal model ofMS (Yao et al....
1995). A simpler explanation is that there are DOt enough oligodendnx:ytes present in the
plaque to cany out the amount ofmyelin repair needed (Ludwin, 1996,1997) or that the
remyelination process is eventually overwhelmed and demyelination again ensues (Raine,
1994).
There is still much debate as to whether the myelin repair observed in multiple
sclerosis is the work ofmature oligodendrocytes or progenitor cells (Ludwin. 1996,1997;
Lassmann et aL. 1997). Coyle (1996) suggested that both mature oligodeodrocyteS and
progenitor cells may be respoDSlble for remyelination.
Remyelinarioo in young patients or patients with acute or early MS may be rapid
and extensive (perhaps even repairing the entire lesion) and may explain the quick
recovery from relapses often obsetved in such patients (Lassmann, 1983; Lassmann et a1.,
1998). Remyelination may also playa role in remissions observed in relapsing/remitting
patients regardless of age or length of illness.
1.9 Tna..eat ofMlIlItip5e Sclerosis
To date there is no ewe for multiple sclerosis or even a treatment tbatcan
completely stop progression ofthe disease. There are therapies that can treat symptoms,
reduce exacerbation rates., and/or halt the formation of new lesions. The most common
treatments are the administration of steroids. interferons, immunosuppressives.. or
immunomodulating agents. There are also a few treatments which may be effective but
are not yet widely used. these include tolernnce induction, the administtation ofchimeric
monoclonal anbDodies. and T lymphocyte vaccination. In genera1. the agents used in the
treatment ofmultiple sclerosis were derived from the EAE models. A major problem in
the clinical testing oftherapeutic agents in multiple sclerosis is the unpredictable nature
oCthe disease. It is often difficult to conclude if improvements are due to the action of
the agent being tested or iftbey are part ofthe natural course of the disease.
1.9.1 Steroids
Panitcb (1996) refers to steroids., such as methylprednisolone. and agents whicb
induce steroid production. such as adreoocorticotropic hormone (ACIH). as the
mainstay of MS therapy for the past 20 years.. These drugs do not have an
immunomoduIating effect but rather act by improving the conduction through a
demyelinated nerve. and/or reduciD8 the edema and lDflam.marion in the MS lesion (Antel
and Amason, 1991). Steroids and ACTII are able to reduce the duration of
exacerbations. but seem to have no effect on the degree of recovery (MiUer et at. 1961;
Rose et at.• i970; Ourelli et at., 1986; Milligan et ai, 1987).
1.9.2 Globallmmaaosappressioa
Drugs which cause non-specific immunosuppression, including azathioprine and
mctbotIexate. have been used in the treatmeIl10fmuJtiple sclerosis for a number ofyears.
The effectiveness ofthese drugs is still controversial The geoeral immune suppression
which results from taking these drugs may have serious consequences. Studies of
azathioprine have shown conflicting results with regard to the benefits of taking the drug.
A review of the most controlled clinical trials concluded that patients given azathioprine
have a greater cbance of being relapse free, than patients who are not receiving the dnJg
(YudkiD et al.• 1991). Metho~xate reduces the exac:erbation rates in some
relapsinglremittin& MS patients (Currier et al. 1993) and is able ro slow the rate of
disease progression in some cbronic progressive patients (Goodkin et al. 1995).
1.903 bterferou
Several recombinanr. iDterferoos have been used in clinical trials. IFN alpba-2a
was shown to reduce the clinical exacerbation rate and the developmcot ofnew lesions.
It was also able to prevent the existing lesions from becoming larger (Durelli et aI.•
1994). Even though lFN aIpha-2a is effective in the treatment of multiple sclerosis. the
majority ofrcsearch has focused on the IFN beta-Ia and -Ib as therapeutic agents. IFN
beta-1a reduces the exacerbation rate and the number and volume ofMS lesions in
relapsinglremittingmultiple sclerosis (Jacobs. et at.• 1995.1996; Pozzilli et aL. 1996). A
more recent study. indicates that treatment with IFN beta·1a not only reduces
exacerbations. but can also delay the progression ofthc disease (pRISMS Study GroUP.
1998). Similarly. IFN beta-lb reduces the rate and seve:rityofrelapses and the number of
active lesions inrelapsinWrem.itting MS (Pary and Li. 1993). In addition,1FN beta-Ib
has recently been shown to be effective in delaying the sustained neurological
deterioration observed in sccondaIy progressive multiple sclerosis patients (European
Study Group on Interferon ~lb in Secondary Progressive MS. 1998).
These clinical trials are evidence that IFN beta can alter lhc course ofmultiple
sclerosis posSlbly through the down-regulation of~inf1ammatorycytokines aodIorthe
up-reguia1ion ofanti-inflammatory cytokines (Amason et aI.• 1997).
1.9.4 Copolymer-l
Copolymer-l (Cop.l) is a synthetic polypeptide: randomly composed oftyrosine,
glutamate. alanine. and lysine. It was produced as a mimic oftbe antigenic properties of
MBP. but was later found to be able to down-regulate EAE and to i.nhJ.bit MBP- and
MOG-specific T lymphocyte lines isolated from mice and humans (McFarland and
McFarlin, 1995; Polman and Hartung, 1995; Ben-Nunet al, 1996). Administration of
Cop-l to reIapsinWremitting multiple sclerosis patients caused a reduction in relapses and
improved disability (Bornstein et al.. 1987; Johnson et al. 1995). Copolymer I is not as
effective in the treattnent of chronic progressive MS patients (Bomstein et aI., 1991).
Copolymer 1 is believed to compete with MBP and MOO for binding to MHC
class IT molecules and can even displace MBP that is a1Ieady bound to MHC class IT
molecules (feitelbalDD et al.• 1988; Racke eta!.. 1992a; Fridkis-Hareli etal.• 1994; Ben-
Nun et aI.• 1996). It bas also been demonstrated that moooclooal amibodies have cross
reactivity between myelin basic protein and. Cop-I (feitelbaum. et aI., 1991).
1.9.5 ToIeraDee IDdaction
A few stUdies have been undertak:en to analyze the effects oftbe oral
administration ofmyelin. Weiner et al. (1993) fotmd that bovine myelin given cmillyto
relapsioglremitting MS patients reduced relapses in almost 50 penxnt oftbe subjects and
reduced the frequency ofMBP-speci6c T lymphocytes. Men, who were HLA-DR2
negative received the most benefit from this treatmeD.L More recent studies have found
that the oral administration ofbovine myelin to relapsing/remitting MS patients induced a
change in the cytOkine pattern of the T lymphocytes. T lymphocytes isolated from these
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subjects showed a higher frequency ofTGF~1 secreting cells after stimulation with
MBP or PLP, than T lymphocytes from MS patients who were DOt given oral myelin
(Fukauraet ai, 1996; Hafleret al, 1997).
TolenmceC3.JI be induced via otber routes as well. Warren et al. (1997) Ylere able
to induce tolerance to MBP by single or repeated intravenous injections ofa soluble MBP
peptide as indicated by the disappearance ofanti-MBP anbbodies
1.9.6 Chimeric Aati-CD4 MODoclonal Aatibody
The administ:nttion ofa chimeric anti-CD4 monoclonal anbbody to chronic
progressive MS patients was shown to dec:rcase the numbel" ofcirculating CD4+ T
Iympbocytes and to prevc:ot the developman ofDeW lesions (Lindsey et al., 1994;
Moreau et aL. 1994). These antibodies consist ofa human constant region coupled with a
mouse variable region. Two of these chimeric anbbodies have actually been tested,
CAMPATH-IH(anti-eDwS2) and CM-T412. TheCM-T412 isthougbt to be the most
promising as its side effects are less devastating (Lindsey et al., 1994).
1.9.7 T Lympbocyte VaccioatioD
1be immunization of multiple sclerosis patients with irradiated, autologous,
MBP-speclfic T lymphocytes leads to the depletion of circulating MBP-reactive T
l)mpbocytesinthcsubjects(Zhangetal, 1993; Medaeret al., 1995). In
relapsinglremining MS patients this immunization docreased exacerbations and stabilized
the lesions (Medacr ctal.• 1995). No effects were noticed with chronic progressive
patients.
so
t.1D AIlimal Models or Multiple Sclerosis
There are several animal models ofmultiple sclerosis. The three most
investigated and best representative of multiple sclerosis are the experimental allergic
(autoimmune) eucepha10myelitis model.., the coronavirus model,. and the lbeilers murine
encephalomyelitis virus (TMEV) model
1.10.1 EJ:pt:rimeDtal Allergic (Alltoimmune) Encephalomyelitis
Experimental allergic (0(" autoimmune) encepbaIomyelitis is an animal model of
multiple sclerosis which is typically induced in rodents. mainly rats and mice. This
disease can also be induced in marmosets but differs in many ways from the disease
produced in rodents, therefore the marmoset model will be discussed separately.
l.1o.l.llaductioD of Experimental Allergic Encephalomyelitis
Experimental allergic encephalomyelitis can be induced in rodents by the
injectionofCNS bomogenatcs (Brown and McFarlin, 1981; BrownetaL, 1982; Munoz
etaI., 1984), the injectionofCNS myelin proteins, sucbas PLP(Yamamura etaI., 1986;
SatohetaL, 1987). MBP (Panitcb and CiccoDe, 1981; Pender. 1988).orMOG(Jobnset:
al.I995),orbythe injectionofpeptidesofMBP{Fritzetal.,1983; SakaietaL, 19883),
PLP (Tuohy et ai, 1989; Greer et aL, 1992), or MOO (Johns ct al., 1995; Kerlero de:
Rosbo et aI., 1995; Mendel et aI., 1996). EAE has also been induced in (PU] X SJUL)F1
mice by using a viral peptide with limited homology (only 5 amino acids) to MBP
(Gautam et a1, 1998). In each case the antigens are emulsified in complete Freund's
adjuvant before injection. In the murine models it is often nec:essary to administer
&rdete/la pertussis as an ancillary adjuvant. This microorganism. causes an increase in
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BBB pem:teability through the action ofa histamine sensitizing factor (Linthicum. 1982).
The ability to produce EAE by immunizing animals with CNS tissue bomogenates or
proteins strongly suggests that MS is an autoimmune disease.
EAE can also be adoptively transferred to naive, syngeneic animals by C04+ T
(ympbocyteS activated in vilro byMBP, PLP. and MOG (Paterson, 1960; Pettinelliand
McFarlin, 1981; Mokhtarian d aI., 1984; Vandenbarlcetal.• 1985;Zamviletal.,1985;
Salohet aL. 1987; Meodcl etal.., 1995,1996) or by a synthetic peptideofMBP (Sun et al
1992).
1.10.1.2 The Course of Experimental Anergic EllIcepbalomyelitis
The amoUIlt of demyelination, the clinical cowse and the symptoms ofEAE vary
with the species and strain ofanimal used. the inducing antigen, the route of inoculation,
the dose of antigen. the age ofme animal at the time of sensitization. and the sex of the
animal (Stone et al.., 1969; Lassmann and Wisniewski. 1979; Lubl.in. 1996).
The symptoms ofEAE generally include weight loss, hind limb paralysis, loss of
tail tonicity, and hiod and forelimb paralysis (Swanborg 1988; Govennan and Brabb,
1996). For some animals the induction ofEAE is fatal, others recover and are resistant to
further induction, while others develop a chronic relapsing disease.
In general, mice develop a chronic relapsing disease with considerable
inflammation and demyelination (Mokhtarian et aI., 1984; Zamvil et al., 1985). By
contrast. rats develop an acute monophasic disease with extensive inflammation but little
demyelination (Lassmann and Linington, 1987; Schluesener et aI., 1987; Martin et aI.,
1992a). However. there an: many variations ofEAE producible in rodents including a
cbroDic relapsing disease with considerable demyelination in rats.
1.10.1.3 The Im...aology ofExpel'iaeatai Allergic EacepbaJomyelitis
The immunology ofexperimental allergic encephalomyelitis is in many ways
identical or very' similar to that of multiple sclerosis. In fact. much ofwhat is known of
the immunology of multiple sclerosis comes from investigations in this animal model
1.10.1.3.1 The T Lympbocyte in ExperilDeatal Alkrgic E8ceplll.lomyelitis
EAE is mediated by CD4+T lymphocytes ofthe TIoI subset which are specific for
myelin antigens (Pettinelli and McFarlin, 1981; Swanborg, 1983; Ando et aI., 1989;
Baron et aI., 1993; Wekerle et at., 1994; Bradl and Linington, 1996; Goverman and
8rabb, 1996). It is interesting then that eDCepbalitogenic T lymphocytes specific for
myelin are found in normal Lewis rats and probably in other rodents as weD (Wekerle et
al, 1994). Then:: an: a number of observations which sbow that the de~lopmentofEAE
is due to the actions ofTlo1 lymphocytes:
1. MBP~ve T lymphocytes are found in fresh relapsing lesions but not in
silent chronic lesions (Cross et al. 1993a).
2. Labelled MBP-sensitized T lymphocytes can be seen to form part ofthe
inflammatory infiltration of tile CNS during acute and early cl1ronic EAE
(Crossetal.,I990)
3. The majority ofcells in the inflammatory infiltnte are CD4+ T lymphocytes
(Stinissenetal.,1997).
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4. Adoptive tIllDsfcr ofactivated CD4+ T lymphocyte lines induces EAE
(pettinel.li and McFarlin. 1981).
5. Antibodies ag:ainst CD4 inhibit EAE (Waldor et aL. 1985).
6. Encephalitogenic T lymphocyte lines express and~ IFN·y. TNF-a. and·
P. and ll.-2. cytOkines known to be secreted byTbllympbocytes (Ando etal.,
1989; Powell etal.• 1990; Mustafuetal.• 1991,1993).
7. EAE cannot be passively transferred by the injection of serum (paterson,
1971).
8. The induction ofT lymphocyte toleraoce to MBP prevents the development of
EAE(MillcretaL.I99I).
However. these T lymphocytes cannot give rise to inflammation and
demyelination without crossing the BBB and entering the CNS. The series of events
concerning the entry ofT lymphocytes into the CNS and subsequent induction of
inflammation in EAE are very similar to those ofmultiple sclerosis. In fact, the majority
of information regarding this process in MS bas been elucidated and extrapolated from
the animal models.
When an animal is inoculated with a CNS antigen. antigen presenting celli in the
draining lymph nodes process the antigen and present it to CD4+ T lymphocytes in the
context ofMHC class n (Lublin, 1996). This leads to the activation ofCJ)4+T
lymphocytes specific for CNS antigen.. Alternatively, CNS antigen-specific T
lymphocytes may be activated in \litro and then injected. inlo the animal In either case,
the activated T lymphocytes bome to the CNS (Cross etal.• 1990). In fact after adoptive
transfer, MBP-responsive T lymphocytes are among the first cells to infiltrate the CNS
(Raine, 1994). Activated T lymphocytes are able to enter the CNS regardless oftheir
antigen specificity, or their ability to distinguish their particular antigen from the other
CNScomponents (Wekerleetal.• 1986; Sedgwick etal.• 1990; Hickey et al., 1991).
T lymphocytes are able to breach the BBB in large part due to the up-regulation
of adhesion molecules, such as VCAM-l and ICAM-I. on the endothelial cells of the
CNS and the up-regulation oftheir respective ligands. VLA4 and LFA-I. on the
activated T lymphocytes (Baron et al., 1993; Dopp et aI.• 1994). The importance of
adhesion molecules in EAE is shown by the changes in adhesion molecule expression
during the disease. For example, up-regulation ofICAM-1 on endothelial cells and LFA-
I on CD4+ T lymphocytes in the CNS occurs during acute disease. These adhesion
molecules are subsequently down-regulated during remissions and are up-regulated again
during any further relapses (Cannella et aI., 1990,1991). As well, several studies using
monoclonal antibodies against various adhesion molecules have also shown these
molecules to be necessary for the production ofEAE. Archelos et aI. (1993) showed that
the administration of anti-ICAM-l antibodies reduced CNS inflammatory infiltrates and
suppressed EAE. Yednock et al. (1992) prevented the accumulation oflcukocytes in the
CNS, and therefore the development ofEAE. through the injection ofanti-VLA4
antibodies. Baron et aI. (1993) demonstrated that a loss ofVLA4 molecules on T
lymphocytes, reduced their ability to enter the CNS. Studies using anti-LFA-I
monoclonal annbodies have found conflicting results. Cannella et at. (1993) found that
the administration ofanti-LFA-I antibodies had adverse effects in one group ofEAE
mice tested, bitt overall there was DO significant effect on EAE. In contrast. Welsh et al
(1993) found that anti-LFA-I anbbodies increased the sevcrityofEAE and even resulted
incarly mortality in some animals. Canncllaetal (1993) suggested that the effects of
anit-LFA·1 anbbodics were dependent upon the stage ofdisease at which they were
injected. In addition. the ooset of signs ofEAE bas beel;l shown to correlate with the
attachment and infiltration of lymphocytes, mostly LFA-I positive T lymphocyteS. and
the appearance oflCAM-1 on vessels of the CNS (Raine etaL. 1990). These authors also
observed that pseudopodia from lymphocytes attach aDd penetrate endothelial cells ofthe
CNS.
Once the activated T lympbocytes have crossed the BBB and~ the CNS.
those whicb ue specific for CNS antigens are reactivated by resident antigen-pR:SeIlling
cells in the CNS. such as microglia(Hickcy and Kimura. 1988; Hohlfeld et aL. 1995) and
remain in the CNS. T lymphocytes which are unable to detect their specific antigens
within the CNS traffic out The re-stimulatcd T lymphocyteS initiate an inflammatory
response through the release ofan uray ofcytokines. including TNF-a and IFN-y. These
cytokines lead to the increased permeabilityofthc BSS to serum proteins and
immunoglobulin, the recruitment ofB lymphocytes. macropbages, and other T
lympbocytes, the up-rcgulation ofadhesion molecules on endothelial cells. and the up-
regulation ofMHC class n molecules on local antigen-presenting cells (powell et aI.•
1990; Wekerleetal.. 1994; Hohlfeldetal.. 1995; Lublin, 1996). InEAE this
inflammatory pathology is generally associated with neurologic deficit (Wekerle et al.•
1994).
A. CytokiDe Prodactioll by T Lymphocytes iD EI:~rimeDtalAlkrgic
E~lullo.yelitis
It is suggested that the cytokine patterns of lesions in EAE vary depending upoo.
the stage of disease. During early disease pro-inflammatory cytOkines. such as IL-I, IL-
2, TNF-a., and IFN-l' are dominant while anti·in£lammatorycytolcines., such as TGF·13
and fi....10 are almost absent. During the recovery phase the levels of these cytokioes
switch with TGF-~ and [1...10 dominating and the infla.mmatory cytokines being down-
regulated (Khoury et aI., 1992; Kennedy et aI., 1992). Kennedy et at. (1992) also
demonstrated that the peak ofmRNA expression for IL-2, 0-4, IL-6 and IFN.y occurs
before the peak ofclinical severity. Declines in the mRNA levels ofthesecytokines
occurred concomitantly with an increase in the IL-IO mRNA level. These changes were
associated with stabilization of clinical symptoms. The importance of cytokines in EAE,.
particularlyTNF~ and rFN.y, has been demonstrated in many experiments. TNF is
believed to be the most important cytolrine in the pathogenic process in EAE (Lublin..
1996). Transgenic mice over-expre:ssing TNF-a spontaneously develop a chronic
inflammatory demyelinating disease and eventually die due to woISelling neurological
symptOms (Proben etal.., 1995). TNF-a. causes myelin damage and is cytotoxic to
oligodendrocytes (Selmaj and Raine, 1988; Zajicek et al., 1992&). Lympbotoxin also
injures oligodendrocytes and is more potent than TNF-a. (Selmaj et ai, 1991b). TNF also
promotes up-regulation ofadhesion molecules. Anti·TNF antibodies have been shown 10
reduce or prevent up-regulation of VCAM·I (Barten and Ruddle, 1994). Annbodies
against 1NF or the TNF receptor can inlubit the development ofEAE (Ruddle et at.,
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1990; Selmaj etal, 1991C; Bakeret al., 1994; Barten and Ruddle, 1994; Selmaj and
Raine, 1995). LevelsoftNF have even been foUDd to correlate withdisc:ase severity
(Owens and Srimm, 1995).
A role for IFN-y iII EAE is indicated by numerous observations. An. increase in
cells producing IFN-y and in the level ofIFN-y is seen during the early phase ofEAE
(Mustafa et al., 1991; Kennedy et aI., 1992; Merrill et aI., 1992). Administration of fFN-
y ameliorn.tes EAE (Voorthuis et aI., 1990; Kalman et aI., 1992), while administration of
anti- IFN-yantibodies c:nhances EAE(BilIiau et aI., 1988; Lublin et d, 1993). lFN-y is
beli~ to up-regulate expression ofclass n MHC molecules and adhesion molecules of
endothelial cells in the CNS (McCarron et al.., 1986; Cannella etal.., 1991; Baron et al.,
1993) and is therefore important in the homingoflympbocytes into the CNS.
TGF-J3 is known to be imponam in the recovery phase ofEAE. This cytok:ine
inhibits IFN-y induced up-regulation of class II MHC molecules and inhibits T
lymphocyte activation (Lublin, 1996). By inhibiting the activation ofT lymphocytes.
TGF-J3 is able to block the production ofIFN-y and lymphotoxin by encephalitogenic T
lymphocytes (McDonald and Swanberg, 1988; Karpus and Swanberg. 1989; Stevens et
al.. 1994). TGF-P aIso interferes with the active and adoptive ttansferofEAE (Kuruvilla
et al., 1991; Johns et al.., 1991; Stevens etal., 1994). For example, the inductionofEAE
by MBP or PLP caD be prevented by TGF.f3 secreting T lymphocyte clooes isolated from
animals tolerized with l\.1BP (Chen et at. 1994). Ad.ministrationofTGF-J3 bas been
shown to reduce the severity ofEAE, to prevent the development ofEA£, and to reduce
the ()CCUI'ROce of relapses (Johns etal, 1991; K.uruvillaet al, 1991; Racke et aL, 1991).
Animals treated with anti- TGF~ antibodies showed wonenmg of clinical and
pathological featun:s ofEAE (lUcke a al. 1992b; Johns and Sriram., 1993).
B. T Cell Receptor Usage in Es:perimental Allergic [neepbUomyelitis
As in multiple sclerosis, the issue ofTCR restriction in EAE models is unresolved
and complex. The TCR response varies with the species and strain of animal used, as
weU as with the antigen and even the epitope used. Many authors found evidence of
prefeRntiai usage of the VpS chain ofthe T cell receptor in PUJ mice (Acha-Orbeaa ai"
1988; Urban aal., 1988; Zamvil aal. 1988). Later it was observed that tbe response to
MBPI·9 in the PUJ mouse was restricted to VpS2 (Zamv:il and Steinman. 1990).
However, deletion ofthe VpS TCR from pUJ mice was not able to prevent the
developmem:ofEAE in all the mice tested, as a small percentage ofthe VP8' mice did
present with EAE (zamvil et aI., 1988; Kalman et al., 1993). Another study found that
the use of anti-Vj3S.2 monoclooal annbodies could also suppress EAE in PUJ mice
(Swanborg, 1995). Slmilar studies with SJl)J mice demonstrated tba1 about 50 percent
ofthe T cell clones specific for MBP89-10 I from these mice express Vp 17a. However,
depletion ofT lymphocytes expressing this V~ cbain does not suppress EAE in this strain
ofmouse (Sakai et al., 1988b). It was concluded tbattbese mice use a broad repertoire of
Vp elements (Sakai et al, 1988b; Su and Sriram, 1992).
Other investigators have oot found TCR VP usage to be as restricted. For
example, Mendel et al. (1995,1996) found that the TeRs ofT lymphocyte lines from H·
,.
2b mice (C57BU6J and C3H.SW) immunized with MQG35·55 TCR used Vp1,2,6, 8,
10, 14, IS, but Vl3 8.2 usage waspref~ T lymphocyte clones isolated from SIUJ
mice immunized with PLP139·151 were fOUDd to use VP2, 6, la, and 17a, with no
preferential usage ofVp chains (Kucbroo et al, 1992).
The same conflicting results are observed with studies ofTCR usage in rats. The
T lymphocyte response to MBP in Lewis rats has been shown to use Vp8.2 exclusively
(Cblubaetal, 1989; Zhang and Heber-Katz, 1992). In contraSt, Sun et aI. (1992) found
that T lymphocyte lines specific for synthetic peptide MBP87-99 did not use Vp8. A
study by Gold et aI. (1992) found that lymph node T lymphocyteS from Lewis rats
responsive to MBP72-89 preferentially use VpS.2. They aIso found that the T cell
receptor usage differs depending upon the location from which the cells are taken. T
lymphocyte clones isolated from the spinal cord specific for synthetic peptides ofMBP
used VP6 predominantly, while T lymphocyte clones with the same specificity isolated
from lymph nodes used an array ofVp chains including VIl6. Furtbennore, Sun et aI.
(1994) reponed thatT lymphocyte lines from Lewis rats reactive with MBP68-88
demonstrated divef5e TCR usage. They also fouod that the majorityofVP8 positive cells
were not enccpbalitogcnic and that T lymphocytes expressing other T ceU recqmrs were
encephalitogenic.
It should be noted that the T ceU receptor usage is not static during the cowse of
the disease. Karin et aI. (1993) used a T lymphocyte line specific forMHP68-86 which
expressed V138, 10,5, 16, and 19 to induce EAE. They found that less than 24 hours
after injection ofT lymphocytes the majorityofVp traDSCripa in the brains ofthesc:
animals wen: the same as those of the transferred T lymphocyte line. Two days after the
transfer VIlS was predominant, but with the onsetOfparalySls the TCR usage became
diverse with respect 10 Vp. During the recovery phase the TCR usage was more
restricted with VPS. 9. 10. and 19 predominating. Offneret al. (1993) also found that
during the T lymphocyte response 10 MBP in Lewis rats Vp usage changes over the
COUISC of the disease, especially as the rats recover.
In general. the TCR V gene usage is restricted within an individual animal, but
there is muehdiversity oftbe TeR V gene usage between animals (Hafler et aI.• 1996). T
cell receptor V gene usage also appears to differ with the location from which the T
lymphocytes are isolated and the epitopt to which the cells are exposed..
1.10.1.3.2 OtIIer lllllllaDe CdJs Implicated la EIperimutai Allergic
Eacepb.alomyelitis
T lYTJ.:lpbocytes are DOt the only cells important in the production and perpetuation
ofEAE. Macrophages are also found in EAE lesions (Lassmann et aI., 1993), in fact
macropbages are the ceU type most often associated with demyelinating lesions (Genain
e1 aI., 1995a). The inhibition ofmacropbage enzymes or the depiction of macropbages
ameliorates the clinical signs ofEAE and inbJbits demyelination (Brosnanet al. 1981;
Huitinga. etai-. 1990; Tran et aI., 1998). Tran et aI. (l99S) concluded that the depletion
ofmacropbages inbJ."bi1ed leukocytes from migrating across the BBB and/or inbJ."bited the
accumulation of these cells in the CNS. Macrophages may damage oligodendrocytes
indirectly via the release of various cytokines. such as TNF-a. (Genain et al.. 1995a) or
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the release of nitric oxide or reactive oxygen species (OL:udaetaL, 1995; Ruuls et aL,
1995). These cells have even been observed pbagocy1osini myelin in lesions ofEAE
(Lampert, 1918; Raine et aI., 1980; Princ:as and Graham:. 1981). Just as important in EAE
are B lymphocytes, or more specifical1ytheir antibodies. I..assmann et aI (1983) found a
correlation between the appearance ofa humoral immune response in sera, esp. and
brain extracts with the development ofIarge demyelinated plaques in chronic relapsing
EAE. Although antibodies to MBP, MOO, and PLP have been identified in the CSF and
serum of animals with chronic EAE (Lassmann and Linington, 1981; Sobel, 1995). the
majority ofstudies have conceottated on the role of anti·MOO annbodics in EAE.
1.10.1.3.3 The mportaace ofMOG aDd ABti-MOG Mtibodies in EJ:peri.eatal
Allerxic EDcephalolDyditis
Before discussing the role of anti-MOO antibodies in EAE. the importance of the
MOO protein in the induction ofEAE will be addressed. A single injection of purified
MOO or MOO peptide can produce relapsing/remitting EAE in rats with extensive
demyelination (Johns et ai, 1995). Antibodies isolated from the sera of these animals
were reactive with MOO, but DOt MBP, MAG, or PLP and were able to degrade MBP in
Vitro. Chronic relapsing demyelinating EAE can also be induced by the injection ofa
syntbeticMOGpeptide (MOG35.SS) (Icbikawaet al, 1996a). Theseexperimeoterswere
unable to induce disease with other syntbct:ic MOO peptides. Injection ofme peptide
also induced a strong humoral response which was restricted to MCX135·55.
Prior to these studies it bad been demonstrated that the transfer ofT lymphocytes
specific for MOG3S·SS into naive Lewis rats led to CNS inflammation, and severe BBB
dysfuoctioo. without demyelination or neurological de6ciL Ho~.co-ttansfer of
these T lymphocytes with ami-MOO monoclonal antIbodies induced a rapidly
progressive form ofEAE with extensive demyelination (Linington et al, 1993).
This was only one ofan array of experiments which demonstrated the necessity of
anti-MOO antibodies for demyelination and more severe EAE. Anti-MOO antibodies
were identified in rats with chronic relapsing RAE induced by intrathecal injection of sera
from guinea pigs with EAE (Linington and Lassmann, 1981). More importantly, the
serum demyelinating activity of the rats in vivo was fmmd to be proportional to the anti-
MOO anobody titer. In 1992. Linington et al used repeued~erof MBP specific
T lympbocy1e:s and monoclonal anti-MOO ann"body to induce chronic relapsing EAE in
Lewis rats. Their observations showed that the fonnationofthe large, focal
demyelinated lesions seen in these animals was dependent upon an autoanubody response
to an appropriate myelin antigen. They also injected. anti-MOO anObodies into Lewis
rats made increasingly resistant to further induction ofEAE by repeated injections of
MBP specific T lymphocytes. The administration oftbe monoclonal anobodies 4 days
after each injection ofT lymphocytes resulted in severe clinical relapses. Similarly. the
injection ofami-MOG anubodies to Lewis rats after the onset ofEAE induced by MBP
specific T lymphocytes or T lymphocyte lines enhanced the clinical impairment and
primalY demyelination seen in these animals (Lassmann and. Linington, 1987; Lassmann
eta1.. 1988; LiningtonetaL. 1988). EAEinduccdbyMBP-specificTlymphocytes and
anti·MOG antibodies appeared. more quickly. progressed very rapidly. and was more
severe thaD when induced by a similar number ofT lymphocytes alone (Namer et a1.•
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1994). Anti-MOO antibodies can also imduce demyelination when given intravenously
to rau immunized with MBP (Schluest:oeretaL. 1987; Pidd!esden d aL. 1993). The
Ia.tter-studies reported incIeased disease s.everityaftertbe injection ofthe antibodies..
Schlueseoer et at. (1987) also found that t;:be injection ofanti·MOG anobodies into SJL
mice during remission induced fatal relapses. Levels of anti·MOG antibodies have been
shown to be higher during relapses than ilD the initial disease (Morris etaJ.• 1997).
The demyelination observed with..anti·Moo antibodies cannot be repeated by the
administration ofanti·MBP. anti·PLP. or ;anti·MAG anobodies (Seil and Agrawal. 1980;
SeiletaJ.• 1981; ScbluescnCT"et.aL. 1987; Kerlero de RosboetaL 1990)
Manyexperimenten have conchded from studies such as these that myelin-
reactive T lymphocytes and anti-MOO anrtibodies act synergistically. There is also direct
evidence for this theory. A study ofEAE induced in Lewis rats by MBP·specific T
lymphocyteS and anti·MOG antIbody sholiWCd that the structure and size of the lesions
was dependent upon the number ofT lymFhocytes which were injected into the animal
(Lassmann et aL. 1988). High numbers offT lymphocytes withanti·MOG antibody
resulted in ubiquitous periYmOUS demyelimation, whereas low number ofT lymphocytes
with anti-Moo annbody resulted in focal confluent demyelinated lesions. Severe
demyelination in Lewis rats immunized w:itb MOG3S-SS was observed only in the
~ofhigb levels ofanti-MOG antiboodies (Ich.ikawaetal.I996b). This study also
showed that the anti-MOO anobodies aJome....-ere DOt sufficient to produce clinical
disease. It is believed that in the T lympbocytc-mcdiated mode! ofEAE in the Lewis rat
encephalitogenic T lymphocytes are respomsible for inflammation in the CNS, but are not
capable of iDducing demyelination. Demyelination depends not only upon the action of
these T lymphocytes, but also upon the action ofaut08DlJDodies (Linington ~ al., 1992;
WekerleetaL,I994).
It is important to note that although anti-MOG anllbodies appear to be lmportant
mediators in demyelination, the majority ofthe oligoclonal bands found in the sera and
CSF ofanimals with EAE are specific for Mycobacterium tubt:rcuJosis, a component of
the adjuvant used in the induction afthe disease (Wbitaereet al., 1981.1982; Mehta et at.•
1985).
The question DOW becomes what is the mecbanism. responsible for the
demyelination elicited by these autoantibodies? A number ofmecbanisms have been
proposed including the activation ofcomplement, enbanced phagocytosis ofmyelin by
macropbages, and activation of myelin proteases with subsequent MBP degradation.
Anti-MOO antibodies can lyse cultured oligodeodrocyte:s, but only in the
presence ofcomplemeDL Ifcomplement is removed or beat inactivated, lysis is DO longer
possible (Linington ~ aL, 1989). This lysis was also found to be dependent upon the
presence of the Fc portion ofthe antibody molecule as incubation ofthe oligodendrocytes
with the F(ab>'l fragment afthe annbody did not lyse the cells. These results are
evidence ofme importance of complement activation by ami-MOO anbbodies. Other
studies have used cobra venom factor, a decomplemeotation agent. to demonstrate the
involvement of complement in demyelination. For example.liningtOn et aL (1989) were
able to completely suppress the clinical signs ofEAE by administering cobra venom
factor to Lewis rats which had been immunized with MBP and given anti-MOG
6'
monocloaal annbody. The injection of the dccompl.ememation factor did DOt completely
prevent demyelination. The authors suggested that the demyelination seen in these
animals may be indicative ofa role for macrophages in demyelination. or it may be the
result of complement synthesized within the CNS by activated macrophages, or the
activation of other complement compooeots which were not susceptible to cobta venom
factOI'". Piddlc:sden et al. (1991) also found that the injection ofcoin. venom factor into
rats immunized with MBP suppu:ssed the clinical signs ofEAE and reducc:d
inflammation in the CNS.
In 1990, Kedero de Rosbo et aL concluded that the induction of demyelination by
anti-MOO monoclonal annlxxiies does not occur in the absence of complement.
Piddlesden eta!. (1993) expanded upon this bydemonstnlting that the ability of anti-
MOO anllbodies to induce demyelination is related to their ability to fix complement.
Antibody-dependent cell mediated cytOtOxicity invoLving macrophages and
microglia is a major mechanism for annbody-mediated demyelination i" vivo (Brosnan et
aI., 1981; Vass et al., 1992). Anti-MOO anulxxlies may enhance phagocytosis of myelin
by macrophages via anllbody-dependent complement activation on the myelin surfs.ce.
This would lead to the release ofcomplement derived macrophage activators and
opsonization of the membrane with C3b. As macropbages express the receptor for this
complement component, phagocytosis could result (LiningtOn et aI., 1989). TbeR: is also
evidence ofFc receptor mediated phagocytosis in EAE as the injection oftbe F(ab>'l
fragment ofthe anti-MOO monoclonal annDody did not affect the clinical course ofEAE
(Linington et aI., 1989). However, this observation may instead support a role for
..
complcmenL Complement can also bind Fc. this may lead to fc-reoeptor mediated
macrophage attack.. Alternatively. it bas also been shown that anti-MOO anobodies can
activate myelin proteases that are able to degrade myelin (Johns etaL, 1995).
The role ofanti·Moo antibodies in demyelination is complicated by studies
showing that the lysis of rat oligodendrocytes in vitro is medi.a1ed by complement and can
occur in the absence ofanti-myelin antibodies (Scolding et al.• 1989a,b; Zajicek et al.,
1992b). Rat oligodendrocytes lack CD59, a complement regulatory protein, the absence
ofthis protein is responsible for the antibody-independent complement mediated lysis
observed in these experiments (Winget ai, 1992; Piddlesdenand Morgan. 1993). In
contrast, human oligodendrocytes are DOt sensitive to complement-mediated lysis in the
abseoce ofannbody and do express CD59 (Zajicek: et ai. 1995).
1.10.1.4 Is EAE • Good Model of MUltiple Sclerosis?
There are, of course. arguments for and against the use ofEAE as a model for
multiple sclerosis. First of all, it must be remembered that EAE. as originally descnbed,
is a disease induced in inbred sttains of rodents. while MS is a spontaneous disease in an
outbred population (Raine, 1994; Goverman and Brabb. 1996). According to DiDter et al.
(1997). using inbred animals restricts the immunological response and limits the validity
oftbe model. It bas also been suggested that the phylogenetic difIen:nce between rodents
and humans may limit the usefulness ofEAE as a model for a human disease (Massacesi
et aI.• 1995). Another concern is that the etiology ofEAE is in no way similar to that of
MSf'Nekerleetal.• I994).
When one compares the c1lnic:a.l aspectS ofEAE with those ofMS, a number of
differences are discovered. As yet there is DO EAE model which presents with all the
clinical and pathological aspectS of multiple sclerosis (Wekerle et aL. 1994; Geoain and
Hauser, 1997). LiningtOD et aI. (1989) stated that observations ofanima1s with EAE
often give conflic:ting results due to the comparison of models which have different
modes of induction, clinical course and pathological responses.
en addition, conflicting results have been observed between the EAE models and
MS. For example, rat oligodendrocytes do DOt express CDS9 and are therefore
susceptJ.ble to aotibody-lndependent complement mediated lysis, whereas human
oligodendrocytes do express CDS9 and are DOt susceptible to such lysis. As well. IFN-T
ameliorates EAE (Voonhuis et al. 1990; Kalman et aL. 1992). but when given to patients
with MS it exacerbates the disease (panitch et al.. 1987). This brings into question the
usefulness of the animal models for the prediction of treatment for multiple sclerosis
patients.
Some experimenters believe that the EAE models of multiple sclerosis are not
representative oflhe human disease. '"Current studies of patients with MS indicate that
the immunological mechanisms in MS are considerably more complicated than in EAE"
(Utz and McFarland. 1994). ..... a far reaching conclusion based, for example on an EAE
model ina single species or strain (or-on a single molecule such as MBP) will Likely
prove to be an oversimplification, and perhaps of uncertain relevance to human disease"
(Sobel et al., 1994).
However, there are reasons to continue work with animal models. Although the
models are DOt perfect representatives ofmultiple sclerosis. they can be used to Stlldy the
basic immunologic mechanisms that are responsible foc the alIlOimmune inflammatory
disease of the CNS and the formation ofiesioDS (Richardson. 1994; Genain and Hauser,
19%). In addition, the use of inbred rodents enables the investigator to study the genetics
oftbe disease and adoptive transferofEAE (Swanborg, 1995). More specifically, the use
of murine models is advantageous since there are a barrage ofmousc specific reagents
available, as well, congenic strains, mutants and transgenic animals are easily developed
(Wekerleetal, 1994;Swanborg. 1995). Ofcourse, rodent models are useful in the
designing and preliminary testing ofpotemial therapies.
1.10.1.5 Epitope Spreadiag in Experimeatal AUergir: Eac:ephalomyelitis
There is circumstantial evidence that epitope spreading is responsible for the
relapses seen in EAE (Tuohy, 1994). In fact. both inter- and intramolecular determinant
spreading bas been shown to occur in EAE. Intramolecular determinant spreading has
been demonstrated by the following experiments:
1. One oCme fim rqxms ofepitope spreading, was made be Perry and Barzaga
in 1987. Theydemoostrated that in BIO.PL XSJUJ mice with EAE induced
by MBP the primary response \W.S directed against an MBP peptide presented
by I-A-. After relapse the immune response included I-E" restricted epitopes
ofMBP. A later study found the immune response to MBP to spread from 1-
AU restricted peptides to I-As restricted peptides (McCarron et al., 1990).
..
2. Chronic MBP-induced EAE is distinguished by spreading of the autoreactive
response to determinants ofMBP not involved in the original immunization
(McCarron et aI.• 1990; Lebmann et aI.• 1992).
3. Determinants ofMBP that are cryptic after primary immuni2ation of (SJL x
BIO.PL)F, mice can become immunogenic dwingtbe course ofEAE
(Lehmann et aI., 1992).
4. T lymphocytes isolated from mice with EAE induced by T lymphocytes
reactive with the immunodominantPLP139-1S1 peptide, are specific for
PLP178-191 (McRaeetaL,l99S). furthermore. thesePLP178-191 reactiveT
lymphocytes were able to transfer relapsing EAE to naive syngeneic animals.
Another study using tbc PLP139-151 peptide to induceEAE in (SWR X
SJL)F I mice found the T lymphocyte response to include PlP249-273 and
PLP173-198 (Yu et ai, 1996).
5. Relapsing EAE was induced in SJUI mice by the adoptive transfer ofT
lymphocytes specific for PLP139-ISl. After the animals reco~ from the
attack, T lymphocytes~ found to proliferate in response to PLPI78-191.
This study also found that T lymphocytes isolated from mice with relapsing
EAE induced by immunization with PLP139-1S1 or by adoptive transfer ofT
lymphocytes specific forPLP139-151 could be used to transfer EAE to naive
recipients after being stimulated with either PLP139-1S1 orPLP178-191
(MilleretaL,I995).
Intermolecular dctenninant sprculing bas been observed in the following
experiments:
1. Spleen cells isolated from SIUJ mice with EAE induced by passive transfer of
MBP87-99 specific ceUs were able to transfer EAE after stimulation with
PLP139-t51 (Cross et aL. 1993b).
2. (SJUJ X PUJ)F I mice immunized with MBP developed relapsing EAE, and
their T lymphocytes were shown to develop reactivity to PLP during the
course of the disease (perry et ai., 1991).
3. T lympbocytes from mice with EAE induced. by MBP84-I04 specific T
lymphocytes developed a response to PLP139-1S1 (McRae et aI., 1995).
4. (SWR X SJL)F I mice withPLP139-ISl induced EAE had T lymphocytes
reactive with other myelin antigens, including MBP87·99 (Yu et ai., (996).
5. Relapsing EAE was induced inSJljJ mice withMBP84-I04. Theseanimals
developed T lymphocyte responses 10 PLP139-1S1 during and after clinical
relapse (Miller et aL, 199:5).
Milleret aL (1995) explained the role ofepitope spreading as follows, "As a result
of myelin damage and opening of the blood-brain barrier during acute disease, T
lymphocytes specific for endogenous epitopes on the same and/or different myelin
proteins are primed and expand. ei.ther in the periphery or locally in the CNS. These
seooodary T lymphocytes initiate an additional round ofmyelin destruction,. leading to a
clinical relapse by production ofadditional pro-inflammatory cytOkines, similar to
bystander demyelination operative during acute disease." McRae et ai. (1995) and Yu et
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al (1996) coDCluded that relapsing paralysis or relapsing clinical episodes were the result
ofepitopespr-eading.
The focus DOW became bow to prevent epitope spreading. Miller et at. (1995)
were able to abrogate epitope spreading by inducing tolerance to the initiating epitope
prior to the primary clinical episode. They also found that inducing tolemnce to PLP139-
151 after the transferofPLPl39~IS1specific T lymphocytes, but before the onset of
clinical signs ofEA£, not only prevented intramolecular determinant spreading to
PLP178~191 but also prevented the developmeDt of relapsing EAE. Not only did this
show that it was possible to prevent epitope spreading, but also confirmed that damage to
the CNS was necessary for the development ofthis pbc:nomenon. McRae et at. (1995)
were able to prevent relapsing EAE by inducing tolerance to intact PLP after the primary
disease episode. Yu et al. (1996) concluded that the induction oftolenmce to the
spreading epitopes after the onset ofEAE prevents progression ofthe disease.
Therefore, it seems that myelin breakdown due to the action ofT lymphocytes
specific for a myelin component leads to the release of autoantigens which in turn may
activate other T lymphocytes and perpetuate the disease (Cross et aI., 1993b~ Govennan
and Brabb, 1996).
1.10.1 The Marmoset Model ofExperiJae.tal Allergic EDttpbalolllyelitis
!be marmoset model ofEAE warrants a separate discussion as it differs in many
respectS from the rodent models ofEAE. Marmosets are non·hwnan primates and are
therefore phylogenetically closer to humans than rodents. The species ofmannoset used
n
as a model for multiple sclerosis is OJI/ithrixjacdrus. Although the individual animals
in multiple births are derived from separate ova that are fertHized independently, the
placentae oftbe embryos fuse. This leads to cross circulation ofbone marrow derived
elements between the fetuses. Therefore each animal is genetically distinct, but each is
tolerant ofthe other's bone marrow derived cell populations (Picus et aI., 1985). This
natural bone marrow chimerism is ememely imponant in the EAE model as it allows
adoptive transfer ofT lymphocytes between outbred animals (Massacesi et aI., 1995).
Chronic relapsinwremitting EAE can be induced in Callithrixjacduls by
immunization with human CNS white matter(Massacesi etal, 1995). This EAE is very
simtlar both clinically and pathologicaUy to multiple sclerosis, with early and prominent
demyelination leading to the fonnatioo of plaques. 1be demyelination appeared to be
media1ed by the macrophage infiltration observed within the lesions.
Genain eta!. (l994) found MBP-reactive T lymphocytes 10 be abundant in
unimmunized. healthy marmosets and to recognize a number ofMBP epitopes. T
lymphocytes from these animals were stimulated with MBP and used to adoptively
transfer inflammatory CNS disease to other normal marmosets. The adoptive transfer
produced a mild disc:ase, with no macrophage infiltration and no demyelination, T
lymphocytes isolated from the immunized animals were responsive to MaP but not PLP.
Two imponant conclusions can be made from this experiment, first ofall. MBP reactive
T lympbocytes are capable of inducing inflammation and clinical signs but~ DOt
sufficient for plaque fonnation. Secondly. "naturally occurring populations ofcirculating
T lymphocytes in a bealthy immunologically normal outbred individual can mediate an
autoimmune disease."
A similar study by Massacesi et al. (1995) used MBP..cea.ctive T lymphocyte lines
from animals immunized with human white matter to adoptively transfer EAE. lbis
resulted in the induction oftbeclinical signs ofEAE in these animals,. but did not
produce demyelination.
An interesting study by Genain et al. (1995a) showed that the clinical signs of
EAE could be induced in C jocchus by immunization with human white maner, MBP,
PLP, a recombinant fusion protein of MOO (rMoo), and combinations ofeither PLP +
MBP,orPLP+ MBP+ rMoo. However, tbecharacteristic pathologyofEAE induced
by immunization with white matter (as descnbed by Massacesi et aI., 1995) was only
reprodUCIble by immunization with either rMoo or rMoo + PLP + MBP. Analysis of
the anubody repertoire of the animals showed thatannbodies against the immunizing
proteins were detected in animals immunized with MEP. PLP, and IMoo. Marmosets
immunized with white matter or with PLP possessed antibodies to all 3 proteins (pLP,
MBP. and IMOG). It is thought that the presence ofanti-MEP and anti-rMOG antibodies
in the PLP immunized animals is the result ofepitope spreading. In any case., from these
results it was concluded that in order to produce the MS-like lesion in C jocchus a T
lymphocyte response to MBP or MOO and an annbody response to MOO are required.
Further experimentatioD by Genain et aI. (1995a) supponed this coDclusion.
Adoptive transfer of anti~whitemaner, anti~rMOG,or anti~MOGmonoclonal antibodies
to MBP immunized marmosets led to demyelination and clinical deterioration, while
immUDization with complete Freund's adjuvant and Bordetella pertussis followed by
anti-MOO monoclonal antIOodies did not induce demyelination. Genain and Hauser
(1996) suggested that the T lymphocyteS were responsible for opening the BBB which
then enabled the pathogenic antibodies to enter the CNS.
A more recent study by McFarland et al. (1999) showed that immunization of
mannosets with l\.1P4, a chimeric molecule containing the known human epitopes of
MBP and PLP, but none of the epitopes of MOO or other myelin antigens, induced EAE
in these animals. Some animals developed an inflannnatory disease, while others
developed a demyelinating disease. Investigation of the demyelinating and
oondemyelinating lesions demonstrated immunoglobulin deposits and anti-MOG
antibodies to be present only in the demyelinating lesions. The authors suggest that the
intermolecular determinant spreading to the MOO determinants resulted in the B
lymphocyte response which was necessary for the demyelinating disease.
A role for macrophages in this demyelination was elucidated by the
admin.istratio~ofRolipram to marmosets with EAE induced with white matter (Genain et
aI., 1995b). Rolipmm is a type IV pbosphodiesterse inhtbitor, which is known to
suppress the release ofTNF-o. from macrophages (Schade and Schudt, 1993; Semmler et
al.• 1993). The administration ofrolipram to these animals completely prevented EAE
and demyelination.
EAE in C jacchus is panly mediated by CD4+ T lymphocytes that produce ll..-2.
IFN-y, and TNF-a in response to MBP (Genain and Hauser, 1996). There does not
appear to be any preferential usage ofTCR VI3 genes (Uccelli et al.., 1997). The
mechanisms mediating demyelination in the mannosets~ thought to be the same as
those occurring in the rodent EAE model so they will not be descn'bed here.
There are many advantages of using the marmoset model ofEAE over the rodent
models for the study ofmultiple sclerosis. These advantages include: the clinical and
pathological similarity between marmoset EAE and human multiple sclerosis; the ability
to perfonn sequential stUdies ofCSF, T lymphocyte. and aDtibody responses in these
animals; the similarity of immune and nervous system genes and proteins between
humans and non~humanprimates; and the ability to perform adoptive transfers between
siblings (Genain and Hauser, 1996). As weu. the MS-like lesion observed in Cjacchus
appears to be due to a diverse immune response to multiple myelin antigens. This is also
believed to be the case in MS.
1.10.3 Vinl Models of Multiple Sclerosis
The IIlOSl extenSively studied viral models of multiple sclerosis and the two that
most closely resemble MS are the 1beiIer's mwine eocepba.lomyelitis virus model and
the coronavirus model. In analyzing viral models ofMS it is important to consideTthree
questions: (I) Is the damage to oligodendrocytes due to the virus itself or to the immWle
response directed against the virus? (2) Is the activation of autoantigen-specific T
lymphocytes tberesult oft:issue destruction brought about bylbe viral infection? (Brad!
and Liningtoll, 1996). For example, the virus may damage certain tissues thereby
releasing sequestered antigens which then become the target oran autoimmune response
(Horowitz et aI., 1998).
1.10.3.1 neiler's M.ritle E_ceplaalolllyelitis Vinu
Tbetler's murine encephalomyelitis virus is a natural enteric picornavirus in mice
(Rodriguez et aL, 1988; Bradt and Linington, 1996) and is also indigenous to colony-
bred mice (Lipton, 1975; McFarland and McFarlin, 1995). This RNA virus preferentially
infects the white mater in the CNS of5USCepbole mice (Steinman and Conlon, 1997).
Infection with TMEV first presents as poliomyelitis. After this initial infection, the virus
is quickly cleared from the peripberal circulation but takes up residence in the glial cells
of the CNS (CIa1Cb etaL, 1990; Tsl.DlOdaand Fujinami, 1996; StcinmanandConlon,
1997). Within a month TMEV induces a chronic progressive CD4+ T lymphocyte (Tb I
lymphocyte) mediated inflammatOl)', demyelinating disease (Lipton, 1975; Lipton and
Da1 Canto, 1976; Clateb etaL, 1986; Brad!. and Linington, 1996; Stelnman and Conlon,
1997). The resulting disease bas a rclapsinWremittiDg course and demyelination
reminiscent of chronic progressive multiple sclerosis (Bradl and Linington, 1996;
Steinman and Coolon, 1997).
The proposed mechanism of demyelination in TMEV infection is similar to that
proposed for EAE. TMEV-specific CD4+ T lymphocytes respond to the virus residing in
the CNS and produce pro-inflammatory cytolrines whicb recruit and activate
macropbages and other lymphocytes (Rodriguez et ai, 1986a,1997; Milleret al., 1990;
Peterson,etaL.I993).
Evidence ofan immune mediated mechanism for demyelination was gained from
several observations:
n
I. During the chronic phase, the CNS infiltrate is composed mostJyof
macrophages and T lymphocytes,. about balfofwhichare CD4. (Lipton and
Dal Canto. 1976; ClalCh et al. 1990). During active demyelination the
infilttate consists of plasma cells, lymphocytes, and macropbages (DaI Canto
and Lipton., 1975).
2. Demyelination late in the disease can be prevented by cyclophosphamide
(LiptOn and Oat Canto. 1976).
3. The administration ofanti I-A monoclonal antibodies to animals with
persistent TMEV infection reversed chronic paralysis and reduced
inflammation and demyelination (Rodriguc:zet al. 1986b; Friedmann et al.
1987). Fatalities were DOted in animals given the antJ."bodies before a
persistent infection bad occurred.
4. Additionally, studies have shown that mice depleted ofCD4"'T lymphocytes
experience diminished demyelination (Welsh et al.• 1987; Gerety et at.•
1994). This is contradicted by experiments showing that depletion of the CD4
Of MHC class II genes results in severe demyelination and clinical illness
(Roder and Hickey, 1996), and that the administration of mooocional
antlDodies to deplete MHC class II molecules early in the disease can lead to
iDcreasod demyelination and even death (Rodriguez and Sriram,. 1988). These
conflicting results may be due to the different sttains of mice. viral isolates or
anoDodies used. It is also possible that the time ofthe depletion ofthe T
lymphocytes may be an imponam factor. Welsh et a1. (1987) suggested that
"
depletion of T lymphocytes before injection ofTMEV may reDder the mice
unable to clear the virus.
In later stages ofthe disease. there is evidc:occ ofepitope spreading ssT
lymphocytes reactive with several PLP peptides and with M0G92-106 have been
identified (Milleret at. 1995.1997). The authors suggested that as there is no cross-
~activ1ty between these peptides and TMEV, these T lymphocyte responses are due to
the breakdown of myelin and the subsequent release ofautoantigens. No such T
lymphocyte reactivity to myelin antigens was demonstrated early in the disease (Miller et
al.. 1987). Further evidence ofepitope spreading comes from the finding that the initial
infection with TMEV is not dependent upon an immune response to myelin antigens.
The induction oftolerance with l'MEV epitopcs inhl"bits disease induction and decreases
the frequency and severity ofvirus induced demyelination (KaJpus etaL, 1995), while the
induction of tolerance with myelin antigens does not (Miller et aL. 1990). Fwthermore,
TMEV demyelination cannot be tr3nSferred by adoptive transfer ofMBP-stimulated T
lymphocytes from TMEV-infectedanimals(Barbano andDal Canto. 1984). bt.ttthe
adoptive transfer ofCD4-+ T Iympbocytes specific for a viral protein increases the
incidence ofclinical disease in TMEV·infected mice (Gerety et ai, 1994). Epitope
spreading may explain the finding that the distnbution of lesions moves from grey matter
to white matter during TMEV infection (Tsunoda and Fujinami., 1996)-
CDS+T lymphocytes may also be important in the clinical signs ofTMEV
infection and/or the demyelination induced by the virus. Transgenic mice with no CDS+
T lymphocytes show demyelination and inflammation and high viral titers•.but only a
mild illness (Roder and Hickey, 1996). The deletion ofclass [MHC molecules by
monoclonal annbodies resulted in less inflammation and fewer lesions and was
independent ofthe stage ofdisease at which the antibodies were given (Rodriguez and
Sriram, 1988). However, Rodriguez (1997) reported that the deletion ofclass I MHC
genes results in severe dcmyelinatiotL In addition. class I molecule expression is up-
regulated in tbcCNS of mice infected with TMEV (fsunoda and Fujinami. 1996) and
CDS'" T lympbocytcs specific for capsid proteins ofTMEV have been found in an.imaJ.s
infected with TMEV (Lin et ai, 1995).
There is also circumstantial evidence to support the importance ofa humoral
response in TMEV-induced demyelination. For example, Yamada et at (1990b)
identified a monoclonal antibody that reacts with both TMEV and myelin. As well,
TMEV can produce demyelination in nude mice (Johnson, 1985). Mice persistently
infected with TMEV have elevated levels ofIgG and oligoclonal bands inCSF, the
majority ofIgG present in the serum and CSF of these mice is specific for virus antigens
(Roos et ai, 1987; Rodriguez et aL, 1988).
It has been suggested that macropbages may be a final effector in demyelination,
as TMEV antigens and RNA have been found in these cells in demyelinating lesions in
chronic TMEV infection (fsun<Kla and Fujinami, 1996). As well, TMEV-infected
macropbagcs possess MBP degrading proteolytic activity (Rodriguez and Quddus. 1986).
Macropbages are the most highly infected cells during both the acute and chronic phases
ofTMEV induced disease (Dal Canto and Lipton, 1982; Clatch et ai. 1990)
Susceptibility to the late disease depends upon the genetic background of the
mouse. or more specifically the ability of the mouse to generate an MHC class II
restricted, T lymphocyte mediated delayed type hypersensitivity (DTII) response to the
virus(Qatchetal, 1985.1986; Miller et aL. 1981). TbeDTHresponsetotheviros
tesiding in the CNS leads to secondary demyelination due: to the virus induced
inflammatory response (McFarland and McFarlin. 1995).
1.10.3.1 Comn.virus
Infection with mouse hepatitis virus (MHV), particularly the JHM strain.
produces encephaJomyelitis with a demyelinating pathology similar to that of multiple
sclerosis (Weiner, 1973; Brad! and Linington, 1996). Although JlTh.{ is a mouse
coronavirus, it can produce demyelinating disease in mice, rats. and primates (Gerber et
aI., 1985). The rat adapted. JHM vinas produces a relapsing disease in the Lewis rat
(Watanabe et aI., 1983). In mice the JHM virus leads to persistent CNS infection and
demyelination due to the direct infection ofoligodeodrocytes (Herndon et aL, 1975;
Johnson. 1985; Da1 Canto, 1996).
TIle lesions in MHV·JHM infection have been shown 10 contain macropbages, T
lymphocytes, B lympbocytes, plasma cells., IgG, and complement C9. suggesting an
immune response is responsible for the demyelination (Zimprich et aL, 1991). This
demyelination has been found to be partly the result of an antibody response to a viral
spike protein (Yamada et aI., 1990b), displayed on the surface of infected
oligodendrocytes in the lesions (Zintprich et aI., 1991; Bradl and Linington, 1996).
There is also a role for T lympbocyteS in this process.. Irradiation of mice infected with
the JHM: virus prevented demyelination. while the transfer of T lymphocytes from
infected mice to these imIdiated mice restored demyelination (Wang et al, 1990).
Epitope spreading is also known to OCCW" in JHM infected animals. Splenic T
lymphocytes from Lewis rats infected with JHM were found to respond to l\.iBP and were
able to transfer relapsing EAE when activated with MBP (Watanabe et a1., 1983; ter
Meulen, 1988). There is no cross reactivity between JHM and MBP (McFarland and
McFarlin, 1995). Therefore corooavirus is able to stimulate T ceI.l mediated autoimmune
reactions (Watanabe etaL, 1983; KyuwaetaL, 1991).
2.0 RypotIIesis
To date. the antigens against which the serum and CSF JgO antIbodies ofMS
patients are directed have not been fully identified.. MS lesions are typically restricted to
the white matteTofthe CNS, the optic nerve, and the retina (Antel and Amason, 1991;
Boccaccio arK! Steinman. 1996; Kerrison, et aI.• 1994; Lucchinetti and Rodriguez, 1997;
Martin. 1997; Stinisson et aI., 1997). one would expect that the expression of
autoantiger:(s) important to MS would also be limited to these areas. Myexperimental
hypothesis was tha1 pote:ntial. autoamigens in multiple sclerosis could be ideatified by
using a modification oftbe SEREX, (Ierological identification ofantigens by
recombinant ~xpressioncloning) method ofSabin et al. (1995). In this thesis. SEREX
involves construction ofa eDNA library: (a) by preparation ofcDNA from mRNA
isolated from MS brain tissues; (b) by packaging the cDNA into a lambda phage vector
(AZaplI); (c) by transfecting the vector into £.s.cMrichia coli; (d) and by colour detection
ofc:xpressed proteins induced by isopropyl tl-D-thiogaIactopyranoside. The recombinant
proteins are transfened to nitrocellulose membranes and screened with patients' sera
The antigens are detected by a colour reaction which recognizes IgG in patients' sera
boWld to the recombinant protein. Positive clones are subcloned to clonality, sequenced,
and the sequences compared with DNA and RNA sequences in various databases.
The mtionale of using a eDNA expression bbrary prepared from MS lesions is
that serological screening should lead to the identification ofboth pl"eViously identified
and DOYel MS autoantigens. This technique is advantageOUS compared with many other
approaches to identify autoantigens since it makes DO a priori assumptions as to the MS
autoantigens.
Moleculartargets potentially relevant to MS are then used as probes in Nonhem
blotting experiments to determine their relative expression levels in various tissues.
2.1 Bacqrou.d
SEREX was developed for use in the identification ofantigens in tumours. Sabin
eta!. (1995) screened eDNA expression bbraries constructed from various malignant
tumors with autologous sera. They identified some antigens with restricted expression in
each nanor, showing that tumon express multiple antigens which are able to elicit
immune responses. A similar study by Scanlan et aI. (1998) used the SEREX. method. to
identify distinct antigens in colon cancer.
The identification of novel autoantigenic targets in MS could lead, in the long
term. to noveL tbcnlpies. Foc example, once an autoantigen is identified as a major
immune target in MS, immunodominaIll epitopes could be defined. Altered peptide
ligands could then, in theory, be prepared for treatmeot. Altered peptide ligands are
peptides which are modified so that they bind to the T cell receptor in a sub-optimal way
and subsequently do not result in the same T lymphocyte response as that initiated by the
original peptide (Steinman. 1996). It is also possible that altered peptide ligands bind
with the same affinity as the native peptide, but result in diffeIent signaling mc:chanisms
(Hafler and Weiner, 1995). Several investigators have already demonstrated the:
usefulness of altered peptide Ligands in causing a switch in the: cylokine patterns to
decrease the production ofIFN.y and increase the production ofTGF·13 (Windhagen et
al., 1995b; Ausubel et al., 1997)
Of course, there are certain difficulties in screening such a library. Annbodies
recognize a particular conformational epitopc:. The recombinant proteins produced in
such a library may DOt undergo the same post-translational modifications as the proteins
produced in the MS patients. In contrast, they may be subjected to certain modifications
in the bacterial system which do not occur in the human system.. Also, although IgO is
known to be increased in MS CSF and serum, there is no way of knowing how much of
this increase is diRlCtcd towards an MS specific antigen{Owen:s et d, 1996). There is
also DO way of knowing if the antigen responsible for inducing MS is actually c:licitingan
annbody response when the serum is taken (fureci et aI., 1997). It is possible that
individual libraries would have to be screened with autologous serum as different
antigens may be responsible for disease induction in diffetent patients (Owens et aL,
1996).
2.2 Studies Rdevaat to tbe Muter's Project Discussed ia tbis Thesis
A numberofinvestigatOlS have used various molecular techniques, including
eDNA lilnries., and peptide IJbraries. in. an attempt to identify peptides., infectious agents
andfoe autoantigens specific to multiple sclerosis patients. Some ofthese experiments are
discussed in the foUowing parngraphs.
Owens etal. (1996) used mRNA isolated from chronic and acute multiple
sclerosis plaques and from periplaque white matter to construct a directional eDNA
expression library. The resulting bDraries were screened with CSF from MS patients. or
with IgG extracted from MS sern. or CSF. lbese authors also used subtracted cDNA
libraries in order to enrich mRNA sequences which were unique or over-represented in
the MS plaque as compared with normal white matter.
Screening oftbese blnries did not detect any sequences unique to MS, nor did it
detect MBP or any other myelin specific proteins. They did suggest sevetal reasons to
account for the absence of detection ofmyelin specific antigens: "(1) the in-frame
expression products are unstable or toxic. (2) the antibodies may recognize post-
tnmslationaJ modifications or secoodary systems not formed by bacterial systems (3) the
antige.n(s) recognized by MS annbodies may be rare or present only in acute plaques",
and (4) the anti-myelin antibodies are at low coocentration in the samples used.
Cortese et al (1996) screened random peptide libraries displayed on phage with
sera and CSF ofMS patients and with sen. of coorrols. They coined the term phagotope
to n:fer to phage displayed epitopes, that is the phage displayed peptides which reacted
with antibody.
Screening with two CSF samples, CSFl and CSF2. showed several bundred
phagotopes are recognized by IgG in CSFI while substantially fewer phagOiopes were
recognized by CSF2. Of these positive clones, 32 were chosen for further study based on
their strong reactivity. Sequencing of these clones revealed three classes ofamino acid
homology. Class I phagotopes showed related sequences with a highly conserved
KPPNP motif. class n phagotopes showed distinct but highly homologous sequences.
Both class I and IT phagotopes were recognized by CSFI. Phagotopes recognized by
CSF2 were grouped as class m, and showed distinct but homologous sequences. The
phagotope5 recognized by CSF2 are totally unrelated to those recognized by CSFI. and
do not react with CSFI. In addition. the phagotopes identified with CSFI and 2 rarely
react with CSF from other MS patients.
It was found that the CSFI and CSF2 selected pbagotopes not only reacted with
sen. obtained from the same patient. but also with seta from a number ofMS patients and
healthy controls. Further studies demonstrated that for the majority ofphagotopc:s the
specific activity oftbe anttbodies reacting with the pbagotopes is greater in the CSF than
in the serum.
These results and similar results obtained bytbis group in 1998 led to the
following conclusions; (I) "'antibodies displaying the same binding specificity are present
in the CSF and serum ofthe same patient, (2) these antibodies may be directed against
ubiquitous antigens. 0) some oftbese antibodies are specifically enriched in the CSF',
(4) it seems that each MS patient bas a diffeIent set ofintrathec:a.Jjy produced antibodies
in the CSF, and (5) anti·pbagotope annbodies are foWK1 in the seraofbealthy individuals
as well as tbatof MSpatients.
Becker et aI. (1997) constructed a normalized eDNA library from plaques of a
chronic progressive MS patient This involved hybridizing single stranded plasmids with
RNA tIanScriptS and removing the resulting DNA:RNA hybrids by chromatography_ By
removing these hybrids they were able to increase the frequeDcy of race eDNA clones and
dc:ccease the frequency ofabundant eDNAs (Soaces. eta!., 1994). Expressedsequence
tagS (ESfs) were produced through the sequeocing of eDNA clones isolated from the
library. Analysis oftbe cDNA bbrary showed the majority of cDNAs represented
unknown or uncharacterized genes. However, 54 cDNAs corresponding to genes known
to be involved in immune activation were identified Most of these encoded produet5
which are imponant in antigen processing and presentation., such as MHC molecules, and
cell adhesion molecules. Others encoded inflammatory mediators, such as cytolcines and
cytOk:ine receptors, and genes typically associated with T and B lymphocyte recognition,
activation, and regulation. Comparison with nonnaliz.cd adult brnin libraries showed
only 16 oftbe 54 eDNAs identified in the MS hbrary to be present in oormaIlxain. In
addition., 19 eDNAs encoding known or suspected aU%oantigens were identified in the MS
library. These included MBP and PLP, as well as 16 autoantigens known to be
associated with other autoimmune diseases., for example systemic lupus erythematosus.
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insulin depeodeutdiabetes mellitu.s, and Graves disease. Only 3 of these 16 genes were
found in the normal adult brain horaries. This study did not identify any eDNA
sequences identical to those ofany infectious agents.
Arcbelos et aI. (1998) used an oligodendrocyte-precursor cell line to construct two
expression libraries., which were subsequently screened with pooled CSF from MS
patients and patients with other neurological diseases. Examination of the pooled CSF
prior to its use in the screening did not detect the presence ofanti-MBP. -MOO. or -MAG
antibodies in the MS patients nor in the patients with other neurologic diseases. This
screening identified only 6 positive clones.. none of which com::spooded 10 a known
protein. However. 5 oCthe 6 clones COD1ai:ned a common 7 amino acid sequence
(EKPCLEK) which is highly homologous to the translated consensus Alu repeat epitope.
After concluding that the positive responses to each of1hese 5 clones was due to the
presence oftbe EKPCLEK motif, the authors created a synthetic peptide, the Alu-6
peptide. which included this motif. This peptide was composed of 12 amino acids.
EKPCLEKPKKKK, and was used in Enzyme Linked Immunosorbent Assays (ELISAs)
so that a number of serum samples couJd be tested for reactivity with this peptide.
Approx:imatc:ly 44% of relapsingl remitting MS patients tested positive for annbodies
recognizing the Alu-6 peptide. A lower percentage of primary and secoodaty
progressive MS patients, healthy controls, and patients with other neurologic diseases
were also found to possess such antibodies. In addition, the ann"body titers of the
relapsing/remitting MS patients were higher than those ofthe other MS patients. the
CODtrols, and the patients with other neurologic diseases. Comparable results were
obtained when CSF was used in the EllSAs.
Alu repeats are short. repetitive elements fOUDd in the iDtrons ofalmost every
Imown protein-cncoding gene ofbumans and other primates (Makalowski et aI.• 1994).
They~ approximately 300 bp in length. arc scattered throughout the human genome
(Bloom et aI., 1996), and may account for as much as 5% ofthe entire human genome
(Garren etal, 1998). These elements are so named due to the presence ofa single
recognition site for the Alu I restriction endonuclease. AGJ. cr. located near the middle
of the Alu element (Bloom etal., 1996). There are a couple of mechanisms by which
these repeats may lead to disease. Alu elements contain nwnerous stop codons and are
therefore coDSidered to cause premature termination if they are present within transcripts.
For this reason, the de novo insertion ofAlurepears may result in genetic disease. The
splicing of intragenic Alu elements into mRNA may have similar coosequences
(Makalowski et aL, 1994). It is also 1cDown that the oligo(A) sequences ofAlu repeats are
often associated with genomic instability (Cben etal, 1995), this may result in
pathogenic genetic rearrangement. Alu repeals have also been shown to be able to
....insert themselves into 0(" in the vicinity ofCis..aeting sequences or into open reading
frames or genes" , where they can fimction and may even direct transcription
(Szmulcwicz et al, 1998). Alu insertions have been directly and iDdirectIy linked to a
number ofhuman illnesses including hypertension, breast cancer. and colon cancer.
The AJupeptides discovered by Archelos et aL (1998) may represent nanslated
Alu repeat cpitopes. epitopes of an unknown oligodendrocyte protein., M regulatory
molecules.
ell.pter- Two Materials and Metllods
2.0 halation orTotal RNA
Brain tissue from an MS patient "..as generously provided by Dr. Barry Rewcastle,
a neuropathologist at the Uni~ityofCalgary. Calgary, Alberta. Sufficient white matter
plaques were removed from this frozen sample to make up 1.89 g oftissue. TRIzoiIM
reagent (Gibco BRL, Gaithersburg. MO) was used to isolate toW RNA from these:
plaques. The tissue was ground to a fine powder under liquid nitrogen using a mortal" and
pestle and added to 19.0 ml ofTRIzoITh( reagent (I ml ofTRlzo1T'Mreagent forevery 50·
100 mg of tissue), in a 30 ml NaIgene Oak Ridge polypropylene centrifuge tube (Nalge
Nunc International, Rochester. N.Y.). This mixture was incubated at room temperature
for 5 minutes and then centrifuged at 12000 g for 10 minutes at 4"C, to sediment any
unsolubilized material. The supernatant was transferred to a fresh tube and 3.8 ml of
chloroform were added (0.2 m.l ofchloroform per ml ofTIUzoITh( reagent used). The
tube was vigorously shaken for 15 seconds, incubated at room temperature for 3 minutes,
and centrifuged at 12 000 g for 15 minulCS at 4"C. The supemata.nt was tr.lI1Sferred to a
fresh tube and the RNA precipitared with 9.5 ml of isopropanol (0.5 ml per m.l of
lRIzoln.< reagent) followed by iDcubation at -2O"C OvemighL
The next day. the precipitate was centrifuged at 12000 g for 10 mintrte:s at4"C
and the pellet washed with 19 ml of75% (vlv) ethanol [diluted in dielbyl pyrocarboll3.te
treated water (DEPC-HJ.O») (1 ml of75% ethanol per ml ofTRIzoIT'Mreagent). This was
vonexed briefly and centrifuged at 7500 g for 5 minutes at 4"C. The pellet was dried in a
beU vacuum and rcsuspended in SOO I-l1 ofDEPC-HzO. then incubated at 6O"C for to
Spectrophotometric readings weR: taken usiDg the WaIburg program of the Soft-
Pac™Module of the Beckman 04"'-64 Spectrophotometer (Beckman Instruments Inc.•
Fullenon, CA) to check the purity and the amount ofRNA isolated.
2.llsolatiOD o(lUeueage~RNA(IIIRNA)
The Poly (A) QuikII) mRNA isolation kit (Stratagene, La lolla. CA) was used to
isolate mRNA from the total RNA. The RNA sample was incubated at 65"C for 5
minutes and immediately placed on ice. Fifty-five i-U of lOX sample buffer{IOO mM
Tris-HCI pH 7.5. I mM ethylenediaminetetraaeetic acid (EDTA). 5 MNaCl] was added
to the denatured RNA sample. The Poly (A) column was anacbed to a 3cc. Luer lock
syringe and the storage buffer pushed out. Next. two 200 J..t1 aliquots ofhigh salt buffer
(10 mMTris-HCI pH 7.5. I mMEDTA., 05 MNaCl)werepusbedthroughtbecolumn.
The RNA sample was then pushed through the column., coUected ina 1.5 ml
microcentrifuge tube. and re-applied to the column. This was followed by another wash
with 200 ~ of high salt buffer and three washes with low salt buffer (10 mM Tris-HCl
pH 7.5. I mM EDTA., 0.1 MNaCl). ThemRNA was eluted from tbecolumn with four
200 ~ aliquots ofprebeated (65'") elution buffer (10 mM Tris-HCI pH 7.5.1 mM EnTA)
and the eluate collected in four 1.5 m1 microocntrifugc tubes. The mRNA was
precipitated with 500)11 ofcold 100% ethanol. per tube. and incubated overnight at-
20"<:.
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The following day the precipitate was cc:oni.fiJged.u 12 000 g for 30 mtnuleS at
4"C, washed with 100 ~ of7oeAt ethanol (DEPC-~).and dried in a bell vacumn. The
pellet was resuspended in 39 J,l1 ofDEPC-HzO and spectropbotometrie readings were
taken as before.
2.2 CoastructioD of a eDNA Library
The eDNA hotary was constrUcted using the ZAP Express™ eDNA Synthesis Kit
(Stratagcne, La Jolla, CA) according to the manufacturer's instructions.
2.2.1 Fint Strud Syuthesis
A hybrid poly (dl) linker·primer and Molooey murine leukemia. virus reverse
t:ranseriptase (MMLV-Rl) were used to synthesize first $tl'2Ild cDNA from the RNA
template. The linker-primer contains an Xbo I restriction enzyme recognition site which
ensures that the eDNA is inserted in the vector in the sense orientation. The reaction was
carried out in a 0.5 ml microcenaifuge tube with 5.0).11 of lOX first strand buffer, 3.0)J.l
offirst strand methyl nucleotide mixture, 2.0 III oflinker-primer(l.41lg/lll), 8.0 J.1I- of
DEPC-H20, 1.0 J..L1 ofRNase Block Ribonuclease Inhibitor (40 UlJ,ll). and 29,S J,t1 of
mRNA(51lg). The first strand methyl nucleotide mixture contains normal dATP.dGTP.
and dTfP. but the dC"Jl> is a S'-methyl analogofdCTP. The addition ofthe S'-methyl
dCTP to the first strand eDNA protects against digestion ofthe eDNA by Xho I in a later
step. The reaction mixture was briefly vortcxed and incubated for 10 min.ute:s at room
temperature to allow the template and the primer to anneal. Following this incubation,
1.S J..L1 ofMMLV-RT (50 UlIJ.,1) was added. The reaction tube was vOrtexed, centrifuged
briefly, and incubated at 37'C for 1 hour, Then immediately placed on ice,
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2.2.2 Secoad Straad Syathesis
The first strand eDNA synthesis \Io'aS nowc:omplete. Next, 20.0 J,J.1 of lOX second
strand buffer, 6.0 JJ1 ofsecood strand nucleotide mixtwe, 11S.9 ..,J. ofsteriIe HzO, 2.0..,J.
ofRNase H (1.5 UI..,J.)' and 11.1..,J. of DNA Polymerase 1(9.0 U/..,J.) were added. The
reaction tube was vortexed, centrifuged briefly, and incubated at Hi"C for 2.5 hours.
Then placed on ice.
During the second strand synthesis, the RNase H breaks the mRNA template into
fragments which are subsequently used as primers for the DNA Polymerase I. The DNA
Polymerase I translates the RNA fragments into second strand cDNA. The second strand
nucleotide mixture contains nonnal dCTP to reduce the chances of 5'-methyl dCTP
becoming incorporated into the second strand cDNA
2.2.3 BluatiDgofcl)NA Termini
At this point the ends of the newl.ysyntheslzed cDNAstrands were uneven. To
produce blunteods. 23 J,J.1 ofbltmting dNTP mix, and 2.0 "'" ofclooed. Pju DNA
Polymerase (2.S U/J,J.1) were added. The tube was vortexed, centrifuged briefly, and
incubated at -rz.oC for exactly 30 minutes. This incuhat:ioo was followed by a phenol-
chloroform extraction to isola1e the cDNA. Two hundred J,J.1 of pheool-chloroform.
[1:I(vlv)] were added to the reaction mixture. The tube was vortexed and then
centrifuged for 2 minutes to separate the organic and aqueous layers. The aqueous layer,
containing the eDNA, was tnlDSferred to a fiesh 1,5 ml mierocentrifuge tube and an equal
volume ofchloroform. was added. The tube was vortexed and then centrifuged for 2
minutes. Tbe aqueous layer was transferred to a fresh 1.5 ml tube and the eDNA was
precipitated with 20.0 JJ1 of3 M sodium acetate and 400 IJI of 100"/0 ethanol. The tube
was inverted several times to mix and incubated at -20"e ovemighL
The next day the pcecipitate was centrifuged at 16 000 g for 60 minutes at 4OC.
The pellet was washed with 75% (v/v) ethanoL, ceottifuged at 16000 g for 2 minutes at
4OC, dried undeT a bell vacuum. and resuspended in 9.0 J..L1 ofEcoR I adapters. The
reaction mixture was incubated at 4"C for 30 minutes to resuspend the eDNA.
2.2.4 Ligating tbe EcoR [Adapters
Next, the &:oR I adapters were ligated to the blunt ended eDNA strands by the
addition of 1.0 !Jl of lOX ligase buffer (500 mMTris-HCI pH 7.5. 70 mMMgCl2, 10 mM
dithiotbreitol), 1.0!J.l of 10 mM rATP, and LO JJ1 ofT4 DNA ligase (4 U/IJI). The tube
was incubated at goC overnight. The following day the reaction mixture was incubated at
7rfC for 30 minutes to inactivate the ligase, centrifuged briefly, and cooled to roomtern_.
u.s lGauiag the EeoR [ Adapten
The &:oR I adapters were k:ina:sed so they were able to ligate into the
depbospboIylated vector arms. When the reaction tube had reached room tempetature
1.0 JJ1 of lOX ligase buffer. 2.0 JJ1 of 10 rnM rATP. 6.0 JJ1 ofstenle H2O, and 1.0 IJ1 ofT4
polynucleotide kinase (10 U/!J.l) were added.. The tube was incubated at3TC for 30
minutes. and then incubated at 7O"C for 30 minutes, to inactivate the kinase. The tube
was centrifuged and cooled to roorn temperature.
"
2..2.6 Xllo I DicatioD
As there is an Xho I recognition site intbe linker-primer, digestion oftbe newly
synthesized eDNA with Xho I removes the residual primer and the &oR I adapter from
the 3' end ofthe eDNA lbis digestion allows the eDNA to be oriented in the vectOf" in
the sense: direction due to over-banging Xho I andEcoR I sites. lbe digestion required
the addition of28.0 jJ! ofXho I buffer supplement, and 3.0 ).l1 ofXho I (40 Ulj.l1). The
reaction tube was incubated at 37'"C fOT 1.5 hoUlS. The tube was cooled to room
temperature and 5.0 jJ! of lOX STE buffer (I MNaCI, 200 mMTris-HCI pH 7.5,100
roM EDTA) was added. The eDNA was then size fractionated using a Sepbacryl S-5OO
Spin Column.
2.2.7 Size Fractiooatioo of eDNA
A I m.l syringe was plugged with a small amount of cotton and filled with
Sephacryl S-500. The syringe was placed in a IS ml Falcon tube and centrifuged at 385 g
for 2 minutes. The syringe was again filled with Sephacryl S-500 and centrifuged at 385
g for 2 minutes. The Sepbacryl $-.500 column was washed with two 300 J,J.1 aliquots of
IX S1E. TIle column was then nansferred to a fresh Falcon tube with a 1.5 ml
microccmrifuge tube in the bottom to collect fractions. Not:e that each fraction was
collected in a fresh 1.5 ml microcentrifuge tube. The eDNA was pipetted into the spin
column and centrifuged at 385 g for 2 minutes. This first ftactjon was removed and
stored in a 1.5 ml tube. Sixty jJ! of IX STE was loaded onto the column and centrifuged
at 385 g for 2 minutes. The second fraction was transferred to a fresh tube. Sixty j.11 of
IX STE was loaded on the: column and centrifuged at 385 g for 2 minutes. The third
fraction was collected.
An equal volume ofpbeDol-chloroform. [l:l(vlv)J was added to each fraction.
The tubes were vonexed and centrifuged at 16 000 g for 2 minutes to sepantte the
aqueous and organic layers. The aqueous layers were transferred to fresh loS ml tubes
and equal volumes of chloroform were added. The tubes were vortexed and centrifuged
for 2 minutes. The aqueous layers were transferred to fresh tubes. The eDNA fractions
were precipitated by adding twice the volume of 100".4 ethanol and incubating overnight
at-20"<:.
The following day the precipitates were centrifuged at 16000 g for 60 minutes at
4°C, washed with 200 IJ1 of 80% (v/v) ethanol, and dried under a bell vacuum. Each
fraction was resuspended in 3.0 JJ1 ofH20.
2.1.8 QuantibtioD ofcDNA Fn~tioDSby EthidiDIII Bromide Assay
The relative concentrations of the eDNA fractions were determined by spotting
0.5 JJ1 ofeach sample and 0.5 fJ.l ofkDown DNA stmdards on a 0.8% (wIv) agarose I
O.SX mE (0.045 M Tris-borate. 0.001 M EDTA) gel The gel also contained 4 JJI ofa
10mWml solutionofethidium bromide. The relativecoocentrarionsofthe: fractions were
determined by comparing the intensities oftbe fractions with those of the known samples
under ultraviolet Lighl
2.2.9 Liption of the eDNA iato tbe Zap EIpres Vector
The ligation ofeDNA into the Zap Express vector gives the best results if 100 ng
ofeDNA is ligated into 1 J,t8ofvector. The first ligation reaction was set up as follows:
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L25,.u of fraction 2 (80 ngfJ.ll}, 0.5 J.l\ of lOX liga.se buffer. 0.5 ,.u oflOmMrATP pH
7.5.1.0 ,.uofZAPExpress vector (I JJ.8IJ.l\). 1.25 J.,LI of sterile HzO, O.s ,.uofT4 DNA
ligase (4 UI,.u). The reaction tube was incubated at 40C for 48 hours. The ligation
reaction was repeated with the n:maining 1.25 J.l\ offraction 2 (80 nWJJ.!). and with 2.5 ,.u
of fraction 3 (40 n.!V'!Jl).
1.2.10 Paebgiag oftbe eDNA Library
One J.l\ oftbe ligated cDNA was added to the packagingextraetjust as the extraCt
began to melt. The reaction was immediately placed on ice. briefly centrifuged and
incubated at room temperature for 1 hour and 38 minutes. Next, 500 J.ll ofSM buffer (5.8
g ofNaCI. 2.0 g ofMgSO.· 7H20, 50.0 ml of I M Tris-HCI pH 7.5, 5.0 rol of2% (w/v)
gelatin) and 20 J.l\ ofchJorofonn were added to the reaction tube and centrifuged briefly
to sediment the debris. The supernatant containing the phages with cDNA inserts was
transferred to a fresh tube.
2.2.11 Platiag aDd Titeriag of the eDNA Library
The size ofthe IJbrary was determined by traosfecting the phages into the host
cells, Xl..I·Blue MRF' bacteria, and COWlting the number of resulting plaques. The XLI-
Blue MRF' bacteria were cultured in LB broth (per liter: lO g ofbactcH:ryptone. 5 g of
bacto yeast extract. and 10 g ofNaCl) supplemented with 0.2% (wlv) maltose and 10 mM
MgSC•• to an optical density (O.D.) of0.5 to 1.0 at600nm. Tbecu1ture was centrifuged
at 500 g for 10 minutes. The media were discarded and the bacteria resuspended in half
the original volume with to mM MgSO•. One J.l\ ofthe packaged reaction, was added to
200 J.l\ ofXLl·Blue MRF' cells. Fifteen J.L1 of0.5 M isopropyl ~·D-thiogalaetopyranoside
(lPTG) and SO!Jl of25() mgfml S-bromo-4<bloro-3-indolyl ~D-gal.actopyranoside(X-
gal) were added to 2 m1 of melted NZY top agar (per liter: 5 gofNaCI. 2 g ofMgSO.
7HZ<>. 5 g of bacto yeast ext:raet, to g ofcasein bydrolysate. 0:70.4 wfvagarose). The
NZY top agar was heated until boiling and then 2 ml aliquots were placed in Falcon tubes
and incubated at s8"C. The phage and bacteria were incuba1ed for IS minutes at 37"C
and then added to the NZY top agar. This was quickly poured over a ISO mm x 15 mm
NZY agar plate (per liter: 5 gofNaCI. 2 gofMgSO.· H10. 5 gofbacto yeastextraet, 10
g of casein bydrolysate. IS g ofbacto agar) and allowed to solidifY before being inverted
and incubated overnight at 31"C. The next day. the number ofrecombinant and DOn-
recombinant clones were counted.
2.2.U A_plifica.tio. oftbe d)NA Library
1be bbrary was amplified to increase the number of each clone and to stabilize
the I.tbrary. The phages were plated so that there were approximately 50 000 plaques per
plate. This time 600 J,J1 XLI-Blue MRF' cells were used. As before. the phagelbaeteria
m.i.xturc was incubated for IS minutes at 31"C. This was then added to the melted NZY
top agar and poured over NZY agar plates. When the top agar had solidified, the plates
were incubated at 37"C UDtil tile plaques were 1-2 mm in diameter. approximately 9
bours. As soon as the plaques reached this size. 10 ml ofSM buffer was added to each
plate. The plates were incubated at 4"C overnight with gentle shaking to allow the
phages to diffuse mto the buffer. The next day the 8M buffer was recovered from each
plate and pooled. The plates were rinsed with an additional 2 ml ofbuffer. which was
added to the pooled buffer. Chloroform was added to a final concentration of5%. the
tube was mixed well and incubated for 15 minutes at room temper.uure. The cell debris
was sedimented by centrifugation at 500 g faT 10 minutes. The supernatant was
recovered and stored at 4°C. Chloroform was tbeo added to a final concentration of
0.3%. The resulting horaty was designated as the MS2 eDNA library.
2.3 Primary Sereealn& of tbe MS2 illNA Library
After amplifying the library, several dilutions were plated to find the most
suitable dilution for screening. The best dilution was found to be lI50. One J.11 of the
1/50 dilution oftbe hbraIy was added to 600 j.il ofXIJ-BIue MRF' cells and incubated
for 15 minutes 813-rc. Fifteenj.il 0£2 MIPTGwasaddedand the mixtwewas
incubated again for 15 minutes 8137"C. This was added to 9 ml ofmehed NZY top agar
and immediately poured onto an NZY agar plate. After the agar had solidified, the plates
were iDcuba1ed overnight at 37"C. The following day the plates were overlaid with
NitroPure nitrocellulose transfer membranes, 0.45 f.dD. 137 mm, (Micron Separations Inc.
Westboro. MA) and incubated at 37"C for 3 hours. A needle was used to punch holes
through the membrane and the agar simultaneously. These holes would be used later in
the screening to match up the positive clones on the membrane with the clotlCS on the
correspoDding agar plate. The membranes were removed from the plates and wasbed
tbreetimes. 10 minutesperwasb, witb a solution of IX TBS (140 mMNaCI.3.0 roM
KCI. 25 mM Tris pH7.4 ) and 0.05% polyoxyethylene..-sorbitan mono-laurate ([ween 20),
with shaking at room temperature. Next. the membranes were blocked for 1 bour with
5% skim. milk: powder in IX TBS and rinsed 5 times with IX TBS.
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Before the patients' sera were used for screening the library, Escherichia coli
antibodies were removed by chromatography on glutaraldehyde activated silica to which
an EscheriCia ooli lysate was coupled. (This cbromatograpby was carried out by Or.
David Haegert.) Five of the sera were p>Oled together in a IJ200 dilution in IX lBS I
0.5% m.il.k./ 0.1% sodiwn azide. Each membrnne was incubated overnight with shaking
at room tempentun:: in 20 ml of the pooled sc:rum... [The sera used in this study were
obtained from a number ofdifferent patiem populations in different countries. As the
criteria for determining the different subtypes ofMS differ somewhat between countries,
it was decided that the 18 sera used in this project would be chosen at random from the
samples available. The 5 sera which were pooled were also chosen at random from these
18 sera.]
The foUowing day the serum was collected and the membranes rinsed five times
with IX TBS. The secondary antibody, alkaline phosphataso-conjugated AffiniPure anti·
human IgO, Fey fragment specific antibody (Jackson Immuno Research Laboratories
IDe., West Grove., PAl was added to the membranes at a concentration of USOOO in IX
TBS / 0.5% milk.. The membranes were incubated at room temperature for 1 hour with
shaking and then rinsed five times with IX ms. The bound annbody wasdetectcd with
the BioRad Alkaline: Phosphatase Conjugate SubstJate Kit (BioRad, Hercules. CAl. Two
bundred and fifty ).ll ofcolour reagent A (mtroblue tetrazolium in dimethyl formamide
with MgCh) and colour reagent B (5-brom().4.chloro-3-indolyl phosphate in dimethyl
formamide) were used per 100 ml of alkaline phosphatase buffer (100 mM Tris-HCI pH
9.5,100 mMNaCI,5 mMMgCh).
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Positive clones are detected as dark purple rings on a lighter purple backgromnd.
The holes in the membranes are aligned with the corresponding plates and the positive
clones are removed from the agar with a 1 ml pipette tip. These agar ~plugs~ containing
the positive clones were incubated overnight at 4°C in 500 JJ1 ofSMbuffer to aIloW'"the
phage to diffuse into the buffer.
2.4 Secondary ScreeniDg oftbe MSZ eDNA Library
The following day 1110 dilutions were made ofthese plugs and I JJ1 ofthe diluted
phage was incubated with 200 IJl of bacteria at 37"C for 15 minutes. Fifteen JJ1 of~ M
IPTG was added to the phagelbacteria mixture and incubated at37"C for 15 minutes.
This was added to 2 ml ofme1ted NZY top agar, and poured onto one quarter ofan :NZY
agar plate. The plaque densities were checked the next day and the volumes and diRutions
were adjusted to give the appropriate number ofplaques per quarter, 15-30, for secc»ndary
=ning.
At this stage each clone was screened with the secondary antibody alone anm with
the pooled sera. Screening with the secondary annbody alone allowed the identification
of clones which expressed immunoglobulin, such clones were discarded. Screening:: with
the pooled sera, for a second time, allowed the identification of false positives. Anyr
clones which were negative on this secondaIy screening were discarded. Clones wl::aich
were positive with secondary screening, and which were not identified as
immunoglobulin, were subjected to further "subeloning" until clonality was achieved.
This was followed by screening with individual sera to determine the number ofsera with
which each clone was reactive.
2..5 AmplifieatioD of Positive Clones by Polymerase Chain Reaction
Before the clones could be sequenced, each clone had to be amplified. This was
accomplished using the T3 (S' AATTAACCcrCACTAAAGGG 3') and T7 (5'
GTAATACGACTCACTATAGGGC 3') primers which are derived from the sequence of
the Zap Express Vector. One hundred J-Ll ofeach clone was heated to 9SoC for 5 minutes
and then placed on ice, to denature the DNA Ten,.u ofthis denatured sample was added
to a 05 ml microcentrifuge tube containing 90 J.Ll ofPCR cocktail. Each cocktail
contained 10 J-Ll of lOX PCR buffer (200 mMTris-HCI pH 8.4, 500 mMKCI),4 ~lofSO
mMMgCl2,. 5 J.Ll of4mMdNTP, 5 J.LI 000 f,lMT3 primer,S j.l1 of 10 J.l.M 1'7 primer, 0.5
III Taq DNA Polymerase (5 U/J-Ll) (Gibco BRL, Gaithersburg, MD), and sterile~ to a
final volume of9O JJ.,1. The final concentrations were: IX PCR buffer, 2.0 roM: MgCI2,
0.2 mMdNlP, 0.5 J.l.M for each primer, 2.5 U Taq DNA Polymerase. The parameters
used for the polymerase chain reaction were as follows: 95°C for S minutes, 94°C for I
minute, 50"C for 1 minute, nOc for 2 minutes, for 34 cycles, and then nOc for 7
minutes. The reaction tubes were stored at 4cC. The amplified clones were
electrophoresed on a 1% agarose I 0.5X TBE gel to check for clonaiity and to check the
relative sizes ofeach clone. The "cleanest" samples oreach clone were chosen to be used
for cycle sequencing.
2.6 PUrificatiOD ofPCR Products
The PeR products were purified using theW~PeR Preps DNA Purification
System (Promega., Madison, WI) according to the manufacturer's directions. The PCR
product was transfened to a 1.S m.l microcentrifuge tube and 100 J.Ll ofWizardtM PeR
tOl
Preps Direct Purification Buffer (50 mM KCl, 10 mM Tris--HCI pH 8.8, 1.5 mM MgCl:,
0.1% Triton*X-lOO) was added. This mixture was vortexed briefly to mix. Next I mlof
PeR Preps DNA Purification Resin was added and the s(uny vortexed 3 times over 60
seconds. The WtzardiM PCR Preps Minicolumns (one for eacb sample to be purified)
were attached to 3cc. Lut:r lock:: syringes and the DNA I resin mixture pushed through the
columns. The Minicolumns were washed with 2 ml of8O% isopropanol, placed in 1.5 ml
microcentrifuge tubes, and centrifuged at 10 000 g for 2 minutes to dry the resin. The
DNA fragments were eluted with 50 J..LI of sterile H20, which was applied directly to the
Minicolwnns. After 1 minute, the columns were centrifuged at 10 000 g for 20 seconds
in a 1.5 ml tube.. The DNA was transferred to a new 1.5 ml microc:enttifuge tube.
2.7 Cycle SequeaciDg of Purified PCR Prodacts
The positive clones were sequenced using the fmolN DNA Sequencing System
(Promega., Madison. wn and the n primer. The T3 primer was first labeUed with [y-
up) dATP. This reaction was carried out as foUows: 2..0 ~of(1O j.lM)T3 primer, 6.0 ~
Of[y_llp) dATP (2000 Ci/mmol), 2.0 IJ,1 ofT4 polynucleotide kinase lOX buffer (500
mM Tris-HCl pH 7.5, 100 mM MgCh, 50 mM dithiothreitol, 1.0 roM spermidine), 2.0
J..LI ofT4 Polynucleotide Kinase (10 UlJ..LI), and sterile H10 added to a final volume of 10
J,ll. The reaction tube was incubated at 3"rC for 30 minutes and then at 9O"C for 2
minutes, before being stored at 4"C.
For- each sample. four 0.:5 ~ microcentrifuge tubes were labelled, one for each
d/ddNI'P. Each tube contained 2.0 IJ,1 ofthe d/ddA,C.G, or T Nucleotide Mix. A
coclaail for each sample was prepared by adding 5.0 IJ,1 ofS){ fmol™Sequencing buffer
,0<
(250 mM Tris-HCl pH9.0, 10.roM MgCh). 1.0 J..Li of template DNA., 1.S J..Li of
[y-13p} dATP labelled T3 primer. 8.5 J..l,1 of sterile H20. 1.0 ~ ofSequencing Grade Taq
DNA Polymerase (S Ulf.,I1). The cocktails were centrifuged briefly and 4 J,il was added to
each ofthe four tubes containing one of the dfddNTP. The parameters used for cycle
sequencing were as foUows: 9S"C for 3 minutes. 9S"C for 30 seconds. 42"C for 30
seconds. 70"C for I minute. 70"C for 1 minute. for 29 cycles, then stored at 4"C. After
the cycle sequencing had finisbed 3 J.L1 offinollM Stop Solution (10 mMNaOH, 9S%
formamide. O.OS% bromopbenol blue, 0.05% xylene cyanol) was added to each sample.
The products ofthe cycle sequencing were eleeuophoresedon a 38 em x 50 em
8% acrylamide 17M urea gel (40.0 ml of30% acrylam.ide Ibis solution 19:1. 15.0 mI
lOX TBE, 63.0 g urea. 20.0 ml deionized. H20). These ingredients were mixed until all
the urea was in solution, the volume was adjusted to 150 ml with deionized H20 and the
mixture filtered and degassed for 5 minutes. The gel was pomed in the same manner as
other acrylamide gels. First., the plug was poured and allowed to polymerize and then the
remainder ofthe gel was poured. The plug was made of35 mI ofthe gel mixture with
180 Jll of 10010 (w/v) ammonium persulfateand the same volume ofN. N. N·. N'-
tetramethylethylenediamine (TEMEO). The remainder ofthe gel was poured after the
addition of2881Jl of 10% (w/v) ammonium persulfate and liS JJ1 ofTEMED.
The sequencing gel was preheated. to 50"C by running at 110 Volts for
approximately I bour. The samples were incubated at 70"C for 10 minutes and then
immediately placed on ice. Three IJ1 ofeacb sample were loaded on the sequencing gel
and electrophoresed for a-pproxirnately 4 hours at 110 Volts.
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The gel was removed from the apparatus, fixed for 15 minutes in 10% methanol I
10-A. acetic acid. and dried for 2 hours at 8O"C. The gel was exposed to film overnight at
-7et>C and developed the foUowing day. The sequences ofthe clooes were read from this
gel and sent to FASTA and BLAST (pearson and Lipman. 1988; Altschul et aL,
1990,1997) for comparison with RNA and DNA databases. These nucleotide sequences
were also analyzed for translation in 6 frames using the Baylor College: ofMc:dicine
Human Genome Sequencing Center website.
2.8 Nortllera Blot Aulysis ofTliree Positive aoaes
:1.8.1 Isobtioe of RNA fro.. Muttip&e Noraal rlSAes
From the: results ofthc: sc:quc:ncing c:xpc::rimeots it was decided that the tissue
distnbution of three ofthe positive clones wuuld be: analyzed by Nonbc:rn blot- Freshly
frozen specimens of adrenal, brain, cervix, colon., kidney, liver, spleen, testes, and thyroid
were: generously obtained by Dr. Desmond Robb, and TRIzol™ reagent was used,. as
previously dc:scn"bed, to isolate: total RNA from each sample. SpectrOphotometric
readings were: taken to check the purity and the amount of RNA isolated.
2.8.2 Dot BlottiDg of tile Isolated RNA
A dot blot was carried out using the isolated RNA from each oftbc: tissues. to
ensure that the RNA samples were: not degraded aDd to oonnalize the: amount ofRNA
Spectrophotometric readings were: used to calculate the volumes of resuspended RNA
nc:ededto give 1 }.Lg ofRNA in a final volumeofl0 1J,l. Tbesamplc:swc:rc: denatured at
65°C for IS minutes, and then placed on ice. Hyoond.NX (Amersham. Life Science,
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BuclriDgba.mshire, Eng\.a.nd) nylon membrane was IabeUed with each ofthe samples
approximately 2 centimeters apart. The dena1ured samples were slowly pipetted onto the
membrane.. The membrane was air dried for 5 minutes, then the RNA was cross-linked
with ultraviolet tight (254 om) for 3 minutes. Next. 5 mI ofpre-.beated (6SC'C)
ExpressHyb'IM Hybridization Solution (CloDtech., Palo Alto, CAl was added to the blot in
a hybridization bag. The blot was pre-hybridized at 65°C for IS minutes. The
[Cl_12p] dCTP (3000 CiImmol) labelled human beta-actin eDNA control probe (Clontech.,
Palo Alta, CA) was added to the hybridization solution and was allowed to hybridize at
6S'C for I hour. TIle bet;a.actin probe was labelled using the rediprimeTM IT random
prime labeUing system(~hamPbarmacia Biotech, BucJcinghamshire., England)
described in the section "Preparation ofProbcs forNortbem Blotting".
Following the hybridization. the blot was wasbcd in 2X sse (3.0 M NaCI, 0.3 M
Na]-<:itrate pH 7.0) 10.1% SDS (sodium dodecylsulfate) at room temperature for 15
minutes. This wash was repeated, and the blot was then washed in a.IX sse I O. 1% SDS
at 65"C for I hour.
lbe blot was exposed to BiomaxlM film (NEN'IM Life Science Products, Boston.
MA) for3 hours at-7ff'C. TbeCbemilmager TM4000 Low Light lmaging System
(CanberTa Packard Canada, MontRal, Canada) was used to measure the intensity ofthe
samples on the blot. This information was used to normalize the amount oCRNA loaded
onto the agarose I formaldehyde gel.
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2.8.3 Agarose I Formaldehyde Gel Electrophoresis of RNA Samples
Twenty J,l.g of each RNA sample was electrophoresed on a 3% formaldehyde I
1% agarose gel (1.755 g ofagarose, 127.5 m1 ofDEPC-~, 15.938 mI of lOX MOPS,
and 15.938011 of37% formaldehyde). MOPS is composed of200 mM: MOPS (3·[N-
morpholino] propanesulfonic acid) pH 7.0,50 mMNaJ-acetale, and 5 roM Naz·EDTA.
In addition, a 0.24 -09.5 Kb RNA Ladder (Gibco BRL) was electrophoresed on the same
gel in order to give standards with which to compare the sizes of the transcripts obtained
by probing with each oftbe 3 clones.
A solution of8% formaldehyde, 65% fonnamide, and 1.0X MOPS was made, and
added to the RNA samples to be loaded on the gel, 3.16 jJ.I per j.1l ofRNA and DEPC-
H~O. The samples were incubated. at 70°C for 12 minutes, centrifuged briefly, and 2 }.lol
of 0.1 mglml ethidium bromide in DEPC-H~and 2.0 jJ.I ofRNA loading buffer (6Q01o
glycerol, 50 mM EDTA, 0.1% bromophenol blue, and 0.1% xylene cyanol) were added.
The samples were loaded on the formaldehyde gel and electrophoresed at 5 volts I em
until the xylene cyanol band was approximately halfway down the gel. The gel was then
photographed under ultraviolet light using the ChemiImager 1M 4000 Low Light Imaging
System to check the quality of the RNA samples.
2.8.4 Capillary Transfer of RNA
The RNA was transferred from the formaldehyde gel to a nylon membrane for
probing. Hybond-NX nylon membrane was cut to the size ofthe gel minus the wells.
The membrane was briefly soaked in DEPC-H2.0 and then soaked for 15 minutes in lOX
sse made with DEPC·HzO. The gel tray was inverted in a glass dish containing about
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300 ml of lOX sse. It is important that the gel tray is not submerged. A piece of
Wbatman #3 filter pape::r was draped over the gel tray so that the ends hung down into the
lOX sse to act as wick:s. A sterile Pasteur pipette. soaked in lOX sse, was used to roll
air bubbles out ofthe filter paper. TheweUs were cut offtbe gel and a nick made in the
upper right hand corneL The gel was then laid upside down on the gel tray and the
bubbles rolled out in the same manner. Next the nylon membnme was placed over the
gel and the bubbles rolled OUL A nick was made in the memlmtne to correspond with the
nick in the gel Two pieces of filter paper slightly larger than the gel were laid on top of
this arrangemenL Saram WraplM was placed around the gel and the glass disb to prevent
the evapouration ofSSC during the transfer. Blotting paper (approximately 12cm high)
was placed on top of the filter paper and this whole assembly was covered with Saran
WrapTM. Finally, a 500 g weight was placed on top. The transfer was carried out
overnight at room temperature.
The following day. the transfer was disassembled and everything was discarded.
except the nylon membrane. The membrane was allowed to air dJy for approximately 30
minutes and was then baked at sere for 2 bows., to immobilize the RNA on the
membr.me. The bands COCTespOodingto the 0.24 - 9.5lCbRNA marker were visualiz.ed
under UV ligbtand a pcmcil used to mark the positions oftbc:se bands on the membrane.
A standard plot was procdu.ced by graphing the size of the standard against the distance
migrated. 1bis plot was. used to estimate the sizes of the transcripts detected by the
Northern blotting experi:ments.
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1.8.S Preparatioa or Probes ror NortHl'D BlottiD&
The probes used in the Nonbem blotting experiments were produced by
amplifying the three positive cloDeS with custom designed primers (Gibco BRL.
Gaithersburg, MO). The sequences of these primers are given in Table 2-1. The primers
were designed using the sequences ofthe clones and the Primed Test Pre·Release
Program (Whitehead Institute for Biomedical Research). The use ofcustom designed
primers ensured that the zap Express vector was DOt a part of the probe.
The eDNA insens were amplified with the polymerase chain reaction using their
specific primers. lbe PCR cocktail used for this set of experiments was the same as
previously descnbed with the exception that the final concentration ofMgCh was
ct\aoged from 2.0 mM to 1.5 mM, making the PCR reaction more stringenL The reaction
parameters were also changed to make the reaction more stringent 95"C for 5 minutes,
94"<: for 30 seconds. 56"C (57"C) for- 30 secoDds, TrC for 45 seconds, for 35 cycles,
then n"C for 7 minutes. and stored at 4°C. One probe. MS2 58.4. bad an annealing
temperature of5rC. while the other two probes. MS2G383 and MS2 7.0, had an
annealing temperature of56"C. The templates in each PCR were 0.5 J,J.1 ofthe purified
TIl T7 PCR products.
The amplified probes were purified using the wi2ard'* PCR Preps DNA
Purification System (Promega.. Madison" WI) and then diluted to 5 ngf,..J. Each oftbese
probes was labelled using the n:diprime"lM II random prime labeUing system (Amersham
Pharmacia Biotech). Twenty- five ng ofthe probe was added to 40,..J of IX 1E buffer
(10 mMTris-HCI pH 8.0. I mMEDTA). This mixture was boiled for 5 minutes and
Table 2-1. Sequences of the custom. primers used for amplification ofthe probes used in
Nonhero blottiD . ents IlDd the clones for which tb are me.
Clone Primer Identification Sequence (5' to 3')
Number
t]Y~'jjlO[j.3ct=jMS2G383P~==EC~CT~GCT~~TG~A~~CC~C~TT~C~A~G~A~G~A~~Ya 10.3 C A OCT CCC OTT CA ATT cr7.0 TGA TIO TGA AGG CTG TGA CC
7.0 TIT CIT GGT TIO ccr TGC TI
58.4 TIC CCA AOA ACG AGA AGG AA
58.4 TGA GAG TIT GAA TOC ACA GCA
III
immediately placcdon ice. The denanucdprobe was added to a redipri.melM IT random
prime labelling system miCtion tube (containing dATP. dGTP. dTTP. exonuclease free
Klenow enzyme, and random. primers). Five J,l1 of[a_J2p) dCJ1:l (3000 Cilmmol) was
also added to the tube and the ingredients mixed by pipetting up and down scveraI times.
The reaction tube was incubated at 3TC for 45 minutes.
Unincorpomcd nucleotides were removed from the labelled probe by Sepbadex
G-SO chromatography. A lee. syringe was plugged with sterile glass wool and filled with
Sephadex G-50 suspended in IX 1E, pHS.O. The syringe was placed in a Falcon tube
and centrifuged at 200 g for 3 minutes. The syringe was again filled with Sephadex 0-50
and centrifuged at 200 g for 3 minutes. The syringe was then placed in a Falcon tube
with a 1.5 m1 microcentrifuge tube in the bottom and the labelled probe was added to the
center ofthe resin. This was centrifuged for 5 minutes at 200 g. Fifty J.l1 of IX IT buffer
was added to thecentc:r oftbe resin and the column centrifuged at 200 g for S minutes.
The probe was tIansfe:rred to a new microcentrifuge tube and IJ,l1 was removed for
counting in the scintillation countr:r. 1be volwne of probe to be added to the Nortbem.
blot was calcula1ed using the following formula: 1.5xlcftCPM - the Dwnber ofJ.l1 of
probe required pc:rml ofbybridization solution.
2.8.6 Hybridization of Probes
The blot was briefly soaked in 2XSSC and sealed in a hybridization bag. Ten ml
ofprewarmed (6S"C) ExpressHyb™ Hybridization Solution was added and the blot was
prebybridized at 65°C for 30 minutes with gentle rocking. The appropriate amount of
probe was boiled for 5 minutes, cooled on ice, and briefly centrifuged before being added
to the prehybridized bloL At this stage it is important that the labelled probe be
added to the hybridization solution in the hybridization bag and not directly onto the bloL
The blot was hybridized at 6S"C for 60 minutes with gentle rocking.
Next, the blot was washed with lXSSC/I% SOS at room tempemturefor 15
minutes, then with O.SX sse I 0.5% SOS at room temperature for IS minutes, and finally
with O.IX SSC I 0.1% SOS at room temperature for IS minutes. trthe background was
still high when checked with a Ge1ger counter. the blot was washed in O.IX SSC I 0.1 %
SOS at 420C for 15 minutes. The blot was exposed to Biomax'tM film (NENThiI Life
Science Products. Boston, MA) overnight at _70°C and developed the next day. Iftbe
film was weak the blot was exposed for a longer period of time before being developed.
The same blot was used for two of the probes., ya 10.3 and 58.4. In addition, the
blot was also probed with beta-actinas a control probe. The remaining probe, 7.0, was
tested on a multi-tissue blot purchased from QODtccb. which was generously provided by
Mr. Mike Witeber (Dr. Allan Pater Laboratory, Memorial Uni~ityofNewfoundland,
SL John's, Newfoundland. Canada). This blot was also hybridized with beta..actin as a
control After each hybridization was complete the blots were -stripped" by incubating in
a boiling solution of 0.1% $OS IIIl1iI counts were no longer detected with the Geiger
counter. The blots were exposed overnigbtat-7ifC and developed the next day to
ensure that there was no radioactivity presenL Before the blots were used again they
were rinsed in 2X SSC.
Chapter Three Results
3.0 Construction aDd Screening or the MS2 eDNA Library
Messenger RNA isolated from several multiple sclerosis plaques was used 10
construct a directionally cloned eDNA expression library in the A. Zap Express vector.
This library, denoted. MS2. contained. approximately 800 000 clones, with tess than 4%
non-recombinants. Primary serological screening ofthe llbrary with pooled patients' sera
identified 62 positive clones. Ofthese, secondary screening showed 30 to be false
positives, while 26 were IgG. Photographs of a representative NZY plate used for
primary screening. and of a nitroceUulose membrane used in the secondary screening
process are in Figw-es 3-1 and 3-2, respectively.
The remaining 6 positive clones were partially sequenced and the nucleotide
sequences sent to FASTA and BLAST for comparison with DNA and RNA databases.
As the time allotted for the completion ofthe Master's project did not permit the study of
all 6 clones. it was decided that only 3 ofthe clones would be investigated. These 3
clones were selected based on the number ofsera with which each reacted, and their
percent homology with known proteins. Two ofthe ''rejected" clones encoded unknown
proteins. The produetofooe ofthese clones reacted with 4 out of 18 sera, while the other
reacted with 3 out of 18. The third clone encoded a nbosomal protein and the product of
this clone reacted with 2 out of 18 sera. Due to the amount oftime required to
characterize a previously unknown protein, by others in the research laboratory ofD.G.
Haeger!, it was decided that the remaining clones would be left for analysis in a future
project. The clone numbers, the FASTA identification, the percent homology, the
Figw-e 3-1. A photograph ofan NZY agar plate used for primary screening. The plate
was incubated overnight at 37"C with 600 J,.Ll ofXLI Blue MRF' bacteria and a suitable
volume ofMS2 eDNA phage to give an appropriate Dumber ofplaques for screening.
The plaques are identified as "holes" in the lawn ofbacteria.
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Figw-e 3-2. Photograph ofa nitrocellulose membrane used for secondary screening. A
quarter of the NZY agar plate was incubated overnight at 31'C with 200 ~ ofXLI Blue
MRF' bacteria and an appropriate volume of a dilution of the "plug". The quarter was
overlaid with the nitroceUulose membrane and incubated for 3 hours at 31'C. The
membrane was subsequently removed. washed with 0.05% Tween 20 fiX TBS, blocked
with 5% milk fiX TBS, then incubated with 112500 patients' serum. Positive clones
were detected with alkaline phosphatase-<:onjugated AffiniPure anti-human IgG, Fey
fragment specific antibody. Positive clones are identified as dark purple circles against a
light purple background, or in this case a dark circle on a lighter background.
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number ofsera with which each c10De was reactive, the RETRIEVE accession code, and
the approximate size ofthe "selected" clones an: given in Table 3-1. The resultsobtaiDed
from the BLAST searches are not given in Table 3-1 as they were virtually ideutical to
those ofthe FASTA searches..
Four hundred eighty-slx base pairs (bp) of clone: ya 10.3 were sequenced from the
S· cod (The preliminary sequcocing ofya 103 was performed by myselt however, the
extension oftbe sequeoce and the selection of intema1 primers was done by Mr. Dante
Galut:iJa..) A FASTA search indicated that this sequence is 98% homologous with that of
testican. The: ya 10.3 clone was approximately Il6S bp and the produetofthis clone
reacted with 2 ofthe 18 sera tested. A search ofthe BLAST dbEST database indicated
that this molecule is expressed in human fetal brain and retinal pigment epithelium. (In
each of the dbEST searches descnbed in this thesis a score of 100 was used as tbecutoff'
point ofsignificancc as descnbed by Blond et al. (1999)). The ya 10.3 sequence was also
submitted to the Baylor CoUege ofMedicine Human Genome Sequencing Center website
and analyzed for translation in 6 reading frames. One hundred sixty-ooe amino acids
were identified in frame +3 with no stop codons.. Therefore,. the ya 10.3 sequence lies
within an open reading frame ofat least 161 amino acids.. This derived amino acid
sequence was compared with the 439 amino acid sequence oftestica.n. Amino acids 1 to
IS7 ofthe ya 10.3 sequence were 97% homologous with amino acids 2.SS to411 ofthe
testican protein. Therefore, ya 10.3 corresponds to a part ofthe open reading frame of
thetestican gene. The remaining 4 amino acids ofthe derived ya 10.3 sequence were not
homologous with the testican amino acid sequence. This is unexpected as the nucleotide
Table 3·1. The FASTA identification, percent homology, RETRIEVE accession code,
estimal:ed size. and Dumber ofsena which gave positives, for each of the three positive
clones found to be suitable for further study.
Clone FASTA p= RE1RIEVE Number of Approximate
Identification Homology Accession Sera which S;ze(bp)
Code gave
Positives 118
Ya 10.3 Testican 98 X73608 2 1165
7.0 H. sapiens 97 AbOll102 2 2015
mRNAfor
KlAA0530
58.4 Hsapien.r 94 L09749 1165
c1ooef4
a,,,,,,,,mbw>e
-torn
sequences of clone ya 10.3 and testicao were 98% bomologous. However. closer
examination ofthe FASTA results revealed that this bomology was obtained through the
insertion ofa "gap" in the testican sequence at positioo 1663. thereby causing a frame
shift. Ifthe sequencing results are correct then c10De ya 10.3 and testican are not
identical sequences. but rather are related sequences. Ofcourse, it is possible that
sequencing errors in either clone may be respoosible for the differences in the amino acid
.....ences.
Two hundred thirty-seven base pairs ofclone 7.0 were sequenced from the 5' end
and this sequence correspooded most closely to Homo sapiens mRNA for KlAA0530.
The sequence had 971'10 homology. The 7.0 clone was approximateLy 2015 bpand the
product of this clone reacted with 2 out of 18 sem. A search of the BLAST dbEST
database demonstrated that this molecule is expcessed in germinal center B lymphocytes.
an ovarian cancer. and oonnal kidney. 1be 7.0 sequence was also analyzed for
translation in 6 reading frames. Seventy-nine amino acids were idenrified in frame +1
with no stop codoos; i.e. the 7.0 sequence lies within an open reading frame ofat least 79
amino acids. A comparison of the clone 7.0 derived amino acid sequence ....-ith the known
amino acid sequeoceofKlAA0530 demonstrated 100% bomologybel'ween the putative
amino acids 1 to 67 ofclone 7.0 and 1083 to 1149 ofKlAA0530. 1be remaining 12
amino acids ofthe putative 7.0 sequence were not bomologous with the KlAA0530
sequence. This at first seems surprising, as the nucleotide sequences of the two were
97% homologous. However. closer examination of the FASTA results revealed that this
homology was obtained by adding "gaps" to the clone 7.0 sequence at positions 200 and
n9
22 L This explains the different reading frames between the two sequences. AsswniDg
that the sequeocingofclone 7.0 is correct,. the rcsuJts suggest that clone 7.0 and
KlAA0530 may be related sequences but I10t identical sequences. Alternatively,
sequencing errors in either clone would lead to the observed differences in amino acid
seq","",.
Two hundred fifty-seveo. base pairs ofclone 58.4 were sequenced from the 5' end.
This sequence corresponded most closely to Homo sapiens clone F4 tnmsmembrane
protein in the FASTA database. The homology was 94%. This clone was the same size
as ya 10.3 and the product oflhis clone reacted with 3 outofl8 sera. A search of the
BLAST dbEST database did Dot find any matches with a score greater than 100. The
58.4 sequence was also analyzed for translation in 6 frames. Eighty-five amino acids
were identified in frame + I with no stop codons; i.e. the 58.4 sequence ties within an
open reading frame ofat least 85 amino acids. Although the amino acid sequence
correspooding to the clone F4 transmembrane protein bas oot been reported. I obtained
the nucleotide sequence from BLAST using the accession code L09749 and submitted the
sequence to tbcBaylor College of Medicine Human Genome Sequencing Center website
for translation in 6 reading frames. Only 64 amino acids were translated before a stop
codon was identified. As well, all 6 reading frames contained multiple stop codons. This
leads me to believe that the sequence submitted by Andrews (1993. UDpublished) to the
database does Dot correspond to the "clone F4 transmembrane protein", 1be submitted
nucleotide sequence does Dot contain an open reading frame, Thus the 58.4 sequence
could be the 3' end ofsome other scqUCDCC that~ homology to the putative clone F4
transmembr.me protein.
Although three clones were not investigated in this study, each was partially
sequenced from the S· end aDd the resulting sequences were compared with the BLAST
dbEST database and wee analyzed for tIanSlation in 6 frames.. There wete DO ma%Cbes
with scores greater than 100 for the two seqUCDCCS whicb encoded unknown proteins..
The third sequcncc was fnund to encode a molecule known to be expressed in a large
number of tissues including thymus, small intestine., T lymphocytes, retina, and fetal
brain and lridney. For simplicity these clones win be referred to as A, B, and C. Clones A
and B encode unknown proteins. clone C encodes a nbosomai protein. Analysis ofthe
1i 8 base pair sequence of clone A for tIanSlation in 6 reading frames identified 37 amino
acids in frame + I before a stop codon was identified. This means that at most the clone
A sequence contains an open reading frame correspooding to 37 amino acids and the
remainder ofthe 3' sequence is noo-coding. The same analysis of me 144 base pair
sequence ofclone B identified 47 amino acids in frame +3 with DO stop codons. Analysis
of the translation in 6 reading frames oftbe 244 base pair sequence of clone C ideutified
80 amino acids in frame +3 with no stop codons. Therefore, clooes B and C likely
contain open reading frames correspooding to at least 47 and 80 amino acids,
respectively.
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3.1 Nortben BlottiDc Experiaeats
Northern blotting was done with PCR-amplified fragments~odingto 428
base pairs ofcloDC ya 10.3, ISS base pairs ofelone 7.0, aod. 190 base pairs ofclone 58.4.
The results oftbese Northern blotting experiments are shown in Figures 3-3 and 3-4. As
descnbed in the section"1>ot Blotting ofme rsolB1ed RNA", the RNA samples used foc
the Northern blotting experiments~ normalized before being electrophoresed on an
agarose , formaldehyde gel by performing a dot blot with a beta..actin probe. The
samples on the Oontech blot were normalized by the manufacturer with a beta-actin
probe. A sequence hybridizing with the ya 10.3 probe was identified in adrenal. brain.
colon, and testis. The intensities ofthe bands were very similar in each of these samples,
indicating similar expression ofthe testican transcript in each oftbese samples. The
remaining samples, cervix, liver, spleen.. and thyroid., showed much weaker bands,
indicative of lower testican expcession, ifany. A sequcocc hybridizing with the 58.4
probe was found to be strongly expressed in testis, with oegIigtble expession in adrenal,
brain, cervix, colon, liver, spleen,. aDd thyroid.. A sequence hybridizing with the 7.0
probe was found to be weakly expressed in all ofthe tissues tested. heart, brain. placenta,
lung, live!", skeletal muscle., kidney, aDd pancreas..
The sizes oftbe transcripts detected on the Northern blots were estimated by
using the standard plot descnbed in the section '"Capillary Transfer ofRNA". The
transcript to which ya 10.3 bound is estimated to be 1.1 Kb, for 58.4 it is estimated to be
3.7 Kb, and for 7.0 it is estimated to be 0.9 Kb, Figures 3-3 and 3-4.
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Figure 3-3 Northern blot ofbeta-actin, ya 10.3, and 58.4. The probes were prepared with
the rediprime™ II random prime labelling s~(em. Hybridization was carried out with
ExpressHyb1M Hybridization Solution at 65 C for 1 hour. The blots were washed with
lX sse I t% 50S at room temperature for 15 minutes, O.5X sse 10.5% SOS at room
temperature for 15 minutes, a.lx SSC/O,I% 50S at room temperature for 15 minutes,
and finally with 0.1 X sse I 0.1% 50S at 42°C for) 5 minutes. The sizes written below
each clone represent the estimated sJzc oftbe transcript to which it is bound. These sizes
were estimated using a standard plot as descnbed in the section "Capillary Transfer of
RNA".
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Figure 3-4 Northern blot (Clontech) ofbeta-actin and 7.0. The probes were prepared with
the rediprime1M II random prime labelling s~tem. Hybridization was carried out with
ExpressHyb1'M Hybridization Solution at 65 C for 1 hour. The blots were washed with
IX sse 11% 5DS at room temperature for 15 minutes, O.5X sse 10.5% 50S at room
temperature for 15 minutes. a.lx sse 10.1% SOS at room temperature for i5 minutes,
and finally with a.lx sse 10.1% SOS at 42°C for 15 minutes. The sizes wrinen below
each clone represent the estimated size: of the transcript to which it is bound These sizes
were estimated using a standard plot as described in the .section "Capillary Transfer of
RNA".
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CUpter Four Diseusioa
4.0 Multiple Sclerosis Aato..tigeas
Multiple sclerosis is believed by many investigators to be an autoimmune disease
(Stinissenetal,I997;EwiDgandBemard, 1998). Iothecontextofautoimmunity.much
work: in multiple sclerosis bas focused upon the identification ofaD autoantigen(s)
rcspotlSIble for the initiation and/or petpetuation ofthe disease. To date it is oot possible
to say with complete confidence that such an autoantigen(s) has been found (see
however, a review by Weiner. Can. J. Neurol Sci., 1998). A number of myelin
constituents have been investigated as poss1bte autoamigens in MS. including MEP, PLP,
MAG. MOO and others. T and B Iympbocytc responses to these proteins have been
demonstrated in patients with MS. As wcn. antibodies specific for these proteins have
been isolated from MS patients (panitch et al.• 1980; Gorny et al., 1983; Wajgt and
Gomy. 1983;Cruzetal., 1987; Link et al.• 1989,1990; MoUeret al., 1989; OtaetaL,
1990; Olsson etal., 1990a.I992; Baigetal., 1991; Stmetal.. 199Ia,b;Cbouetal.• 1992;
Kerlero de Rosbo et al.. 1993,1997; Gerritse et al., 1994). Perhaps the strongest evidence
implicating these proteins as autoantigens in MS is that they can induce EAE in animal
models (Paniteh and Ciccone, 1981; Yamamura et at., 1986; Satoh et al., 1987; Pender.
1988; Johns et al., 1995).
Although there is DO definitive evidence to support these myelin compooents as
being responsible for the myelin damage observed in multiple sclerosis. there is evideDoe
which questions their importance in this process. Fim, T and B lymphocyte responses,
and ann"body responses, to these autoantigens are not specific to MS. In each of the
studies cited above these responses~ also observed in healthy controls and patients
with other neurologic disorders.. Second. in the majority ofMS patients the oligocloaal
baDds in the CSF do DOt contain significant amounts of anti-myelin annbodies (Nobile-
Orazio etal.• 1987; Kaiser etal., 1997). It is possible that the immune responses to these
myelin proteins observed in MS patients are the result of previously sequestered
autoantigcns being released after myelin injwy.
Since the lesions in multiple sclerosis typically involve the white matteroftbe
CNS, the optic nerve, and the retina (Antel and Amason, 1991; Boccaccio and Stcinman,
1996; Kerrison. et al., 1994; Lucchinettiand Rodriguez, 1997; Martin, 1997; Stinissen et
al, 1997), one would expect that the expression ofautoantigen(s) important in MS would
also be mainly limited to these areas. In particular, they should be limited to the myelin
andfoc the myelin producing cells ofthe CNS, the oligodendrocytes, or to some other
component ofthe CNS such as astrocyteS ortbe endothelial cells ofthe BBB. 1be fact
that lesions are identified in the retina ofMS patients is unexpected as the retina does not
possess myelinated fibers, however, it does express CNP (Walsh and Murray, 1998). If
MS is indeed an autoimmune disease, then it is also important that the autoantigen(s) be
accessible to the immune system. Both MOO and PLP, unliJce MBP and MAG,~ found
only in CNS myelin. and MOO is found on the extracellular surface ofoligodendrocytes
and the myelin sheath. Although PLP is an integnL1 hydropbobic membrane protein. it
too is somewhat accessible to an immune response.
A number of autoantigcns have been identified in MS. However, the question
still remains as to whether these autoantigens actually initiate the immune response which
leads to myelin damage or whether they become immune targets as a result ofbystaDder
activation. The importance ofthe immune response to these autoantigens in the
destruction ofmyelin is also still under investigation.
The majority of studies which have identified myelin constituents as autoantigens
relied on methods which n:quired the investigator to examine the immune response to a
particular autoantigen, for example solid-phase radioimmunoassays, immunoadsorbent
assays, ELISA., immunoblot assays, the: use of monoclonal anllbodies to myelin
constituents. and antigen-induced secretion ofIFN..y. These techniques are necessarily
"biased" with respect to the autoantigen which they are able to identify. As there is no
concrete: evidence implicating an immune response to myelin components in the initiation
of multiple sclerosis. I thought that a more unorthodox approach to identify potential
autoantigens in MS was warranted.
4.1 The SEREX TecbDiql1e
The work. described in this thesis was basc:d on the hypothesis that one or more
previously unidentified autoantigens may be targets ofan anllbody response in MS. The
approach was designed to identify autoantigeos without any a priori assumptions as to
what these autoantigens would be. The SEREX technique developed by Sabin and
Tureci (Sabin etaL, 1995) had previously been used to identify novel tumor antigens in a
number ofdifferent cancers and so was adapted faT use with multiple sclerosis. The
SEREX method identifies autoantigeos which have elicited a high titer antibody response:
(Chen et a1., 1997). This implies that the antigens identified are not only B lymphocyte
antigens. but are also T lymphocyte antigens. as the production of high anubody titers
requires T lymphocyte help. Therefore. even though the aetuaI. identification of
autoantigens through SEREX relies upon antibodies in the patients' sera. these
autoantigens could subsequently be examined for a role in the cellular immune response
ofthe patient. In fact, the SEREX technique bas identified tumor autoantigens. which
had previously been identified by cytotoxicity assays (Chen et aL 1995). This is an
importanl: p:lLnt. as multiple sclerosis is believed to be primarily a T lymphocyte mediated
disease (Stinissen ct aI., 1997), see also the section "The Role of the T Lymphocyte",
The SEREX technique adds a potentially new dimension to serological screening.
The identification ofa putative autoantigen can be easily and quickly followed by cDNA
sequencing and investigation ofmRNA expression patterns. In addition, SEREX is able
to reoognize both intracellular and cell swface antigens (Chen et al., 1997).
When considering the antigens which can be recognized by the SEREX technique
it is important to differentiate between confomllltional and linear epitopes.
Conformational epitopes can be defined as epitope:s in which the amino acids are not
close together in the primary strucnue of the protein, but are brought closer together
through protein folding. Although the conformation of the protein is integral to the
immune response of such as epitope. certain pans ofconformational epitopes can be
mimicked. by peptides, known as mimotopes (Morris, 1996). In contrast, lineae epitopes
are simply a series ofadjacertt amino acids. Such epitopes can easily be mimicked by
peptide sequences. B lympbocytes are able to recognize both conformational and linear
epitopes, while T lymphocytes recognize peptides presented by the MHC molecules.
Slncc: a DOvel autoantigen in MS could represent a previously unknown molecule,
there is no way ofpredieting if its recognition by the immune system will be due to
confonnarional or lineae epitopes. Iftbe autoantigens in multiple sclerosis are recognized
through conformational epitopes. they may be difficult or even impossible to identify
through the annOody screening ofan MS cDNA expression library. The reasons for this
are as follows: (1) the correct folding of the protein. or protein fragment, may not occur
in the bacterial expression system. (2) the expression oftbe full transcript may be
oecessary to produce the native form ofthe protem. and therefore the conformational
epitope (in general the cDNA insetted into the phage vector does oot cootain a full
transcript), (3) the post-translational modifications which may be required for the
recognition ofsuch epitopes do not occur in the bacterial system wbich expresses the
protein, and (4) it is also poss:i'ble that certain conformational changes of the epitopes may
occur when they are expressed in the bacterial system (Tureci et aL, 1997). However, if
the antibodies produced against the conformational epitopes are able to recognize
mimocopes, then they would be expected to be recognized by SEREX. OfCO~,
antibodies produced in response to linear epitopes should also be detected with this
methodofscreening.
Although it is generally believed that the majority ofhUIDOl3.1 responses are
direc::ted against conformational epitopes, Genain et at (1999) were able to demonstrate
that specific autoantibodies bound to myelin can be identified using gold-conjugated
peptide antigens. 1berefore. it is possIble that even if the antibodies in the patients' sera
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are produced against conformational epitopes they may recognize the proteins expressed
in the MS2 expression hbrary.
4.1 Studies Usiag Ubnuia to Ideatify Malti.pk Sclerosis ADticeu
Sttldies similar to the ODe descn'bed here have been reported. but did not idemify
autoantigeo(s) specific to multiple sclerosis. Owens ct al (1996) used mRNA isolated
from chronic and acute multiple sclerosis plaques and from periplaque white matter to
construct a directional eDNA expression hbrary. The resulting libraries were screened
with CSF from MS patients, or with IgG extracted from MS sera or CSF. These authors
also used subtracted cDNA libraries in order to enrich mRNA sequences which were
unique or over-represented in the MS plaque as compared with normal white matter.
Screening of these libraries did not detect any sequences unique to MS, D.or did it detect
MBP or any other myelin specific proteins.
Cortese: ct al. (1996) screened random peptide horaries displayed on phage with
sera and CSF ofMS patients and with sera of controls. Although screening this hbrary
with two CSF samples did DOt rew:a.l any MS specific antigens. it did identifY eenain
common motifs. More importantly, this study and a similar study by this group in 1998
led to the following conclusions: (I) "'annbodies displaying the same biDding specificity
are present in the CSF and serum of the same patient. (2) these anbbodies may be
directed against ubiquitous antigens, (3) some oftbese anbbodies are specifically
enriched in the CSF', (4) it seems that each MS patient has a different set ofintrathecally
produced antibodies in the CSF, and (5) anti-pbagotope (phage displayed epitope)
annbodies aJe foWKl in the sera ofhealthy individuals as well as those of MS patients_
Beck.eret al (1997) constIUClcd a oonnaIizcd eDNA library from plaques ofa
chronic progressive MS patient. The majority of cDNAs in the library represented
unknown or uncharacterizcd genes. However, 54 cDNAs correspooded to genes kDov.n
to be involved in immune activation, such as those encoding MHC molecules, cell
adhesion molecules, and cytOkines and cytOkioe receptors. In addition, 19 cDNAs
encoded mown or suspected autoantigeos., including MBP and PLP. This study did not
identify any eDNA sequeoces identical to those ofany infectious agents.
Archelos et aI. (1998) used an oligodendrocyte-precursor cell line to construct two
expression ltbraries, which were subsequently screened with pooled CSF from MS
patients and patients with other neurologic diseases. This screening identified only 6
positive clones, none ofwhichcorrespooded to a known protein.. However, S of the 6
clones contained a common 7 amino acid sequeoce (EKPCLEK) which is highly
homologous to the translated consensus A/u repeat epitope. These investigators were
able to show tha1 approximately 44 percent ofrelapsingfremitting MS patients possess
annOodies specific for this moti[ Although a lower percentage of primary and.sccoodary
progressive MS patients. healthy controls, and patients with other neurologic disorders
also possess these anbbodies. the titers are highest among the relapsinglrem.ittiDg
subjects. This group of investigators have come closest to identifying MS specific
autoantigens.
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Alu repeats are short. repetitive elements found in the moons ofalmost every
known protein.encoding gene ofhumans and other primates (Makalowski et al., 1994).
There are a number of mechanisms by which these repeats may Lead to disease, these are
discussed in the section "Studies Relevant to the Master's Project Discussed in this
Thesis". The Alu peptides discovered by Archelos et aI. (1998) may represent translated
Alu repeat epitopes, epitopes ofan unknown oligodendrocyte protein, or regulatory
molecules.
In summary. it seems clear that even though use ofexpression libraries bas
potential to identify autoantigens in MS, the method bas led to few findings of
significance to date.
4.3 Reoognition of Self-pr'Oteins or SeIf-peptides as AntoantlgeDS
Why would self.proteins or -peptides be identified as autoantigens by the
immune system? There are a number of possibilities to explain this:
I. Failure ofcentral tolerance (negative selection). The process of negative
selection, which occurs in the thymus, is responsible for the "e1imination" of
self-reactive T lymphocytes. either through anergy or deletion (Abbas et al.,
1994). If this process fails then potentially self-reactive T lymphocytes are
released into the periphern1 circulation.
2. Failure of peripheral tolerance. Peripheral tolerance is the process which
maintains tolerance when self-reactive T lymphocytes escape negative
selection, or when tissue-specific antigens are DOt present in the thymus
(Abbas etal. 1994). Peripbera! toler.wce is believed to result from anergy or
deletion. For example. when seIf...antigcns are~ to T lymphocytes by
anrigen.presenting celts which do DOt expr!:SS the proper co-stimulatory
molecules the T lymphocytes are rendered anergic (Brown et at.• 1998).
However. if these antigen·presenting cells are activated., by cenain cytokines
for instance. and the expression oftile co-stimulatory molecules is up-
regulated, then tolerance may be lost.
3. 1be autoantige:ns may be released following injury to the myelin sheath. 1be
myelin sheath is located in an immunologically privileged site. Therefore the
release of myelin coastituc:nts, such as MBP, might be expected to elicit an
immune response (Martin et aI•• 1992a; Poser. 1993; Hoblfeld et at.• 1995)-
4. Defects in immune regulation. A number ofimmunological aboonnalities
have been demonstrated in multiple sclerosis patients. For example.
Neighbour (1984) found that lymphocytes isolated from MS patients and
subsequently stimulated, produced lower levels ofIFN.y than lymphocytes
from control subjects. In addition, a significant proportion oftbc MS patients
bad reduced. levels ofendogenous and augmented NK. cell activity. Coomen
et al. (1988) demoostrated that patients with progressive multiple sclerosis bad
decreased functional suppression and decreased autologous mixed Lymphocyte
reactions as compared with controls.
5. The epitopes of the self-protein may be processed and presented differently by
the antigen·presenting cells ofmultiple scl.erosis patients as compared with
normal individuals, or the post-translational modifications of tile proteiD may
differ in MS patients as compared with normal individuals.
The identification of a potc:oti.al autoantigen usmg the SEREX technique must be
followed by a study of: (1) the tissue specificity of tile antigen, (2) the annbody responses
to this antigen in both the sen. and CSF ofbcalthy coatrols. patients with other neurologic
disoniels. and a larger number ofMS patiems. and (3) the T lymphocyte response to the
antigen in vitro.
4.4 Tile Serological ScreeniDc of tbe MS2 eDNA EIpreuioD. Library
The serological screening of a eDNA expression library constructed with mRNA
extracted from MS plaques yielded a total of6 positive clones. In the lnterestoftime. it
was decided that only 3 of these clones would be investigated. those corresponding most
closely in sequence to testican, clone F4 transmembrane protein, and KlAAOS)O. The
other 3 cloocs. a nbosomal protein and to.\ou unknown proceins. were excluded because
they did not react with more than 2 seta (the clone which eocoded the n"bosomal protein)
or because time did DOt permit the cbaracterization of tile proteins (the clones which
encoded unkno",n proteins). However. these clones are still worthy offurther study. If
time bad permitted. sequences from these clones would also have been amplified and
used as probes in Nonhero bloltiog experiments, as were ya 103, S8.4, am 7.0. As well,
the sequences ofthese clones could have been extended S·, the proteins isolated, and used
in ELISAs and Western blots to study anu"body reactivity to these proteins using a large
number of sera and CSF samples ofMS patients and healthy controls.
4.4.1 ClooeVal0.J
The sequence obtained for the ya 10.3 clone corresponded to put oftile open
reading frame encoded by the testican gene. Testican was identified by Alliel et aI. in
1993, using a probe which corresponded to the lim 13 amino acids ofa
g1ycosaminoglycan-bc:aring peptide from human seminal plasma to probe a human
testicular DNA library. In 1996. Bonoct etal. identified testican in mouse brain. They
found that the protein core oftbeirproteiD was 95% homologous with its hwnan
testicular counterpart. In the mouse brain. testican appeared to be present mostly in the
postsynaptic regions ofa subpopulation ofpynunidaJ neurons in a specific area ofthe
hippocampus. Although the function oftestican bas yet to be elucidated, this
multidomain protein shares similarities with proteins involved in adhesion, migrn.tion,
cell proliferation, neural development, synaptogenesis, and synaptic transmission (Bonnet
et aI., 1996} Amore recent study established the location of the testican gene, now
known as the SPOCK (an acronym for. SPARCIosteonectin. CWCV. andKazal-lilce
domains ofproteoglycan) gene, to be Sq31 (Charbonnieret al.. 1998). This is
particularly interesting as this region contains the genes encoding growth factors.
eytokioes, and oeurotransmitter and bonnone receptors. The SPOCK gene borders the
smallest commonly deLeted region ofchromosome 5. To date there is DO information
regarding the investigation ofthis region ofchromosome 5 in relation to multiple
sclerosis. However. a Finnish study provided evidence for an MS swcepttbility Locus on
Spl4-p12 (Kuokkanen et aI., 1996).
The BLAST dbEST database idcatified the molecule conesponding most closely
to clone ya 10.3 as being expressed in brain and retina. This suggestS that ya 10.3 may be
an important amigen in multiple sclerosis. as brain and retina are two areas in which
lesions are observed in MS patiems (sec however, the DCXt pan.grapb). The fact that part
of tile ya 10.3 amino acid sequence: is homologous with amino acids 255 to 411 ofthe
testican protein indicates that ya to.3 likely enc:odes for part ofthe test:ican molecule.
However, the homology between the two sequcoces tenninatesat amino acid 411 of the
testican gene. This unexpected result can be explained by the fact that the FASTA
program inserted a "gap" into the test:ican sequence at position 1663 in order to achieve
maximal alignmenL There are two possible explanations for the non-homologous region
between clone ya 10.3 and testican. First, cycle sequencing is DOt 100 percentaccurale
(Alpbey, 1997) and therefore, a nucleotide maybave been erroneously inserted in the
clone ya 103 sequence leading to a frame shift compared to testican. Second, the ya 10.3
clone and testican are related genes. To resolve this issue it is necessary to extend the ya
10.3 sequence both S· and 3' and compare the derived amino acid sequence with the
amino acid sequence oftestican..
Northern blotting experiments carried out as part of the work for this thesis, found
transcripts hybridizing to the putative testican probe to be present in 4 out of g tissues
tested, adrenal, brain, colon, and testis, Figure 3-3. In contrast, a study by Mart et al.
(1997), demonstrated that test:ican mRNA was present in high levels in a human vascular
endothelial cell line. This suggests that testican mRNA should be present in most human
organs. Northero blotting experiments perfonned. by this group detected testican mRNA
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in samples ofa number ofhwnan organs. However, they did not detect mRNA specific
for testican in the other cell lines they tested. This led them to conclude that testican is
differentially expressed. Ifthis is true., then the expression oftestican may differ in
patients with multiple sclerosis as compared with normal bealthy individuals..
In the section "'Multiple Sclerosis Autoantigens", it was hypothesized that a
relevant autoantigen in MS would be restricted to the central nervous system.. However,
the study by Man et aL (1997) demonstI31ed that testican mRNA is present in most
human organs. lbis creates a dilemma. Iftestican is oot a CNS-restricted protein., bow
can it be a relevant autoantigen in MS'? The most plausible explanation is the bystander
effect According to Ebers (1998), ..... tissue injury mayOC(:ur as part ofa bystander
effect and that myelin could be injured as the result of an immune reaction to a
nonmyelin antigen". Perhaps. the primary target is present in the CNS, but is neither a
myelin nor an oligodeDdrocyte antigen, for example it could be an endothelial antigen.
such as testican. An. immune response against. a specific endothelial antigen may lead to
majorcbanges in the BBB, including a breakdownoftbe BBB si.milarto that observed in
MS patients. Why such cbanges would be localized to the CNS is uncertain since
endothelial cells are almost ubiquitous in the body.
The estimated size oftbetestican tJ:anscript is 1.1 Kb. Th.is is approximately the
same size as the cLone ya 10.3 which was isolated from the MS2 eDNA library, Table 3·
I. Knowing that ya 10.3 does not encode for the entire testican protein it is DOt expected
that the clone and the tnmscript: to which it hybridizes would be the same size. Perhaps
this is due to the imprecise method ofestimating the sizes oftbe bands on the gels (Dr. D
Healey. personal communication}. Ifthe sequence for testican submitted to BLAST
represents the entire testican gene., then the transcript would be expected to be
approximately 3.5 Kb, as this is the size of the sequence submitted by Alliel et al. (1993)
However. Marret al. (l997) reponed thataltbough the sequence published by Alliel et aI.
(l993) represents the entire open reading frame., the testican mRNA is in fact closer to 5
Kb. They also state that more than 60 percem. ofthis mRNA is 3' untranslated sequence.
The fact that the expected and estimaIcd ttanscript: sizes arc different may be due to the
ya 10.3 clone being homologous with the test:ican transcript only at the sequences that
were compared. Perhaps ifthe ya 10.3 clone were compared with the testican sequence
outside this region the two would not be as similar or may not share any homology at 8;11.
It is also possible that the ya 10.3 clone is the product of a related gene and/or that the
testican andya 10.3 gene producu belong to the same gene family.
4.4.2 Cloae 7.0
A FASTA search of tile sequence obtained for clone 7.0 fouod it to correspond
most closely with KlAA0530 (97% homology). However. a comparison of the amino
acid sequence ofKlAA0530 with the putative amino acid sequence ofclone 7.0 found
that only 67 of the 79 amino acids encoded by clone 7.0 were homologous with the
sequeoce ofKlAA05JO. This unexpected result can be explained. by the fact that the
FASTA program inserted two "gaps" into the nucleotideseq~of clone 7.0 at
positions 200 and 221 in order to achieve maximal sequence alignment. As with clone ya
10.3. two possible explanations may be suggested for the nem-homologous regions of
clone 7.0 and KlAA0530. First. cycle sequencing does lead to sequcncingerrors
(Alpbey, 1997) and therefore nuc:leorides could have been erroneously omitted from
clone 7.0 leading to a frame shift compared to KlAAOS30. Second, the molecule
encoded by 7.0 could be the produe:tofa gene related to the KlAAOSJO gene. Further
work. including extending the sequeoce S· and 3' and once again comparing the derived
amino acid sequence with the amino acid sequence oflQAA0530 and with a database: of
other known amino acid sequences is needed to resolve this issue.
The KIAAOSJO protein bas not been extensively stUdied KlAAOS30 was isolated
from a human brain cDNA library by Nagase et aI. (1998). This protein has been
identified as a zinc finger protein and is encoded on chromosome 6. The zinc finger
proteins are a group of transcription factors (Mathews and van Holde, 1990). Antibodies
specific for such proteins could inhibit the transeription of certain mRNA molecules,
thereby preventing the production of the proteins encoded by the paniculac mRNA. In
the case ofmultiple sclerosis such proteins may include those necessary for the
production andfor maintenance of myelin.
A search of the BLAST dbEST database identified the molecule conesponding
most closely to clone 7.0 as being expressed by genninal center B lympbocytes and in
normal kidney. The Nortbem blotting experiments camed~ as panoftbe worlc for this
thesis. using clone 7.0 as a probe; detected transcripts in heart. brain. placenta, lung. liver,
skeletal muscle. kidney. and pancreas,. Figure 3-4. Based on the original hypothesis for
this thesis, i.e. that relevant autoantigens would be relatively restricted in their tissue
distnbution.. detection of putative transcripts correspondlngto clone 7.0 in all ofthe
tissues tested. strongly suggests that clone 7.0 does DOt encode an important autoaDt:igen
in multiple sclerosis. The study by Nagase etal (1998) used l'e"llenetranseriptase
polymense chain reaction (RT-PCR) to examine the tissue expression ofKlAAOS30.
They did DOt detect KlAAOS30 in any oftbe 13 tissues, heart, brain. placenta, lung. liver,
skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, and small
intestine, which were tested. It is surprising that this group isolated KlAAOS30 from a
human brain cDNA library, but were unable to detect it by RT-PCR ofbfain tissue (the
~ do DOt address this discrepancy in the paper). Perhaps this protein is only
expressed in certain areas ofthe brain. Maybe if the investigatorS bad used the same
tissue samples. or samples from the same area of the brain. for bath the construction of
the eDNA h"brary and the RT-PCR they would have detectm KlAAOS30 by RT-PeR. In
contrast to the results ofNagase et al. (1998), the Northern blotting experiments
performed as pan of this project, which used clone 7.0 as a probe, detected transcripts in
a number oftissues. Tb.is may indicate that clone 7.0 does not encode for KlAA0530, but
rather encodes for a related gene product Of course, it is also possible that the Northern
blotting experiments were not sufficiently stringenL Ifthis is the case. then the Northern
blots may have cross-hybridized with other transcripts related to KlAAOS30, aDd DOt
hybridized 10 the KlAA0530 1ntnscrip1 itself. Ofcourse, iftime bad permitted RT-PCR
could have been carried out to test this using the same samples which I bad used for the
Northern blotting experiments.
The estimated size ofthe transcript obtained from the Nonhem blot is 0.9 Kb. this
is much smaller than the expected size ofthe KlAAOS30 transcript, approximately 6.5
Kb, assuming that the sequence submitted byNagase et al (1998) repre5enlS the entire
KlAA0530 gene. Perhaps this is another indication that the product encoded by clone 7.0
is DOt KlAA0530, but may be: a related gene. This 0.9 Kb transcript is also smaUer than
the 2.0 Kb (Table 3-1) c10De 7.0 isolated from the MS2 eDNA library. Perhaps the clooe
7.0 is derived from beterogeneous nuclear RNA (hnRNA), while the transcript detected
on the Northern blot is cytoplasmic mRNA. Since hnRNA is the precursor of mRNA
and is typically much larger than mRNA (Lewin. 1997), the clooe 7.0 would therefore be:
larger than the: transcript on the Northern blot.
4.4.3 Clone 58.4
A FASTA search ofthe: nucleotide sequence of clone 58.4 identified it as
corresponding most closely to the nucleotide sequence encoding clone F4 transmembrane
protein. Translation oftbe clone 5g.4 sequence in 6 frames revealed that the sequence
encoded for-at least 85 amino acids. The amino acid sequence of tile clone F4
transmembrane protein bas DOt been reponed. However, J did submit the 1.6 Kb
nucleotide sequence ofthis protein to the Baylor CoUege ofMedicine Human Genome
Sequencing Center website for translation in 6 reading frames. This did not identify a
nucleotide sequence capable ofcoding for a protein. Only 64 amino acids were
translated before a stop codon was identified. and all 6 reading fiames identified multiple
stop eadons. Perhaps Andrews (1993. unpublished) did not submit or obtain the entire
sequence for the clone F4 transmembrane protein, or perhaps only the non~g
sequence was obtained by this investigator. In either case. it is not easy to understand
bow Andrews YI'aS able to identify a transmembrane protein from this sequence.
Therefore, it is DOt posslllle to speculate on the relation between. the prodUCt of clone 58.4
and the clone F4 tmnsmembrane protein.. Instead it seems tbaJ: the clone 58.4 may be the
3' end ofanother sequence that shares homology to the puwive clone F4 transmembrane
protein. The BLAST dbEST database was unable to identitY any matches for the
nucleotide sequence ofthe 58.4 clone with a score greater than 100. Thus, tissue
distnbution cannot be further commented upon based on searches in BLAST and FASTA
da"""'=.
To date there is no published literature on tbeclooe F4 transmembrane protein.
This protein was originally isolated from a eDNA library constructed from human bone
marrow stromal cells (Andrews, 1993, unpublished). The Northern blotting expc:rimeots,
sbowed that clone 58.4 hybridized with a transcript present in testis. Transcripts were
either absent or expressed at very low levels in adrenal, brain. cervix, colon, liver, spleen,
and thyroid, Figure 3-3. The fact that the clone F4 transmembrane protein was identified
from an MS brain eDNA hbrary, but r could not detect a corresponding transcript in a
normal brain sample deserves further discussion. Ifone assumes that clone F4
transmembrane protein and clone 58.4 are identical, the clone F4 transmembnne protein
may only be expressed in MS tissues. for example in regenerating-or proliferating tissues,
or it may be very M:llk:Iy expressed in normal brain and ~regulatedin MS tissues. As a
second possibility, the clone F4 uansmembraDe protein could be irrelevant to MS but be
expressed in proliferating astroeytes or in oligodendrocytes associated with regeneration.
Ifso, this protein could well be detected at the margins of cerebral infarcts or other
oerebrailesioDS. Of course, to test this hypothesis it would be oecessaIY to perform a
Northern blotting experiment using several normal and multiple sclerosis brain samples,
as well as samples ofotheroerebrallesioDS. This was oot done as pan of this work-due to
time constraints aDd the difficulty of getting MS brain samples. A third possibility is that
the 58.4 clone cross-hybridized with a molecular species similar to but DOl identical to
clone F4 transmembrane protein in the Northern blot experiments.
The estimated. size oftbe transcript hybridizing with clone 58.4 from the Northern
blot is 3.7 Kb. In contrast, the sequence of the nueleotides encoding the clone F4
transmembrane protein submitted by Andrews (1993, unpublished) gave the expected
size ofthe transcript as approximately 1.6 Kb. However, as this sequenoedoes oot
contain an opeD reading frame and therefore, does not encode a protein it canoot be used
to predict the size ofthe clone F4 transmembrane protein transcript. In addition, this 3.7
Kb transcript is larger than the 1.1 Kb (Table 3-1) cloDe 58.4 isolated from the MS2
eDNA library. This size difference may be due to the full length transcript not being
represented by the clone 58.4 and/or the detection ofbeterogeneous nuclear RNA on the
Nortbem blot.
4.4.4 Failure to Detect Mydia COllllpoDe.ts
It is surprising that screc:ning of the MS21ibrarydid not detect MBP or other
myelin components. There may be several possible ex:pJanatiODS for this:
I. The IgG antibodies for these particular proteins were not present in the sera
used for screening. Perhaps such antibodies are only present during certain
phases or stages of the disease or lC$ion development and were not prc:seal
when the samples used in this study were taken (Tureci et al., 1997). Another
possibility is that the antibodies specific for myelin constiruc:nts were DOt
present at high enough titers to be detected by the SEREX technique (Owens
etaL,I996).
2. Anti·mydin annbodies may have been present but of a different isotype,
specifically 19M. The methodology used in this project assumes that the
antibodies relevant to multiple sclcrosis are IgG, bowever there arc studies
which have shown IgM antibodies may also be important in MS. For
examplc, intratbecal fractions isolated from MS patients are 20 percent IgM
(Reiber et at., 1998), 33 percent ofrelapsinglremitting MS patients were
shown to have elevated levels ofIgM antibodies reactive with MBP in CSF
(Annunziata et al., 1997), and IgM: annbodies specific for CNP have been
detected in high titer in the sera of74 percent ofMS patients (Walsh and
Munay,I998).
3. Thc MS2 library was not large enough to include clones for proteins which
are notcxpressed at high levels in the brain. In order to "represent all ofthe
different mRNAs in a human cell type, a eDNA library must contain more
than Iif independent clones" (Burton and Kaguni, 1997). The MS2 hbrary
contained approximately 850,000 clones in the primary eDNA library. The
MS21ibrary was the resultofa number of attemptS to consttuet such a library.
The size of this library is almost cenainly due in part to the fact that thc
tissues used for its construction were obtained aJ: autopSy. It is known that
remyelination OOCW'S in MS plaques (pmcr and Gregoire, 1965; Suzuki et al,
1969; Gledhill and McDonald, 1977; Lassmann, 1983; Prineas et al., 1993a;
Rodriguez et al., 1993; Bruck et al., 1994; Rodriguez and Scbeithauer, 1994).
Therefore, one would expect mRNA encoding myelin constituents to be
abundaDt in these plaques. However, mRNA is metabolically unsrable
(Mathews and van Holde, 1990) and degraded mRNA cannot be used to
construct a cDNA library (Stnn:ageoe, La Jolla, CAl. For these reasons, ifa
particular tissue is to be removed during an autopsy and subsequently used to
construct a eDNA library, it is imperative that the interval between the death
ofthe patient and the time of autopsy be short. As well, it is also important
that ooce the tissue has been removed it is property sto«d(undcr liquid
nitrogen) within minutes. Such measures reduce the amount of degradation of
the mRNA As the tissues were provided by an outside source. I cannot be
certain as to the times between death and autopsy, and between autopsy and
the freezing ofthe tissues. Therefore, degradation ofthe mRNA may have
contributed to the small size: ofthe MS2 library. It is impanant to remember
that in a directional), ZAP eDNA l1brary only one in three clones is expected
to place the insert eDNA in frame with the Lac Z geoe (Burton and Kaguni,
1997). This means that only one in three clones is ex:pectcd to produce the
correct fusion protein Unlike a nucleotide probe which simply binds to the
correct sequence, an antibody probe requires that the correct protein, or a part
thereot: be exprc:ssed. Therefore, even though. the eDNA insert for a
particular protein may be present, only one in three insertions of that eDNA
gives a protein which bas the potential to be recognized by an antibody.
Perhaps screening the MS2 library with a nucleotide probe for MaP, MOO,
MAG, or PLP would identify one or more of these constituents. As the
purpose ofthis project was to screen a eDNA expression hbrary without any a
priori assumptions as to the identity of the autoantigens, DO specific
nucleotide probes were used
An additional issue is thai. the cDNA lIbrary was screened after amplification
ofthe hbraryand this could have led to some distortion ofthe primary library
with the loss of rare c10DeS (Snead et a1., 1997).
4. The mRNA encodiog these myelin components may not have been present in
the plaques used to construct the library, as the cells which express these
proteins may not have been present in these lesions. In order to determine if
this is a valid explanation, the plaque bistology would have to be determined.
Ifan acute plaque was used to construct the MS2 h'brary, then myelin
components sbouId have been detected as acute MS lesions are known to
contain myelin (Eben, 1998). Ira cbronicactive plaque bad been used then it
is possible that myelin components would have been detected as this type of
plaque typically undergoes remyelination at its borders (Prineas and GTaham,
1981; Raine et aI., 1981). Therefore, if the border of the plaque bad been
included in the sample used to construct the libnuy then myelin components
,..
should be present. However. ifa chronic silent plaque bad been used then it is
less likely that myelin components would have been detected, as the chronic
silent plaque contains large number- ofdemyelinated axons and docs DOt
typically undergo remyelination (Raine. 1991b).
S. The method used to construct the eDNA library used oligo (dl) priming. This
means that the 3' ends ofthe mRNA are preferentiaUy included in the library
and therefore the S· ends are less likely to be transe=ribed into eDNA Forthis
reason it is possIble that the immunodominant epitopes ofMBP, MOO and
other myelin proteins were oot expressed in the MS2 Library. Without
knowing the length ofthe insert ofeach protein in the MS2 library. there is no
way to predict whether or oat these proteins or thea immunodominant
epitopes would be expressed in the lIbrary. For example, the
immunodominant epitope ofMBP occurs between 2llIioo acids 84 aDd l06.
On first considern.tion, an MBP eDNA insert greatC'f than 350 bases would be
expected to include the immunodomioanl epitope. Indeed, the vast majority
of inserts in the MS2 lIbrary are much larger than 3S0 bases. However, it is
possible that a large eDNA molecule may be mainl~DOn-coding and ioch~
only a small pan ofan open reading frame. Thus, the immunodominant
epitope ofMBP, as an example, may weU not have been included in the
6. Myelin constituents may not be important autoantigens in multiple sclerosis.
or they may not be imponant autoantigens in the pa:tieots stUdied io this work
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It is possible that the autoanrigens important in multiple sclerosis differ with
the patient examined or with the type ofMS diagnosed. There are a few
investigators who have also voiced this opinion. For example; Lassmann et
aI. (1998) pointed out that different demyelinating mechanisms may result in
different forms of MS. As well. McFarland el aI. (1999) suggest that
"'Responsiveness (in MS patients) to multiple antigens may indicate that the
inciting antigen could differ in different individuals....". Archelos et al
(1998) found that a higher percentage of relapsinglremitting patients weIe
positive for anb1:KM1ies against the Alu-6 peptide than primary and secondary
progressive patients and that these antibody titers were higher in the
relapsi.nglremitting patients as wen. Although, this does not prove that the
different forms ofMS are the result of an immune response against. different
autoantigens, itcerta.in.ly does raise the question. In light of this. it maybe
advantageous to screen eDNA expression libraries with autologous serum
(Owens et al.• 1996). Such autologous screening was DOt possible in this
study because I did not have access to autologous serum. In addition. such a
project would aec:essi.tate the construction of a Iazge number of IJ.lnries and
even more screening.
Overall, the most likely explanations for the inability to detect: clones expressing
myelin cornpoDCD1S is that nucleotide sequences encoding immunodominant myelin
epitopes were underrepresented in the libnuy. One cannot, ofcourse, exclude
I"
alternatives such as the sera having been used at too high dilutions for screening or that
the antigenic targets are more likely to react with IgM than IgG.
4.4..5 Detectioa of lIIlmuaoglobu.li.D.
It was expected that imoumoglobulin would be detected in the screening ofthe
MS2 library, since B lymphocytes and plasma cells are often present in MS lesions
(Prineas and Wright, 1978; Ozawa et al., 1994; Bruck etal., 1995) and therefore the
clones would contain immunoglobulin fragments. However, it "'as thought that during
secondary screening these clones would be identified as encoding IgG and then
eliminated The fact that some oftbese clones were sequenced and only then identified
as immunoglobulin is easily explicable since the secoodary antibody (goat anti-buman
IgG) used in the screening process is specific fortbe Fc portion ofhwnan IgO.
Therefore. iftbe clone encoded determinants within the Fab fragment ofIgG or the hinge
region orIgG the clone would not have been detected by incubation with the secondary
antibody alone. Indeed, the majority oftbe clones which were fOWKi upon sequencing 10
be immunoglobulin did encode the hinge regions oftbe annbody.
4.5 Northern Blotriag E:lperimcou
Northern blotting experiments were performed in this study to examine the tissue
expressionoftranseripts that hybridize with three c1oDCS, ya iO.3, 7.0. and 58.4, and to
estimate the sizes oftbe transcripts. Although both Northern blotting and Reverse
Transcripta.se·Polymerase Chain Reaction (RT-PCR) can be used for such studies. only
Northern blotting allows the determination ofthe size of the transcript (Walker and
Gaastra. 1983). RT~PCR does have several advantages over Northern blotting. It is
more sensitive, and can even be performed on less than 1 ng of total RNA. It is easier
than Northern blotting, and bas a rapid rum-around time (Larrick and Siebert. 1995).
However, the sensitivity ofRT-PCR can be a hindrance when used in studies to
determine the expression of proteins in different tissues. For example. Scanlan et al.
(1998) used both RT-PCR and Northern blotting to investigate the tissue expression ofa
particular tumor antigen which they bad isolated from a colon cancer using the SEREX
technique. The results oftbe RT·PCR showed the antigen to be universa1lyprescnt,
while the results ofthe Northern blotting experiments showed a gastrointestinal-restricted
expression. This finding suggests that the RT-PCR method may have detected tiny
amounts oftranscript in many tissues.
The quantitation ofmRNA levels in a number oftissues is more difficult with RT-
PeR than with Northern blotting (Larrick and Siebert, 1995). The quantitation ofmRNA
levels in Northern blots requires normalizing the amount ofRNA with a 13-actin probe.
In contrast, the quantitation ofmRNA using RT-PCR. requires estimating when the
exponential accumuiatioD plateaus so that the produet5 are analyzed only during the
exponential phase ofPCR, thereby eliminating the differences in amplification
efficiencies (Larrick and Siebert, 1995). Since Nortbcm blotting is able to identify the
size of the transcript and is an easier method ofquantifYing mRNA levels, it was used in
thisprojea:.
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4.6 Colorimetric Venus Radiolabel Methods of Deteding Posi.tive CIODes
The SEREX technique as originally reported (Sabin et aI., 1995) uses an alkaline
phosphatase method for the detection of positive clones. This is also the method which r
chose to use. Radiolabel methods would have been more sensitive, detecting 10 pg or
less ofmern.brane bound protein (BioRad, Hercules. CAl, but would certainJ.y have made
the task of screening 106 clones, followed by secondaIy and tertiary screening ofthe
clones a much more laborious and expensive task. In addition, the sensitivity of
radiolabel methods may have dramatically increased the number of false positives. As
well. radioisotopes have a certain half-life, in the case of32P, 14 days. Therefore, a
radiolabel method can only be used for several weeks before a new radioisotope must be
purchased (Burton and Kaguni. 1997), this is expensive and a waste of reagents. Of
course. a radioisotope with a Longer half-life. such as l~ could be used but this also
increases the risk to the experimenter. In contrast, colorimetric reagents can be stored for
much longer periods of time (BioRad). The colorimetric method also allows easier
identification ofpositive plaques on the agar plate by IiniDg up the nitrocellulose filter
with the agar plate. Such a technique would not be possible with a radiolabel method.
From the sheer volume of screening which must be done when using the SEREX method,
colorimetric methods seem to be the best option. The experiments performed to date by
the Sahin and Tureci groups. using the SEREX method to identify tumor antigens have
not discussed the use ofalkaIine phosphatase as being a potential problem. We have no
reason to suspect that it may be so in this study.
lSI
4.7S....ry
!be study described in this thesis was undertaken to searcil for potentially DOvel
and also known autoantigc:ns in multiple sclerosis. It was hypothesized that screening a
eDNA expression Librazy coosttueted from the mRNA extracted from MS plaques with
patients' sera would allow the identification ofnovel autoantigens. The advantageS of
this method were that no assumptions would be made as to the identity of the
autoantigens and that such screening might be able to recognize the majority of
auroantigens in multiple sclerosis. 11Lree novel autoantigcns have been ideotified using
this metbod. It seems unlikely based on the antibody screening, that any of these are
really important in MS as only a minority of sera reacted with the clooal products.. Also,
no CODttol sera were used and thus DO real conclusions can be made as to wbetherthese
are important antigens in multiple sclerosis. At pr-esent we can only say that they
represent, at most, potential autoantigens in multiple sclerosis. Also, at this stage it is
still unknown if immune reactivity to these proteins actually represents a primary
humoral response. ifthe immune targetS are cross-reactive species, or ifthey are targets
as the result of epitope spreading.
lbe relevance ofthe identification of the three potential. autoantigcns to the
oligoclonaJ. bands in the <::SF orMS patients remains to be elucidated. Perhaps these
purified proteins could be examiDcd in adscxption assays to see ifany oftbem is capable
ofbinding to <::sF oligoc:lonal bands or these proteins could be isolated and used in
ELISAs with CSF from. patients with MS. As well. one could re-screen the IJbrazy with
CSF isolated from MS patients to see if the same autoantigens are identified.
1S2
This is the first report ofclones hybridizing with transcripts having sequence
homologies to tcstican, KlAAOS30. and the clone F4 transmembrane protein being
identified as posslble autoantigens in multiple sclerosis.. As we did DOt detect the
"conventional'" autoaDtigens.. MaP. MOO. etc.• it is difficult to make conclusions about
the usefulness oftms method in the search for autoantigens in multiple sclerosis.. It is
important thal in investigating this disease one does not become "caught up" in trying to
reproduce the work ofothers by using a different method. lbat is to say that maybe we
should not have expected to detect MBP. or MOG or other myelin constituents in this
libraty as there is no soLid evidence that these autoantigens ate important in MS. Rather
the goal should be to identify new possibilities so that they too can be investigated. The
hypothesis oftbis project was that the SEREX method could be used to identify novel
potential autoantigens in multiple sclerosis. We have succeeded in doing just that.
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4.8 Future Work
1. The three clones isolated in this study have only been screened with a small number
ofMS patients' sera and have not been screened with any control sera. In order to
determine their potential importance as auroantigens in multiple sclerosis it would be
particularly important to screen these clones with a large number of sera from healthy
controls as well as patients. Obviously, a clone which reacts wilhequal numbers of
patients' and control sera is unlikely to be an important autoantigen in MS, while a
clone which reacts with a greater number of sera from MS patients than from controls
may have relevance to the disease.
2. The sequences ofthc: clones 7.0 and 58.4 could be extended S· and 3' and analyzed for
translation in 6 frames. The derived amino acid sequences would be compared with
those ofKIAA0530 and clone F4 transmembrane protein. respectively, and would
also be submitted to a protein database (BLAST) for identification.
3. As MS is typically believed to be a T lymphocyte mediated disease (Stinissen et aI.•
1997) it would be interesting to test the three clones, 7.0. ya 10.3. and 58.4, in T
lymphocyte proliferation assays. to determine if they are capable ofactivating T
lymphocytes. The three clones which were not chosen for funher study could also be
used in such proliferation assays.
4. One ofthe possible explanations for not detecting myelin components in the MS2
eDNA IJ.brary was that the anti-myelin antibodies may have been IgM and not IgG.
There are studies which indicate that IgM antibodies may be imponant in multiple
sclerosis (Anmmziata et aI., 1997; Reiber et aI.• 1998; Walsh and Murray, 1998). As
the secoodaIy antibody used in the screening ofthe MS2 eDNA library was specific
foeIgG. IgM was DOt detected in this study. Therefore. the MS2 library. or a
C()IIlIIle[Cially available library, should be screened using a secondary annbody which
"","",,!gM
5. Annbodies are known to be pa:settt in the CSF of multiple sclerosis patients (Link
and Tibbling, 1977; Towtellone, 1985). The MS21ibrary could be screened 'Nith
CSF from MS patients.
6. Another possible approach ofsignificant future poteotialis to screen a brain library
with T lymphocyteS isolated from MS patients. This could be accomplished by
incubating a certain number ofclones per well in 96 well plates, adding T
lymphocytes and performing proliferation assays. The wells which lead to
proliferntion oftbe T lymphocytes could be plated to allow isolation of individual
plaques. Next single clones would be added to wells of the 96 well plate and the
proliferntion assays repeated (Dr. John Webb, petsooal communication). In this way
single clones which activate T Iympbocytes from MS patients could be isolated. Of
course. this would be followed by nucleotide scqueocing. analysis for translation in 6
reading framc:s., and mRNA tissue expression studies.
7. Perhaps a commercial library could be used for screening with patients' sera a»'or
CSF. Such bbraries are typically optimized for large inserts. Using a commemial
library would also avoid the problem ofdetecting sequences for proteins with
epitopes at the e-term:inus.
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